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1. INTRODUCTION  As a clinician I am frequently asked by patients newly diagnosed with dementia due to 
Alzheimer’s	   disease	   (AD)	   and	   their	   families,	   ‘How	   severe	   is	   the	   disease?	   Will	   it	   get	  
worse?	  How	  much	  longer	  before	  it	  gets	  bad?	  ’	  The	  ability	  to	  predict	  progression	  rates	  in	  
Alzheimer’s	   dementia	   would	   aid	   clinicians,	   patients	   and	   families for the long-term planning of care and treatment of patients. Better predictive markers would also be important for clinical trials to assess the efficacy of disease-modifying therapies.   AD is progressive and the commonest form of dementia, responsible for 60 to 80 
percent	   of	   all	   dementia.	   Alzheimer’s	   disease	   is	   characterized	   by	   gradual	   decline	   of	  memory and other cognitive functions, in addition to progressive loss of daily functioning and associated neuropsychiatric symptoms (APA, 1984). Each year 39,400 more people are diagnosed with Alzheimer's disease in England and Wales; that equates to one new case every 14 minutes (Copeland et al., 1999). As a consequence of an aging population, the prevalence of AD is set to rise in coming decades (Mashta, 2007), resulting in a huge financial and emotional burden for society and for caregivers.  AD likely begins histopathologically many years before clinical symptoms manifest (Braak and Braak, 1991). The insidious onset of symptoms makes it difficult for the patient and family to be definite when the abnormal cognitive or functional state actually started and patients therefore come to a medical diagnosis at variable intervals after the first symptoms begin (Doody et al., 2001). Previous studies have reported average estimates of disease duration from 3 to 4.5 years at the first clinical presentation (Kraemer et al., 1994, Morris et al., 1993, Bracco et al., 1994). A period of symptomatic disease often exists at the time of presentation, allows an estimate of initial rates of decline, that is; relatively predictive of subsequent disease progression (that is initial rapid progressors will continue to decline faster than the initial slow progressors) (Doody et al., 2001, Doody et al., 2010). Natural history studies and data on placebo groups from drug trials have reported tremendous heterogeneity between-subjects and between-groups of measured progression rates, which reflects multiple phenomena, including, 1) true difference in disease progression rates between patients, 
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2) differing properties, i.e., floor and ceiling effects, of the measures used, 3) differences  in the end point selected to represent progression (cognitive decline, functional decline, nursing home placement, or death), 4)other methodological differences, such as the number of patients, duration of follow up and interval between visits, 5) differences in medical comorbidities, and 6) differences in patient care (Doody et al., 2001). Some authors have suggested that the initial stage of disease at the beginning of the observation period (“how	  far”)	   is	  an	   important	  predictor	  of	  subsequent	  decline	  (“how	  
fast”)	  (Kraemer et al., 1994). Most staging measures fail to document linear decline over 
the	   course	   of	   AD	   and	   as	   a	   result	   both	   ‘bilinear’	   and	   ‘trilinear’	  models	   of	   decline	   have	  been proposed (Morris et al., 1993, Stern et al., 1994, Brooks et al., 1993, Doody et al., 2001). However, no clear, predictive models of progression have been developed and validated for AD. Baseline cognitive function has been shown to correlate with future cognitive decline (Sona et al., 2012). Among several studies which investigated clinical predictors in AD, some authors have associated extrapyramidal signs, severe cognitive impairment at baseline and high preprogression rates (PPRs) with rapid decline (Schmidt et al., 2011). The concept of PPRs introduced by Doody describes the rate of cognitive decline before the time of diagnosis (Doody et al., 2001). Hereby, the difference of the Mini Mental State Examination (MMSE) of healthy contemporaries at the time of clinical onset and the MMSE at diagnosis is divided by the time span between onset of AD and diagnosis (Doody et al., 2001). Nevertheless, this was studied in a single patient group (n=298). A recent study which re-examined	  Doody’s	  hypothesis	  that PPRs predict short-term decline of AD patients (n=78) within the first year after diagnosis in a different cohort and found that PPRs were associated with the decline of instrumental activities of daily living (iADL) but not MMSE decline (Schmidt et al., 2013).   Disease progression is heterogeneous; the rates of decline in cognitive and functional capacities are variable, and there are different rates of institutionalization and death between patients (Cortes et al., 2008). The factors that influence or predict progression are not well understood (Kraemer et al., 1994, Marra et al., 2000). Disease progression is measured, most commonly, by change in cognition over time (Kraemer et al., 1994, Marra et al., 2000). However, clinical and neuropsychological measures may lack sensitivity to change, are subject to day-to-day variability, and are influenced by 
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behavioural fluctuations and inter-current illness and medications (Sluimer et al., 2008).   The purpose of this study is to identify disease progression markers for dementia due to AD. While there are potentially various kinds of markers such as neuropsychological, neuroimaging etc that may be used to predict disease progression in AD, I attempted to identify markers using complementary approaches that may, if successful, help in prognostication using simple inexpensive tests. Hence, one of the approaches that I have taken is to investigate whether a simple bedside clinical measure of olfaction could predict disease progression. Another complementary approach that I have taken builds on my previous gel based proteomic discovery work and involves examining if certain plasma proteins predict disease progression in AD. Lastly, examined MRI brain structural regions for markers of cognitive decline in patients with AD dementia. 
 
2. Objectives: 1. To test whether smell identification test can be used as a predictor for illness progression in patients with mild-moderate AD dementia and to study the rate of smell dysfunction with illness progression. 2. To test if there is difference in plasma protein concentrations between the rapid and non-rapid progressors and if this predicts the progression of illness. 3. To examine the relationship between baseline hippocampal volume, entorhinal cortex thickness and whole brain volume with baseline cognitive measures and with subsequent cognitive change over one year period.    
2.1 Olfactory dysfunction in general and impaired odour identification in particular have been reported in AD and occur at early stages of the disease (Mesholam et al., 1998). Odor identification tests have demonstrated high sensitivity and specificity in discriminating AD patients from controls (Morgan and Murphy, 2002), wherein 12 patients with AD and 12 matched healthy controls were tested for smell identification and olfactory event related potential. Combination of the odor identification scores with olfactory P3 latency measures resulted in a correct classification rate of 100%. Smell identification test has also been studied as a marker for predicting conversion from mild 
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cognitive impairment (MCI) to AD (Devanand et al., 2008, Devanand et al., 2000). This longitudinal study followed up 148 outpatients with MCI over 3 year period and found smell identification as one of the 5- predictors when combined strongly predicted conversion to AD.  There has been a proposal to include olfactory dysfunction within the diagnostic criteria of AD (Foster et al., 2008).  It has been indicated that involvement of the olfactory bulb and tract is one of the earliest events in the degenerative process on the central nervous system in AD in an autopsy study of 110 cases- 91 AD cases and 19 controls (Christen-Zaech et al., 2003). Tau pathology in the olfactory bulb increases has also been shown to increase with severity of AD (Attems et al., 2005), suggesting a possible link between measures of olfaction and disease progression in AD.   I have previously investigated the utility of smell identification test as a predictor of response to treatment with cholinesterase inhibitors in patients with AD dementia (Velayudhan and Lovestone, 2009)  The current study further extends this work to examine whether performance in a smell identification test can be a reliable marker of disease progression in AD.  Olfactory dysfunction has not been investigated as a progression marker, although it has been studied as a diagnostic marker as well as a marker of conversion in AD. As this is an inexpensive, brief test that is easy to carry out in a clinical setting with minimal training, it may have application in clinical settings in adjunct with other measures in monitoring the progression of AD.  
This	  part	  of	  study	  has	  been	  described	  in	  detail	  in	  Chapter	  3:	  ‘Smell	  identification	  test	  as	  
a	  marker	  for	  severity	  and	  progression	  in	  AD’. 
 
2.2 Plasma protein markers:  Studies have evaluated biochemical diagnostic markers in both cerebrospinal fluid (CSF) and blood in AD. Because of the invasive nature of lumbar puncture for obtaining CSF, particularly in elderly people, biomarkers that are detectable in blood, which is more easily obtained, are considered more practicable in a clinical setting.  Recently, progress has been made in identifying plasma proteins as potential diagnostic biomarkers for AD and for differentiating from other dementias, using proteomics technologies (Hye et al., 2006, Lovestone et al., 2007b, Song et al., 2009).  Using filter-
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based sandwich ELISAs, a panel of 18 plasma signalling and inflammatory proteins was identified from screening 120 known signalling proteins (Ray et al., 2007). Combined multivariate analyses of this panel of proteins enabled the accurate identification of AD patients and predicted the progression to AD in individuals with MCI. This has raised the possibility of investigating whether plasma proteins may also serve as markers of disease progression in AD (Lovestone et al., 2007b, Song et al., 2009).    The accumulation of the amyloid-beta	   (Aβ)	   peptide,	   the	   main	   constituent	   of	   the	  "amyloid plaque", is widely considered to be the key pathological event in Alzheimer's disease (Vardy et al., 2005). An increasingly detailed understanding of proteolysis in 
both	  Aβ	   deposition	   and	   clearance	   has	   identified	   some	   of	   these	   proteases	   as	   potential	  therapeutic targets for Alzheimer's disease. In addition to a number of in vitro studies, in vivo studies with amyloid precursor protein (APP) transgenic mice indicate that APOE and a related molecule, clusterin (also called apolipoprotein J), have profound effects on the onset of Aβ deposition, as well as the local toxicity associated with Aβ deposits both in the brain parenchyma and in cerebral blood vessels (Holtzman, 2004). Transthyretin (TTR) was the third protein found to interact with Aβ after apolipoprotein E (ApoE) and clusterin in AD CSF biomarker studies (Li and Buxbaum, 2011). TTR, a systemic amyloid precursor, can suppress Aβ aggregation in vitro and in vivo and ameliorate its pathologic effects in a well-validated transgenic mouse model of human AD (Li and Buxbaum, 2011).  In a pilot gel based proteomics discovery work, using 2DGE proteomic approach and LC/MS/MS, I identified potential plasma proteins that can serve as a disease progression marker in AD dementia. The plasma proteins identified were associated with immune regulation, inflammation, transporters of lipid, and also included Aβ binding proteins such as clusterin and TTR.  The lab-based component of the present work involved testing clusterin and TTR proteins as AD dementia progression markers in independent and larger cohort.   
The	  work	   published	   as	   part	   of	   the	   thesis	   is	   described	   in	   detail	   in	   chapter	   4:	   ‘Plasma	  
proteins	  as	  progression	  markers	  for	  AD’.  
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2.3. MRI neuroimaging markers MRI has demonstrated significant value in the prediction of conversion and disease progression (Fennema-Notestine et al., 2009b). It has been shown that MRI is useful for detecting atrophy in the medial temporal structures affected early in the neurodegenerative process (Fennema-Notestine et al., 2009b). Numerous studies have used baseline and serial MRI measures to predict future cognitive decline but mostly for conversion from mild cognitive impairment (MCI) to AD (Varon et al., 2011, McEvoy et al., 2009, Cardenas et al., 2011, Mungas et al., 2001) and there is need for assessing these MRI measures as potential markers of disease progression in AD.  Previous reports from European Union AddNeuroMed multi-center MRI study have shown that structural MRI measures discriminated AD from controls and MCI; and also demonstrated potential for prediction of conversion from MCI to AD (Costafreda et al., 2011, Liu et al., 2010b, Westman et al., 2011c, Liu et al., 2011a, Westman et al., 2011b, Westman et al., 2011a). My hypothesis was that smaller brain structures would be associated with worse baseline cognition and greater cognitive decline.   The paper now accepted for publication is described as chapter 5: Other AD progression 
markers:	  ‘Entorhinal	  cortex	  thickness	  as	  marker	  of	  cognitive	  decline	  in	  AD’.  

























2. OVERVIEW: DESIGN AND METHODOLOGY 
2. 1. Olfactory dysfunction as progression marker:  
2.1.1 Subjects: 
 Alzheimer’s	   disease dementia participants: Participants with late-onset, mild to moderate dementia due to AD (NINCDS-ADRDA criteria) (McKhann et al., 1984), were  recruited and followed up through 2007-2011 (n= 39), from community mental health team (CMHT) within the mental health for older adults (MHOA) and through the Dementia Case Register, NIHR BRC IOP and South London and Maudsley (SLaM) NHS Foundation Trust. Patients were also recruited from the Charnwood Memory Service within the mental health service for older persons (MHSOP), Leicestershire partnership NHS Trust (2011-2012, n=25), where I am working now, following ethical committee approval for including it as an additional site. 
Exclusion criteria: Dementia other than AD; history of psychiatric disorder, including substance abuse; medical conditions which affect olfactory functioning (e.g., blocked nasal passages, polyps etc.); current history of cigarette smoking.  
Non demented controls (NDC): Eligible elderly volunteers as healthy controls were invited and recruited from other on-going research projects at the department of Old Age Psychiatry, Institute of Psychiatry (2009-2012, n= 28).   
2.1.2 Study design and outcome measures Cognitive testing with Mini Mental State Examination (MMSE) was used to classify AD patients into rapid and non-rapid decliners, a commonly used cognitive test to assess severity and decline in clinical settings (Behl et al., 2005). Those with a loss of 2 or more MMSE points at study inclusion, compared to their recorded score 6-months before will 
be	   classified	   as	   ‘Rapid	   cognitive	   decliners’,	   while	   the	   rest	   classified	   as	   ‘Non-rapid 
cognitive	  decliners’.	   Assessments were performed at baseline and at follow up after 3 months for both AD dementia and NDC groups i.e., Neuropsychiatric Inventory; Bristol Activities of Daily Living Scale; MMSE and olfactory identification function using the University of 
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Pennsylvania Smell Identification test (UPSIT). UPSIT is a standardised "scratch 'n sniff" test of odour identification.   
2.1.3 Statistics  
2.1.3.1 Power Calculation: A sample size of 24 in each group will have 80% power to detect a difference in means of 4.500 assuming that the common standard deviation is 5.400 using a 2-group t-test with a 0.050 two-sided significance level. The effect size from the given power calculation is 0.14. Although it is a small effect size, it would indicate 54-58% of a rapid decliner group below the average non-rapid decliner AD patient. This would still be substantial, given smell test is an easily applicable test in a clinical setting and it would be valuable as an adjunct with other tests. Also it would be feasible within the time-frame of this proposal.  
2.1.3.2 Data analysis: Chi-Square,	   student’s	   t-test and non-parametric Mann-Whitney tests were used for comparing the socio-demographic, clinical parameters (MMSE, NPI, UPSIT and BADL). Bivariate correlations were performed to determine correlation between MMSE, UPSIT, ADL and NPI scores and rapid and non-rapid decliners groups. Regression analyses were used to determine if baseline UPSIT measures predicted future MMSE. 
2.2 Plasma proteins as progression markers:  In this study, initially gel based proteomics using 2DGE proteomic approach and LC/MS/MS was done to identify potential plasma proteins that can serve as a disease progression marker in AD dementia. The proteins were then tested in independent and larger cohort for its robustness using immunoblotting experiments. 
 
2.2.1 Subjects and Samples: The proposed study accessed a sample resource collected as part of the AddNeuroMed project, a European Union study cohort of AD dementia patients (AddNeuromed: http://www.innomed-addneuromed.com). As part of this study, individuals with mild-to-moderate AD dementia (NINCDS-ADRDA) have already been recruited and assessed. Following recruitment, they are assessed clinically and blood obtained at quarterly intervals over a year.  
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2.2.2 Pilot Work (Discovery phase):  I examined plasma samples from 51 subjects with mild-moderate AD dementia from the AddNeuroMed cohort, using a 2 Dimension Gel Electrophoresis (2DGE) proteomic technique. Patients were characterised as fast progressors based on a decline of 2 or more points on the Alzheimer disease assessment scale – Cognitive (ADAS-COG) score from baseline to the 6-month follow-up time point. Using this criterion, 22 subjects 
were	   characterised	   as	   ‘rapid’	   and	  29	   as	   ‘non-rapid’	   progressors.	   I	   identified	  9	  protein	  spots of interest following silver staining of the gels, image analysis using Progenesis same spot software (Nonlinear dynamics), and partial least squares discriminant analysis. Proteins from these spots which discriminated the two groups of patients were identified using LC/MS/MS. 
2.2.3 Validation-phase (present work): In the current project, I attempted to validate the proteins discovered from my previous study (described above), using specific assays, like Western blotting or Enzyme Linked immunoassay (ELISA), in an independent, larger patient sample (n~ 300). Relative and absolute quantification of the proteins in the different subject groups helped to establish their robustness as a marker. 
2.2.4 Statistics:  SPSS 15.0 was used for statistical analysis of the data. Chi-Square, student’s	   t-test and non-parametric Mann-Whitney tests were performed to compare the socio-demographic, clinical parameters (ADAS-cog, MMSE, NPI and BADL) and protein levels (µg/ml) between the groups. Bivariate correlations performed to determine correlation between protein levels and changes in cognitive measures (MMSE and ADAS-cog scores) from baseline to 6 months. Regression analyses were used to establish if baseline plasma protein levels predicted changes in cognitive measures. 
2.3 Neuroimaging markers of cognitive decline 
2.3.1 Participants, assessments and analysis This study included data from participants from the AddNeuroMed study, a longitudinal, multi-centre European Union study, of biomarkers for AD 
20 
 
(AddNeuromed:http://www.innomed-addneuromed.com). As part of this study, subjects underwent MRI scanning at baseline and cognitive testing at baseline and every 3 months up to one year. Cognitive testing was done with Mini Mental State Examination (MMSE)(Folstein et al., 1975) and Alzheimer disease assessment scale – Cognitive (ADAS-cog) (Rosen et al., 1984) and stage of dementia with Clinical Dementia Rating (CDR) (Hughes et al., 1982) sum of boxes score.   These subjects had structural MRI data which was acquired as designed to be compatible with the Alzheimer Disease Neuroimaging Initiative (ADNI) (Jack et al., 2008). MRI was done within a month of the clinical/cognitive assessments and blood sampling. Freesurfer pipeline (version 4.5.0) was applied to the MRI images to produce regional cortical thickness and subcortical volumetric measures - hippocampal volume, entorhinal cortex thickness and whole brain volume.   Rates of cognitive decline were determined by change in the cognitive measures – MMSE and ADAS-Cog total scores. These measures were estimated by fitting a random intercept and slope model using xtmixed in STATA 10 (Stata Corporation, College Station, TX, USA). An interaction between the MRI-based brain volumes and follow- up time was used to indicate the association of baseline brain volume with baseline cognitive assessment score and the effect of brain volume on cognitive decline over time.  The results were based on using the brain measures as continuous variables and the quartiles for graphical view.              
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SMELL IDENTIFICATION DYSFUNCTION AS A SEVERITY AND 












Background: Factors influencing or predicting progression in dementia due to 
Alzheimer’s	  disease	  (AD)	  is	  not	  well	  understood.	  Olfactory dysfunction, impaired smell identification in particular, is known to occur in AD. Mesial temporal lobe, important for memory function is also critical for the processing of olfactory information. In view of the common anatomical substrate for both memory deficits and the olfactory function in AD, this study aimed to evaluate the smell identification test for assessing illness progression in AD dementia patients.  
Methods: Fifty seven outpatients with late onset mild to moderate AD dementia and 24 elderly non-demented controls (NDC) were assessed, at baseline and a follow up after 3 months, for mini mental state examination (MMSE), University of Pennsylvania Smell Identification Test (UPSIT), Bristol activities of daily living and Neuropsychiatry Inventory. AD dementia participants were classified as Rapid Cognitive Decliners (RCD) 
defined	  on	   ‘a-priori’	  with	   a	   loss of 2 or more points in MMSE within the previous six months.    
Results: AD dementia participants had lower olfactory scores than NDC. RCD had lower olfaction scores compared to Non-Rapid Cognitive Decliners (NRCD). Although the baseline UPSIT scores were associated with baseline MMSE scores, it did not interact significantly with change in MMSE over the follow up period. Using a median split for olfactory scores, the AD dementia participants were classified as Rapid Olfactory 
Progressors	   (ROP)	   (UPSIT	   ≤	   15)	   and	   Slow	   Olfactory	   Progressors	   correlating	  significantly with RCD/NRCD groups. The ROP group with higher olfactory impairment indicated more symptomatic illness or severity, i.e., lower cognition, higher functional dependence and presence of behavioural symptoms.  
 




3.1 BACKGROUND Olfactory dysfunction in general and impaired odour identification in particular, have been reported in AD and are found to occur at early stages of the disease (Mesholam et al., 1998). 
 
3.1.1 Evidence 
3.1.1.1 Olfactory impairment in AD and other neurodegenerative disorders: Olfactory impairments in Alzheimer's disease were first reported by in 1974 (Waldton, 1974) and it is now well established that those with AD have abnormal olfactory function.  The different tests for olfaction are: 
Olfactory identification: In odor identification tasks an odorant is presented at a suprathreshold concentration and subjects are required to identify the odor from a list of descriptors. This forced-choice procedure controls the subjects' response bias. 
Odor discrimination: Subjects have to determine which of the suprathreshold odorants smell different. Thus, they demonstrate the ability to distinguish between odors, not to recognize or identify them. 
Odor fluency: Olfactory analog to verbal fluency tests (Bacon Moore et al., 1999) , in odor Category Fluency (OCF), exactly as in the verbal fluency test, participants are asked to generate as many things that belong to the category, odors, or things with odors, as they could within 60 seconds. Odor Letter Fluency (OLF), participants are told that they would be given a letter and asked to name as many things with odors as they could that began with the specific letter they were given. Finally, Odor Stimulus Fluency (OSF), participants are presented with an odorant stimulus and asked to name all of the odors that the stimulus brought to mind.  
Odor recognition memory: Ability to verbally recall previously presented odors and to learn this task across trials (immediate and delayed recall both free and cued). 
Odor threshold: The concept embedded in threshold tests is that a subject is repeatedly exposed to ascending and descending concentrations of the same odorant and is required to identify the least detectable concentration for this individual odor.  
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Olfactory dysfunction is also known in other neurodegenerative disorders such as, 
frontotemporal	   dementia,	   Lewy	   body	   dementia,	   Huntington’s’	   dementia	   and	  
Parkinson’s	  disease.	  A	  meta-analysis concluded that impairments have been shown on tests of olfactory identification, olfactory recognition memory and olfactory threshold in both patients with AD and PD relative to controls (Mesholam et al., 1998). Patients with 
AD	  (n=40)	  and	  Huntington’s	  dementia	  (n=11)	  had	  impaired	  odor	  fluency	  compared	  to	  age matched controls (Bacon Moore et al., 1999). Poor odour recall and recognition memory were found in patients with pathologically confirmed AD and Lewy Body variant of AD compared to elderly controls (Gilbert et al., 2004). Performance on tests of odour discrimination, naming, and matching was compared in patients with 4 distinct neurodegenerative disorders and, severe impairment was found in identification in semantic dementia and AD, with mild impairments in frontotemporal dementia and corticobasal degeneration (Luzzi et al., 2007).  A recent meta-analysis (Rahayel et al., 2012) which included 39 articles with AD and 42 with PD, suggests that AD even more than PD, affect more strongly odour identification and then odor detection. PD patients are more impaired on detection thresholds than AD patients. These results suggest that PD patients are more impaired on low-level perceptual olfactory tasks whereas AD patients are more strongly impaired on higher-order olfactory tasks involving specific cognitive processes.   
3.1.1.2 Smell identification and AD Severe deficits in odor identification in AD have been well documented (Doty et al., 1987, Morgan et al., 1995, Moberg et al., 1997, Chan et al., 2002). A recent meta-analysis shows that there are no published reports of smell identification in AD which have failed to find deficits relative to healthy elderly (Rahayel et al., 2012).   Odor identification and detection was tested in 55 patients with AD dementia and 57 elderly control subjects by using the University of Pennsylvania Smell Identification Test (UPSIT) (Serby et al., 1991). Significant deficits in olfactory identification were present in patients, and these deficits increased as AD progressed and smell identification test scores were correlated with Mini-Mental State scores.  In a small study, combination of the odor identification scores with olfactory event related 
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3.1.2 Anatomical correlates The entorhinal cortex is a target of incoming olfactory information from the olfactory bulb, via the lateral olfactory tract. Entorhinal cortex supplies important input to the hippocampus CAI neurons, with feedback from the hippocampus to the mesial entorhinal cortex. In the case of olfactory input to the hippocampus, the entorhinal cortex represents the direct and substantial link between incoming olfactory input and the hippocampus. The entorhinal cortex is multimodal and its integrity is critical for flow of olfactory information. In addition to hippocampal projections, entorhinal cortex projects to orbital frontal cortex and receives input from frontal cortex and amygdala, areas important for olfactory function (Carmichael et al., 1994). Thus, the areas that evidence early neuropathy in AD, particularly in the mesial temporal lobe, are areas that, in addition to their well-known importance for memory function (Squire, 1992), are also critical for the processing of olfactory information.   The olfactory deficits in AD are also supported by missing electrophysiological response  to olfactory stimulation (Peters et al., 2003). A strong relationship between left hippocampal volume losses in AD was found with performance on verbally based odour identification tasks (Murphy et al., 2003).  It has been shown that involvement of the olfactory bulb and tract is one of the earliest events in the degenerative process on the central nervous system in AD (Christen-Zaech et al., 2003) and also that tau pathology in the olfactory bulb increases with severity of AD (Attems et al., 2005).  A study showed that association with odour identification was robust for tangles in the entorhinal cortex and CA1/subiculum area of the hippocampus (Wilson et al., 2007a).  In summary, mesial temporal lobe, in addition to having importance for memory function is also critical for the processing of olfactory information (Figure 3.1).  
Figure 3.1- Simplified diagram of cortical regions thought to be involved in the 
processing of olfactory information as it passes from the olfactory epithelium to 






3.1.3 Olfaction and cognition Olfactory discrimination and identification have been more closely associated with higher cognitive functions and with subsequent cognitive decline (Sohrabi et al., 2009, de Wijk and Cain, 1994, Sohrabi et al., 2012). A strong association between cognitive functions and olfactory functioning has been reported and it has been concluded that compared with the ability to detect odours, identification of odours is more challenging, perhaps due to a lack of access to verbal or visual representations of odours (Richardson and Zucco, 1989). Similarly, Schab noted that odour identification may represent a semantic memory function (Schab, 1991). Some researchers suggest that olfactory identification is primarily predictive of memory decline (Swan and Carmelli, 2002).  Olfactory dysfunction has been suggested to be included in the diagnostic criteria of AD (Foster et al., 2008).  Studies have reported association between olfactory impairment and subsequent cognitive decline in community dwelling older people (Wilson et al., 2007b, Wilson et al., 2006, Schubert et al., 2008, Sohrabi et al., 2012) and it has also been studied as a marker for predicting conversion from mild cognitive impairment to AD (Devanand et al., 2008, Devanand et al., 2000).  Within AD patients, those who were carrying one or two ApoE epsilon4 alleles had a higher coefficient of correlation between the MMSE scores and the smell identification test scores than patients not carrying an ApoE epsilon4 allele (Suzuki et al., 2004).   
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However there is little known about association of olfactory identification impairments and cognitive decline with illness progression in AD dementia patients. In view of the common anatomical substrate for memory deficits and the olfactory function in AD, I hypothesized that olfactory identification ability at baseline would correlate with the cognitive ability and also predict altered cognitive function in a follow-up assessment. The specific questions examined by the current study were the following:   1) Is there any association between olfactory function and cognition in mild-mod AD dementia and can olfactory function predict future cognitive decline?  2) What is the difference between olfactory identification function between mild-mod AD dementia and non-demented control (NDC) subjects?    3) Is there any association between olfactory function and other non-cognitive symptoms in AD dementia?  
 
3.2 Subjects and Methods 
3.2.1 Subjects: 
AD dementia : Inclusion criteria: Patients with probable mild to moderate dementia due to  AD (National Institute of Neurological and Communicative Disorders and Stroke 
and	   the	   Alzheimer’s	   disease	   and	   Related	   Disorders	   Association	   [NINCDS-ADRDA] criteria) (McKhann et al., 1984), Mini Mental State Examination (MMSE) (Folstein et al., 1975) score range between 15 and 25, age 65 years or above. Exclusion criteria: significant neurological or psychiatric illness other than AD, significant unstable systematic illness or organ failure; medical conditions that may alter cerebral functioning or other conditions known to affect olfactory functioning (e.g., common cold, blocked nasal passages, polyps etc.). Subjects had either no history at all of cigarette smoking or had stopped smoking for 20 years or more. All were living in their own homes and had family members as reliable caregivers.   




3.2.2 Recruitment methods:  
AD dementia: Potential AD dementia participants were identified through discussion with the clinical team for mental health for older adults (MHOA) services of the South London and Maudsley (SLaM) NHS Foundation Trust and Mental Health Services for Older People (MHSOP), Leicestershire partnership NHS Trust.  
Diagnosis	   of	   probable	   late	   onset	   dementia	   due	   to	   Alzheimer’s	   disease	   was	   made	  according to NINCDS-ADRDA criteria (McKhann et al., 1984), following a semi-structured interview with the patient and an informant and detailed case history by the 
respective	   team	   in	   consultation	   with	   the	   team’s	   senior	   clinician.	   All	   participants	   had	  investigations including neuroimaging as part of their routine clinical care and investigations. 
NDC: Potential NDC were identified from other research projects at the department of Old Age Psychiatry, Institute of Psychiatry  i.e., AddNeuroMed project, a European Union study, which has recruited a cohort of healthy elderly controls, AD and MCI subjects. (AddNeuromed:http://www.innomed-addneuromed.com).  Eligible participants were invited to participate in the study and given the information sheet. Informed consent was then sought from those who have indicated willingness to 
participate,	  after	  a	  “cooling-off period”	  of	  at	  least	  24	  hours.	  	  Especial	  care	  was	  taken	  to	  emphasise that refusal to participate, or withdraw from the study at any time, will not 
affect	   participant’s	   clinical	   treatment	   in	   any	   way.	   Consent	   was	   also	   sought	   from	   the	  participants to obtain further demographic and clinical data from the medical notes. A time convenient for the participant was arranged for the assessment and was conducted at their own home or in outpatient clinic.  
3.2.3 Study design and assessments Baseline assessments were performed with a follow up assessment after three months.  The clinical assessments carried out were as described below:    3.2.3.1. Mini-Mental State Examination (MMSE) (Folstein et al., 1975) General cognition was assessed using the MMSE which is a brief cognitive test used widely in clinical and research setting to screen for cognitive impairment and decline 
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(Salmon et al., 1990, Behl et al., 2005). The MMSE assesses orientation, immediate and short-term recall, attention, language and copying of a drawing. The MMSE has a maximum score of 30. It has been shown that the MMSE is equally sensitive to change in the mild to moderate demented Alzheimer patients (Salmon et al., 1990). A number of investigators have reported average annual rate of change (ARC) of approximately 2 to 4 points for the MMSE (Salmon et al., 1990, Behl et al., 2005, Galasko et al., 2000, Morris et al., 1993). The patients and families account of symptom progression was also noted in addition to loss of points on the MMSE in the previous 6 months.  
3.2.3.2. Neuropsychiatric Inventory (NPI) (Cummings et al., 1994) NPI is a useful instrument for characterizing the psychopathology of dementia syndromes and for assessing the efficacy of treatment. The NPI is based on a structured interview with a caregiver who is familiar with the patient. It evaluates 12 neuropsychiatric disturbances common in dementia: delusions, hallucinations, agitation, dysphoria, anxiety, apathy, irritability, euphoria, disinhibition, aberrant motor behaviour, night-time behaviour disturbances, and appetite and eating abnormalities. The severity and frequency of each neuropsychiatric symptom is rated and a total score calculated. Test-retest scores of all measures have been significantly correlated; with overall correlation of 0.79 for frequency (p=0.0001) and 0.86 for severity (p=0.0001) (Cummings, 1997).   
 
3.2.3.3. Bristol Activities of Daily Living Scale (BADL)  (Bucks et al., 1996) The assessment is a carer rated instrument consisting of 20 daily-living abilities. It has good 'test-retest' reliability as measured by Cohen's Kappa and it correlates well with the Mini-Mental State Examination. 
 
3.2.3.4. Olfactory identification test: University of Pennsylvania smell identification test 
(UPSIT) (Doty et al., 1984a) UPSIT is a standardised test of odor identification with good test-retest reliability (r=0.95) and strong correlation with detailed olfactory threshold tests (r=0.80) (Doty et al., 1995). This "scratch 'n sniff" olfactory test consists of four booklets containing 10 odorants apiece; one odorant per page. The stimuli are embedded in 10-50microm 
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diameter microcapsules fixed in a proprietary binder and are positioned on brown strips at the bottom of each page. Above each odorant strip is a multiple-choice question with 4 response alternatives for each item (figure 3.2).   Only people fluent in English were recruited. Patients with history of language or speech difficulties (dysphasia) were not included. A formal testing for object recognition was not carried out.  Previous literature shows that one of the most dramatic ways to affect odor identification performance is to provide people with alternative labels for an odor they are trying to name. For familiar odors, identification performance is about 85% or better when alternative odor labels are provided (Cain and Krause, 1979, Doty et al., 1984b). This has been demonstrated and replicated in a study which demonstrated that recognition memory and odor naming were both better when the naming task provided participants with odor label alternatives (Frank et al., 2011).  UPSIT used in the current study provides 4 alternatives for each item, which are familiar odors from day to day life such as rose, onion, lemon etc. (Doty et al., 1984b). 
 




The items follow	   a	   standard	   format.	   An	   example	   is:	   ‘this	   odour	   smells	   most	   like:	   a)	  
chocolate;	  b)	  banana;	  c)	  onion;	  or	  d)	  fruit	  punch’.	  This	  is	  a	  forced	  choice	  procedure;	  for	  the test to be valid, participant must make a choice, even if they smell nothing. The tests were administered in a standard way used by the University of Pensylvania group, with one exception; the odor tapes were divided in half so that each booklet could be used for two subjects, done previously in AD studies (Warner et al., 1986).  A short explanation was given at the first and then the odour was released by scratching the strip using the pencil provided with the booklet. The odour was immediately released from the test strip and the participant was given the booklet to smell. The participant smelled the strip on the booklet, and then read the four choices given. They were allowed to smell and read out as many times as they needed to make a choice. An examiner assisted all subjects with the test and allowed them unlimited time. The UPSIT has been used in British population to differentiate dementia patients from normal elderly British subjects tested in their homes (Gray et al., 2001) and as a treatment response marker (Velayudhan and Lovestone, 2009).   
3.2.4 Statistical analysis: 
Power Calculation: A total sample size of 46 will be required, assuming a conservative effect size (f2) of 0.3, for UPSIT to predict MMSE decline, with a power of 0 .95 and alpha error probability of 0.05 (2-tailed) in a linear regression model (Faul et al., 2009).  
Data analysis: SPSS 20.0, STATA 10 and Excel 2010 were used for statistical analysis of the data. Chi-Square,	   student’s	   t-test, correlation analysis (Spearman non-parametric test) and non-parametric Mann-Whitney tests was used for comparing the socio-demographic and clinical parameters (MMSE, NPI, UPSIT and BADL) between groups: AD dementia subjects and NDC; rapid cognitive decliners and non-rapid cognitive decliners. Linear regression was performed with the MMSE scores over follow up as the dependent variable and baseline UPSIT scores, age, baseline MMSE scores, duration of illness, gender, education and follow up time as predictive variables within the whole 
Alzheimer’s	  disease	  sample.  Patients were classified as AD dementia Cognitive Rapid Decliners (RCD), based on a 
decline	   of	   ≥2	   points	   at	   baseline	   in	   the	   previous	   6	   months,	   of	   Mini Mental State 
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3.3 Results  Of 64 AD dementia patients who were eligible and agreed to participate in the study, 57 successfully completed both the baseline and follow up assessments. 7 patients dropped out owing to developing stroke, being hospitalised or moving to institutional care in a different locality. In the NDC group, out of the 28 subjects recruited, 25 subjects completed both the baseline and follow up assessments.  Among the AD dementia participants some received either donepezil 5 mg/day (n=18) or galantamine 8mg/day (n= 13) for initial 4 weeks, which was then increased to 10mg/day (donepezil) or 24 mg/day (galantamine) by their respective clinical teams as per the local Trust policy respectively. 3 patients were already on donepezil 10 mg/day at the point of recruitment. Some patients (n=23) were not on cholinesterase inhibitors because of reasons such as cardiac contraindications, intolerance, patients not willing for therapy or compliance issues. None of the patients reported subjective impairment in olfaction. All participants were white Europeans, except for one male and a female in each group.  Within the AD dementia subjects, 28 were classified as rapid decliners as defined by the on-priori definition with loss of 2 or more MMSE scores in the previous 6 months.  
 
3.3.1 Association of olfactory function with baseline cognition and prospective 
cognitive decline in mild-mod AD dementia  As described above, the AD dementia subjects were classified as RCD (n=28) and Non-
Rapid	  Cognitive	  Decliners	  (NRCD)	  (n=29),	  based	  on	  a	  decline	  of	  ≥2	  MMSE	  points	  in	  the	  previous 6 months, at the baseline. The 2 groups were not different in age, gender, duration of illness; follow up period, family history or the number of subjects on cholinesterase inhibitors therapy. However, the RCD had lower baseline MMSE (statistically significant) and UPSIT (statistically not significant) measures compared to NRCD (Mann-Whitney U test) (table 3.1b, figure 3.3). The follow up MMSE and UPSIT scores were both low for the RCD compared to NRCD (statistically significant) (Mann-Whitney U test) (table 3.1b, figure 3.3). The baseline UPSIT score correlated with both 
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Table 3.1- Comparison of socio-demographic-clinical parameters between the 
groups: a) AD dementia subjects and non-demented controls; b) Within AD 
dementia cohort: rapid cognitive decliners and non-rapid cognitive decliners     




a. AD dementia subjects and non-demented controls       b. Comparisons within  AD dementia  subjects (n=57)                                                                                                           














  (n=29) 
 
p-value       
 Female/male  35/22  14/10 N.Sª  16/12  19/10 N.Sª Age, years 81.4 (5.4)  77.3 (6.6) <0.01* 80.6 (5.7)  82.1 (5.1) N.S* Education 10.6 (1.4)  14.2(4.7) <0.001*   10.7 (1.5) 10.4(1.3) N.S* Duration of illness 27.8 (27.1)    n/a  n/a 27.5 (21.5)  28.1(22.4) N.S* MMSE baseline 21.6 (3.7)  29.1(0.9) <0.001*   20.1 (2.9)  23.0(3.5) 0.001* MMSE FU 21.7 (3.9) 29.2 (0.7) <0.001*   20.4 (3.5) 22.9 (4.0) 0.02* UPSIT baseline 16.1(5.3) 28.6 (5.8) <0.001*   15.0 (4.9) 17.2 (5.2) 0.07* UPSIT FU 16.1 (5.4) 28.8 (5.9) <0.001*   14.4 (5.3) 17.8 (5.2) 0.02* BADL baseline 9.3 (7.3) n/a n/a 9.5 (7.6) 9.1 (7.1) N.S* BADL FU 9.6 (7.1) n/a n/a 9.4 (7.6) 9.9 (6.6) N.S* NPI baseline 7.0 (9.9) n/a n/a 7.1 (9.2) 6.9 (10.8) N.S* NPI FU 5.5 (7.9) n/a n/a 5.2 (5.6) 5.7 (9.5) N.S* Family H 16 (34%) 0% 0.001ª 8 (28.6%) 8 (27.6%) N.Sª Follow-up in weeks 19.9 (10.1) 28.1(11.9) <0.01* 21.8 (13.2) 18.2 (5.4) N.S* UPSIT time 26.7(9.2) 18.4 (6.4) <0.01* 26.9 (10.6) 26.6 (7.6) N.S* CI Therapy 34 (59.6%) n/a n/a 14 (50%) 20 (69%) N.Sª 
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Table 3.2 - Linear regression analysis with the follow up MMSE scores as the 
dependent variable and baseline UPSIT scores, age, baseline MMSE scores, 
duration of illness, gender, follow up in weeks and cholinesterase therapy 
alternatively (Model 1) or simultaneously (Model 2) entered as predictive 
variables	  within	  the	  whole	  Alzheimer’s	  disease	  sample. 
 
 R2 (%)  Beta T-value P value    Model 1             UPSIT baseline 0.16  0.401 3.243 <0.01*        Age in years 0.01  0.075 0.560 0.578        Education 0.00  -0.017 -0.122 0.903        Duration of illness 0.03  0.179 1.337 0.187        MMSE baseline 0.49  0.698 7.237 <0.001*        Gender 0.08  -0.285 -2.209 0.031*        Follow up in weeks        CI therapy 0.01 0.01  -0.112 0.085 0.837 0.631 0.406 0.531    Model 2             UPSIT baseline                    MMSE baseline                 Gender   
   0.165 0.619 -0.205 1.685 6.321 -0.229 0.098 <0.001* 0.030*            
  
 R2 (%) = R2 value in percent for the overall model; *, p < 0.05  MMSE, Mini Mental State Examination; UPSIT, University of Pennsylvania Smell Identification Test; CI, Cholinesterase inhibitor  
3.3.2 Comparison of AD dementia and NDC subjects:  The socio-demographic and clinical comparison between the AD dementia subjects and the NDC are as described in Table 3.1a. The NDC were younger and had higher education. They scored higher on the baseline MMSE and UPSIT measures. The AD dementia patients took longer to complete the UPSIT and more AD dementia patients had a family history of dementia. At follow up the MMSE and the UPSIT loss was not different from baseline within the groups (table 3.1a, figure 3.3). The subjects who dropped out were similar to the subjects in main data in their demographic and baseline data. The 7 AD dementia patients had mean age of 84.6 years (±5.5), 12.8 years of education (±2.7), mean MMSE scores 21 (±4) and mean UPSIT scores 14.4 (±7.3). The 4 NDC subjects had mean age of 77.5 years (±11.5), 15 years of education, mean MMSE scores 28.8 (±0.5) and mean UPSIT scores 26.5 (±11.8). 
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Figure 3.3 - Line plot representation of baseline and follow up MMSE and UPSIT 
scores	  between	  subjects	  with	  Alzheimer’s	  disease	  dementia (Rapid Cognitive 























Table 3.3 - Characteristics and cognitive performance of rapid olfactory 
progressors and slow olfactory progressors AD patients 
  Values are mean (SD) or n (%); ª Calculated using the χ² test, b Calculated using the t test, *   Wilcoxon paired test; AD,	  Alzheimer’s	  disease;	  NDC,	  non-demented controls; MMSE, Mini Mental State Examination; UPSIT, University of Pennsylvania Smell Identification Test; CI, Cholinesterase inhibitor; FU, follow up; BADL, Bristol Activities of daily living, NPI, Neuropsychiatric Inventory 
Variables                           Rapid Olfactory 
Progressors (n=25)  
Slow Olfactory 
Progressors (n=32) 
p-value       
 Female/male  17/8  18/14 N.Sª Age, years 81.9 (6.0)  80.9 (4.9) N.S* Education 10.8 (1.5)  10.3(1.2) N.S* Duration of illness 27.3 (19.0)  28.1 (24.0) N.S* MMSE baseline 20.2 (3.1)  22.7(3.6) 0.01* MMSE FU 19.7 (3.1) 23.3 (3.3) 0.001* UPSIT baseline 11.8(2.2) 19.6 (4.1) <0.001* UPSIT FU 13.4 (4.5) 18.3 (5.2) 0.001* BADL baseline 13.5 (7.3) 6.0 (5.4) <0.001* BADL FU 12.5 (8.1) 7.0 (4.8) <0.01* NPI baseline 9.7 (11.2) 5.0 (8.6) 0.05* NPI FU 7.4 (5.7) 4.2 (9.2) <0.01* Family H 7 (28%)  9 (28%) N.Sª Follow-up in weeks 20.6 (11.3) 19.4 (9.3) N.S* UPSIT time 27.4(11.5) 26.2 (6.9) N.S* CIs 16 (64%) 18 (56%) N.Sª 
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3.3.3 Association between olfactory function and other non-cognitive symptoms 
in AD dementia  Using a median divide the AD dementia participants were further classified into Rapid 
Olfactory	   Progressors,	   ROP,	   (UPSIT≤15;	   n=25) and Slow Olfactory Progressors, SOP, 
(UPSIT	   ≥16;	   n= 32). The two groups were similar in their socio-demographic data, family history, follow-up time and cholinesterase inhibitors treatment (table 3.3). However the ROP subjects had lower MMSE and lower UPSIT implying more cognitive and olfactory impairment (table 3.3). They also had higher BADL and NPI scores reflecting more functional deficits and more non-cognitive behavioural and psychological symptoms (table 3.3).   
3.4 DISCUSSION Olfactory dysfunction has been studied as a diagnostic marker as well as a marker of conversion in AD dementia . However, this is the first study to investigate olfactory dysfunction as a severity and progression marker in dementia due to AD to my knowledge.  AD dementia  participants were deliberately chosen in the early stages (mild-moderate) of the disease, so that there is little question of their ability to understand and perform the smell test. None of the AD dementia participants had speech or language difficulties.  
 




3.4.2 Olfaction and cognition:  This study showed clear evidence of a relation of olfactory function with cognition. A) Olfactory identification function was correlated with baseline cognition. B) The rapid and slow olfactory progressors correlated with the rapid and non-rapid cognitive decliners group.   Previous studies have found strong correlations between olfactory identification and cognitive performances (Serby et al., 1991, Larsson et al., 1999, Hidalgo et al., 2011). Olfactory discrimination and identification have been more closely associated with higher cognitive functions and subsequent cognitive decline (Sohrabi et al., 2009, de Wijk and Cain, 1994, Sohrabi et al., 2012). A large-scale study in older adults (n=1920) on the relationship between olfactory identification ability and general cognitive functioning (as measured by MMSE) indicated that olfactory dysfunction at baseline was significantly predictive of future cognitive impairment after 5 years (odds ratio (OR)=6.62; confidence interval (CI)=4.36–10.04) (Schubert et al., 2008). A strong association between cognitive functions and olfactory functioning has been reported and it has been  concluded that compared with the ability to detect odours, identification of odours is more challenging, perhaps due to a lack of access to verbal or visual representations of odours (Richardson and Zucco, 1989). Similarly, Schab noted that odours identification may represent a semantic memory function (Schab, 1991). Some researchers suggest that olfactory identification is primarily predictive of memory decline (Swan and Carmelli, 2002). In a functional magnetic resonance imaging (fMRI) study, the blood oxygen level-dependent (BOLD) signal at primary olfactory cortex (POC) was found to be weaker in AD than in healthy control subjects (Wang et al., 2010). At the lowest odorant concentration, the BOLD signals within POC, hippocampus, and insula significantly correlated with UPSIT, MMSE, DRS-2, and CDR scores, demonstrating that olfactory fMRI is sensitive to the AD-related olfactory and cognitive functional decline (Wang et al., 2010). 
 
3.4.3 Olfaction and non-cognitive symptoms:  The present study showed that higher olfactory impairment was associated with more dependence in functional abilities at the baseline. Olfactory function has been 
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associated with functional dependence previously in subjects with MCI and normal elderly (Wilson et al., 2007b). A previous report from our cohort had shown that olfaction scores predicted improvement better than cognitive scores as indicated by global and functional improvement in AD dementia patients receiving cholinesterase inhibitor therapy (Velayudhan and Lovestone, 2009).   Interestingly the present study also found an association in the olfactory rapid decliners group with behavioural symptoms (NPI) (Table3.3). This has not been reported previously. This could be as most of the previous studies have focussed association of olfaction with cognition. This needs to be explored further in future studies.  On the whole, the study results reflect that higher olfactory impairment is indicative of more symptomatic illness or severity, i.e., lower cognition, higher functional dependence and presence of behavioural symptoms.   The baseline UPSIT scores predicted the follow up MMSE in an unadjusted model, however, losing this effect in adjusted model with MMSE and gender. Further a linear mixed effect model showed that although baseline UPSIT was associated with MMSE at the baseline, there was no association between baseline UPSIT and MMSE change (decline) over the two time points. This could have been the influenced by the cholinesterase inhibitors therapy in some patients which influences UPSIT scores more than the cognitive scores (Velayudhan and Lovestone, 2009a) and also the short follow up period. Also there were more females than males in the cohort, who perform better on the olfactory tasks than men (Murphy et al., 2002, Mullol et al., 2012).  Main limitations of the study are its small sample size and single point follow-up over a short duration. Longer follow up with multiple point testing and assessments of cognitive, functional and behaviour changes, would be more informative of predictive ability of the olfactory function for illness progression in AD dementia.   Gender was predictive of lower follow-up MMSE scores, with women losing more MMSE points over follow up period. The possible explanation could be that women have a higher risk of developing AD above 80 years of age (Copeland et al., 1999). The present 
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AD dementia cohort had a mean age above 80 years (81.5), so the progression too must have been faster in women than men.  A diminished sense of smell has practical implications in relation to AD dementia, such as decreased appetite, with resultant weight loss and poor nutritional status. Other problems may be the inability to detect noxious odours such as gas and smoke. Patient and family, both should be made aware of this deficit and the potential problems this may cause.  In conclusions, the study confirms associations of olfaction with cognition in mild to moderate AD dementia and supports the utility of the smell identification function as an adjunct clinical measure to assess severity in AD dementia. Further work, including larger longitudinal studies, is needed to explore its value in predicting AD dementia progression. 























PLASMA PROTEINS AS MARKERS OF PROGRESSION IN ALZHEIMER’S	  
DISEASE          
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 4.1 Paper 1 
Association of Plasma Clusterin Concentration with Severity, Pathology, and 
Progression in Alzheimer Disease Thambisetty M, Simmons A, Velayudhan L, et al. Archives of General Psychiatry, 2010  
4.1.1 MY CONTRIBUTION In this novel proteomic-neuroimaging discovery paradigm; a multi-authored complex paper which used multiple techniques, I made an essential contribution towards the discovery and identification of the clusterin, in human plasma, as a marker of disease progression	  in	  Alzheimer’s	  disease	  (AD)	  dementia.  
‘Slow	  vs	  fast	  progressors	  in	  AD’	  section	  of	  the	  paper In this study I contributed to the design, carried out the proteomic experiments, did detailed statistical analysis, and interpretation as described below. I contributed to writing up of this part of the manuscript and to the necessary corrections following submission and anonymous peer review process, under the supervision of Prof Simon Lovestone who was the principal investigator of this collaborative project and the corresponding author.   The methods and results for identification of the plasma protein clusterin, as AD progression marker, are described below: 
 
4.1.2 METHODS 
4.1.2.1 Samples and subjects Samples used came from two studies – the Alzheimer’s	  Research	  Trust	  funded	  cohort	  at	  KCL (KCL ART) (Hye et al., 2006) and AddNeuroMed (Lovestone et al., 2007a) studies. The KCL ART study is a cohort of people with AD, MCI and normal elderly started in 2001 for the purpose of biomarker discovery and validation. All subjects were white UK citizens with grandparents born in the UK and are assessed annually.  AddNeuroMed is a cross-European cohort founded for biomarker discovery; AD dementia cases are assessed 3 monthly in the first year and annually thereafter, MCI and control groups are 
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assessed annually. All subjects are white Europeans recruited from UK, France, Italy, Finland, Poland and Greece.  Cases with probable AD according to NINCDS-ADRDA criteria were recruited through secondary care as previously described (Hye et al., 2006) and evaluated with a standardised assessment previously shown to have high diagnostic validity against assessment at post mortem (Foy et al., 2007)(Institute of Psychiatry ethics number 06/Q0706/50). The full standardized assessment includes demographic and medical information, cognitive assessment including MMSE (both studies), ADAS-cog (AddNeuroMed only) and CERAD battery, and scales to assess function, behavior and global levels of severity including the CDR. Cases with amnestic MCI were defined as subjective memory complaint, CDR score <1 and evidence for objective memory impairment using the CERAD delayed word list recall (-1.5SD cut off). MCI cases were recruited from both primary and secondary care. Normal elderly controls, defined as having no evidence of cognitive impairment, were recruited systematically from primary care patient lists in the case of the KCL ART study and from primary care and from elsewhere in the AddNeuroMed study. Peripheral venous blood has been collected at baseline (initial assessment) and at subsequent time points and stored at -80°C according to rigorous standard procedures. The blood samples are collected in 9ml EDTA tube for plasma. 
 
4.1.2.2. Discovery-phase proteomic experiments 
4.1.2.2.1 Subjects and samples I examined samples from 51 subjects with mild-moderate AD dementia (NINCDS-ADRDA criteria; target MMSE>10) from the AddNeuroMed cohort. Patients were characterised as fast progressors based on a decline of 2 or more points on the Alzheimer disease assessment scale – Cognitive (ADAS-COG) score from baseline to the 6-month follow-up	  time	  point.	  Using	  this	  criterion,	   I	  characterised	  22	  subjects	  as	   ‘fast’	  






4.1.2.2.2 2D Polyacrylamide Gel Electrophoresis (2-D PAGE)  I analysed the plasma samples from selected AD dementia subjects from the AddNeuroMed cohort using 2DGE and followed it by tandem mass spectrometry as previously described (Hye et al., 2006). Briefly in 2DGE plasma proteins were separated in the first-dimension according to isoelectric points, on immobilised pH (3-11) gradient strips. This was followed by the second-dimension step, SDS polyacrylamide gel electrophoresis, separating proteins according to molecular weight. Separated proteins were then visualised following silver staining.    I used Progenesis SameSpots v3.0 (Nonlinear Dynamics) for 2D gel image analysis and to obtain the spot normalised values from each gel. Prominent spots were used to manually assign vectors to each gel image. The vectors were used to warp the images and align the spot positions to a common reference gel. Image warping is a nonlinear deformation, basically a smooth mapping between 2 image planes that maps every point in one image to a point in another; in this case every spot in an image to a point in the reference image. The proprietary warping algorithms used by Nonlinear Dynamics spatially align common motifs within different gel images to a common reference gel, thus compensating for any distortions of protein spot patterns arising from gel-to-gel variation. Nonlinear Dynamics uses a combination of image warping and matching to achieve the best possible matching data, to compare identical protein spots across different gels, facilitating the exploration of expression changes under different experimental conditions.  Spot detection was performed on this reference gel after editing and removing artefacts after visual checking of each spot.  Of the 1157 spots identified, I successfully matched 413 spots across every gel between the two subject groups.   Statistics Statistical analysis was performed using SPSS (15.0) and Partial least squares discriminant analysis (PLS-DA).  Shapiro-Wilk test was done to test for normality of the integrated optical densities (OD) of spots on the 2D gels. Multivariate analysis (PLS) was 
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done to derive a panel of protein spots that discriminated between fast and slow progressor groups of AD dementia patients. Non-parametric tests (Mann-Whitney) with correction for multiple comparison tests was then used to compare individual spot OD between subject groups. I found 27 spots that were significantly different between the 2 groups with fold changes between 1.1-1.4.  Based on protein spots with highest Variable of Importance (VIP), 9 spots were excised, proteolysed and the resulting peptides analysed using LC/MS/MS (figure 4.1). 
 













Figure 4.1 - A representative of 2 dimensional gel electrophoresis blot of from one 












Table 4.1 - Results of LC/MS/MS analysis on nine 2D gel spots of interest of 
Human plasma  
        
Spot Protein I.D. Species Accession MW pI No. Percentage Sequence Matched 
ID     No. (Da)   Peptides Coverage   
            Matched     0023 Complement C4-A precursor  Human P0C0L4  192650 6.65 7 6%   694 Fibrinogen gamma chain precursor  Human P02679  51479 5.37 11 38%     Hemopexin precursor  Human P02790  51643 6.55 7 18%     Ig gamma-4 chain C region  Human P01861  35918 7.18 3 11% GPSVFPLAPCSR                 STSESTAALGCLVK                 NQVSLTCLVK 1149 Complement component C8 gamma chain precursor  Human P07360  22264 8.49 8 54%   162 Clusterin precursor  Human P10909  52461 5.89 5 10% EIQNAVNGVK                  TLLSNLEEAK                  KTLLSNLEEAK                  ASSIIDELFQDR                  EPQDTYHYLPFSLPHR  510 Complement C4-A precursor  Human P0C0L4  192650 6.65 23 16%     Ig gamma-1 chain C region  Human P01857  36083 8.46 5 22% GPSVFPLAPSSK                 FNWYVDGVEVHNAK                 NQVSLTCLVK                 GFYPSDIAVEWESNGQPENNYK                 TTPPVLDSDGSFFLYSK 502 Complement C4-A precursor  Human P0C0L4  192650 6.65 26 15%     Ig gamma-3 chain C region  Human P01860  32310 7.89 2 9% SCDTPPPCPR                 EPQVYTLPPSREEMTK   Ig gamma-1 chain C region  Human P01857  36083 8.46 2 7% FNWYVDGVEVHNAK                 NQVSLTCLVK 183 Apolipoprotein A-I precursor  Human P02647  30759 5.56 34 86%   1085 Apolipoprotein A-I precursor  Human P02647  30759 5.56 36 84%     Apolipoprotein M Human O95445  21239 5.66 6 26%     Lysozyme C precursor  Human P61626  16526 9.38 1 8% STDYGIFQINSR   Serum albumin precursor  Human P02768  69321 5.92 1 1% LVNEVTEFAK 1542 Transthyretin precursor  Human P02766  15877 5.52 13 73%   
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4.1.2.3  Validation-phase experiments 
4.1.2.3.1 Clusterin  Clusterin was a protein found common in the discovery study and another study by a colleague within the centre, comparing AD dementia patient and controls. Therefore, further validation of clusterin protein was planned, in larger cohort, to test for its robustness as a progression marker.   Clusterin, a major glycoprotein was identified by Irving Fritz and his laboratory in 1983 and named so since it was able to aggregate several cell types, e.g. Sertoli cells, and was involved in spermatogenesis (Fritz et al., 1983). Clusterin has been called a number of different names due to its versatile functional capacities, e.g. apolipoprotein J (ApoJ),  sulfated glycoprotein-2 (SGP-2), secreted glycoprotein gp80, complement-associated protein SP-40,40, complement lysis inhibitor (CLI), and testosterone repressed prostate message 2 (TRPM-2).  Clusterin was approved as the official name at the First International Clusterin Workshop in 1992.  The first time that clusterin was associated to Alzheimer's disease was in work done in the laboratory of Caleb Finch (May et al., 1990). They demonstrated that the expression of clusterin was clearly increased in hippocampal samples of patients with AD compared to the age matched controls. After these original observations, the role of clusterin has been extensively studied in the pathogenesis of AD (Nuutinen et al., 2009a). It was observed that clusterin can bind amyloid-β	  peptides and prevent their fibrillization (Ghiso et al., 1993, Zenkel et al., 2006). Clusterin is also involved in the clearance of amyloid-β	   peptides and fibrils by binding to megalin receptors and enhancing their endocytosis within glial cells (Hammad et al., 1997, Cole and Ard, 2000, Bartl et al., 2001, Wang et al., 2006).  Clusterin is a complement inhibitor and can suppress complement activation observed in AD (Choi-Miura et al., 1993, Zwain et al., 1994, Santilli et al., 2003). Clusterin is also present in lipoprotein particles and regulates cholesterol and lipid metabolism of brain which is disturbed in AD (Calero et al., 1999, Reid et al., 2007, Hooijmans and Kiliaan, 2008, Hirsch-Reinshagen et al., 2009). Clusterin is a stress-induced chaperone which is normally secreted, but in conditions of cellular 
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stress, it can be transported to cytoplasm where it can bind to Bax protein and inhibit neuronal apoptosis (Zhang et al., 2005). Clusterin can also bind to Smad2/3 proteins and potentiate the neuroprotective transforming growth factor- β	   (TGFβ)	   signalling (Lee et al., 2008). An alternative splicing can produce a variant isoform of clusterin which can be translocated to nuclei where it induces apoptosis (Leskov et al., 2003).  To confirm the findings from the discovery phase that the plasma clusterin levels was altered between fast and slow progressors, quantitative analysis of clusterin was carried out in a larger independent cohort of AD dementia patients and correlated with the rate of cognitive decline and severity.   
4.1.2.3.2. Subjects and samples details Samples used came from two studies – the Alzheimer’s	  Research	  Trust	  funded	  cohort	  at	  KCL (KCL ART) (n=114) (Hye et al., 2006) and AddNeuroMed (n=239) (Lovestone et al., 2007a) studies. The KCL ART study is a cohort of people with AD, MCI and normal elderly started in 2001 for the purpose of biomarker discovery and validation. All subjects were white UK citizens with grandparents born in the UK and assessed annually. AddNeuroMed is a cross-European cohort founded for biomarker discovery; AD cases were assessed 3 monthly in the first year and annually thereafter, MCI and control groups assessed annually. All subjects were white Europeans recruited from UK, France, Italy, Finland, Poland and Greece.  Cases with probable AD according to NINCDS-ADRDA criteria were recruited through secondary care as previously described (Hye et al., 2006) and evaluated with a standardised assessment previously shown to have high diagnostic validity against assessment at post mortem (Foy et al., 2007). The full standardized assessment includes demographic and medical information, cognitive assessment including MMSE (both studies), ADAS-cog (AddNeuroMed only), and scales to assess function, behaviour and global levels of severity including the CDR. Normal elderly controls, defined as having no evidence of cognitive impairment, were recruited systematically from primary care patient lists in the case of the KCL ART study and from primary care and from elsewhere in the AddNeuroMed study.  Peripheral venous blood has been collected at baseline (initial assessment) and at subsequent time points and stored at -80°C according to rigorous standard procedures. 
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The blood samples were collected in 9ml EDTA tube for plasma. All samples were collected in the morning following a 2 hour fasting. They were processed and stored within 2 hours of collection. Plasma samples from AD dementia patients identified from both the AddNeuroMed (n=239) and KCL-ART (n=114) with longitudinal assessments over 1 year studies were used for these experiments. Since ADAS-Cog scores were not obtained in the KCL-ART study, rate of decline in MMSE scores was used for classification of fast and slow progressors. MMSE scores obtained at the baseline blood sampling were used to derive an annualised retrospective progression rate in order to stratify AD patients into fast and slow progressors by using the equation: Progression rate = (30)-(MMSE score at the time of blood sampling)/duration of illness in years. The fast progressors were those with a decline of more than 2 MMSE points per year. Similarly, an annualised prospective progression rate was calculated in the combined AddNeuroMed and KCL-ART cohorts by calculating the decline in MMSE score one year after blood sampling and those with a decline of more than 2 MMSE points per year were defined fast progressors. 
4.1.2.3.3 Clusterin ELISA assay Plasma concentration of clusterin was assayed by a commercially available ELISA kit (Human Clusterin ELISA, RD194034200R, Biovendor Laboratory Medicine Inc). All samples were run in duplicate and the overall coefficient of variance (CV) was 3.5%.   




4.1.3 RESULTS: The sociodemographic and clinical parameters for rapid and non-rapid progressors in the discovery and validation phase are demonstrated in table 4.2 and 4.3. A significant increase in clusterin concentration in AD dementia patients was observed with accelerated cognitive decline prior to blood sampling (Figure-4.2) (ANCOVA; n=344; t(341)=3.40; p=0.0007; duration of disease as covariate) and an increase in clusterin concentration in AD dementia patients with faster cognitive decline subsequent to blood sampling (N=237; independent samples t-test, p=0.01).  
 









 Values are expressed as mean ±(SD)  § Differs from non-rapid decliners; p<0.001 
 
 
Table 4.3 - Validation phase:  AD dementia fast vs. slow decliners- combined ART 
and AddNeuromed Cohorts 
 Values are expressed as mean ± (SD); * p<0.001 
 
 
 Rapid progressors 
(n=22) 
Non-rapid 
progressors (n=29) Gender (M/F) 9/13 11/18 Age (years) 76 (7.1) 79 (6.8) Disease duration (years) 4.1 (3.3) 5.0 (4.0) MMSE  20.7 (4.3) 20.9 (5.2) Rate of decline in ADAS-Cog score  7.95 (5.2)§ -3.3(4.5) 
 Retrospective decline Prospective decline  Fast decliners (n=219) Slow decliners (n=125) Fast decliners (n=115) Slow decliners (n=122) Sex (M/F) 74/145 54/71 43/72 47/75 Age (years) 78.0 (6.2) 77.7 (6.4) 77.7 (6.3) 77.5 (6.4)  Rate of decline in MMSE per year 4.5 (2.7) 1.1 (1.0) * 5.0 (3.2) -0.9 (2.0) * Disease duration (years) 3.9 (2.4) 6.4 (3.8) * 4.7 (3.3) 4.0 (3.3) 
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Figure 4.2 - AD dementia patients with a rapid retrospective progression rate  

















This study which used a combined proteomic and neuroimaging approach, showed plasma clusterin was positively associated with brain atrophy in the hippocampus and entorhinal cortex, baseline disease severity, and rapid clinical progression in  dementia due to AD, suggesting it as a possible plasma biomarker of AD (Thambisetty et al., 2010). This result was confirmed in transgenic mice that had marked cerebral Aβ	  deposition and cognitive defects (Thambisetty et al., 2010).    Clusterin and its role as an amyloid chaperone is further discussed in chapter 6, section 6.4.1. 
 
ORIGINAL ARTICLE
Association of Plasma Clusterin Concentration
With Severity, Pathology, and Progression
in Alzheimer Disease
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Context: Blood-based analytes may be indicators of
pathological processes in Alzheimer disease (AD).
Objective: To identify plasma proteins associated with
AD pathology using a combined proteomic and neuro-
imaging approach.
Design:Discovery-phase proteomics to identify plasma
proteins associatedwith correlates of ADpathology. Con-
firmation and validation using immunodetection in a rep-
lication set and an animal model.
Setting:Amulticenter European study (AddNeuroMed)
and the Baltimore Longitudinal Study of Aging.
Participants: Patients with AD, subjects withmild cog-
nitive impairment, and healthy controls with standard-
ized clinical assessments and structural neuroimaging.
Main OutcomeMeasures: Association of plasma pro-
teinswith brain atrophy, disease severity, and rate of clini-
cal progression. Extension studies in humans and trans-
genicmice tested the association between plasma proteins
and brain amyloid.
Results:Clusterin/apolipoprotein J was associated with
atrophy of the entorhinal cortex, baseline disease sever-
ity, and rapid clinical progression inAD. Increased plasma
concentration of clusterin was predictive of greater fi-
brillar amyloid-!burden in themedial temporal lobe. Sub-
jects with AD had increased clusterin messenger RNA in
blood, but there was no effect of single-nucleotide poly-
morphisms in the gene encoding clusterin with gene or
protein expression. APP/PS1 transgenic mice showed in-
creased plasma clusterin, age-dependent increase in brain
clusterin, as well as amyloid and clusterin colocaliza-
tion in plaques.
Conclusions: These results demonstrate an important
role of clusterin in the pathogenesis of AD and suggest
that alterations in amyloid chaperone proteins may be a
biologically relevant peripheral signature of AD.
Arch Gen Psychiatry. 2010;67(7):739-748
P ERIPHERAL COMPARTMENTSincluding blood and cerebro-spinal fluid exhibit signals re-flecting neuropathologicalchanges in Alzheimer dis-
ease (AD).1,2 In cerebrospinal fluid, these
include a decrease in amyloid-! peptide
(A!) and an increase in total and phos-
phorylated tau concentrations,3 reflect-
ing amyloid sequestration as plaques and
neurofibrillary degeneration, respec-
tively.4,5 Similarly, while numerous ar-
ticles suggest that plasma concentrations
of several metabolites and proteins might
represent responses to neuropathologi-
cal changes in AD,6-11 these findings have
not been conclusively replicated.12 A limi-
tation of such studies may be their reli-
ance upon demonstrating changes be-
tween affected and unaffected people, a
design of study that might identify sec-
ondary changes lacking relevance to core
disease biology.
Advances in methods such as pro-
teomics present a further challenge in
case-control studies, often generating
data showing numerous analytes differ-
entially expressed in AD patients. How-
ever, validating these results with alter-
native methods in independent patient
Author Affiliations are listed at
the end of this article.
(REPRINTED) ARCH GEN PSYCHIATRY/VOL 67 (NO. 7), JULY 2010 WWW.ARCHGENPSYCHIATRY.COM
739
©2010 American Medical Association. All rights reserved.
57
populations has been difficult.13,14 These studies also
ignore the clinical heterogeneity in disease progression
in AD, wherein some patients show rapid cognitive
decline, while others remain relatively stable and/or
progress slowly.15,16
We applied mass spectrometry–based proteomics to
discover plasma proteins associated with disease, using
brain atrophy in AD as well as rapid clinical progres-
sion, rather than binary distinction between case and
control. As a proxy measure of in vivo pathology, we
used structural neuroimaging of atrophy in the hippo-
campus and entorhinal cortex (ERC), 2 components of
the medial temporal lobe (MTL) that show early patho-
logical changes in AD.17 For rate of clinical progression,
we used both retrospective and prospective measures of
cognitive decline. We initially performed 2 independent
discovery-phase studies using proteomic analysis of
plasma in separate groups of subjects. In the first, we
sought proteins that reflect hippocampal atrophy in
mild cognitive impairment (MCI) and established AD.
In the second, we identified proteins differentially
expressed in rapidly progressing AD patients relative to
those with a less aggressive disease course. Our aim was
to identify plasma proteins common to both paradigms,
followed by replication using quantitative immunoas-
says such as enzyme-linked immunosorbent assay
(ELISA) in a large independent cohort of AD, MCI, and




We used samples from 2 studies: the Alzheimer Research
Trust–funded cohort at King’s College London (KCL-ART)7
and the AddNeuroMed study.18 The KCL-ART study, which
began in 2001, includes a cohort of people with AD and
MCI19 and healthy elderly individuals. All subjects are white
UK citizens with grandparents born in the United Kingdom
and are assessed annually. AddNeuroMed is a cross-European
cohort; AD cases are assessed at 3-month intervals in the first
year and annually thereafter; MCI and control groups are
assessed annually. All subjects are white Europeans recruited
from 6 centers in the United Kingdom, France, Italy, Finland,
Poland, and Greece. Standardized assessments include demo-
graphic and medical information; cognitive assessment,
including the Mini-Mental State Examination (MMSE) (both
studies; all subjects), Alzheimer Disease Assessment Scale–
cognitive subscale (ADAS-cog) (AddNeuroMed only), and
Consortium to Establish a Registry for Alzheimer’s Disease
battery; and scales to assess function, behavior, and global lev-
els of severity, including the Clinical Dementia Rating. Cases
with probable AD (National Institute of Neurological and
Communicative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association [NINCDS-
ADRDA] criteria) and amnestic MCI were identified as previ-
ously described7 and evaluated with a standardized assess-
ment shown to have high diagnostic validity.20 Cases with
amnestic MCI were defined as having subjective memory
complaints, Clinical Dementia Rating scores of less than 1,
and evidence of objective memory impairment using the Con-
sortium to Establish a Registry for Alzheimer’s Disease
delayed word list recall (−1.5-SD cutoff). Normal elderly con-
trols, defined as having no evidence of cognitive impairment
(MMSE score "28), were recruited systematically from pri-
mary care patient lists in the KCL-ART study and from both
primary care services and elsewhere in the AddNeuroMed
study. Blood samples were collected and stored as previously
described.7,18 In total, we studied 95 and 689 subjects in dis-
covery and validation studies, respectively, with an additional
60 subjects from the Baltimore Longitudinal Study of Aging
(eTables 1-4, available at http://www.archgenpsychiatry.com).21
Ethical approval was obtained in each of the participating
countries.
NEUROIMAGING
Magnetic Resonance Imaging Data Acquisition
In the KCL-ART study, whole-brain coronal 3-dimensional
spoiled-gradient recalled images (repetition time=14 millisec-
onds, echo time=3 milliseconds, 256#192#124 acquisition
matrix, 1.5-mm slices) were obtained on a GE Signa 1.5-T
neuro-optimized magnetic resonance system. In the
AddNeuroMed study, whole-brain sagittal 3-dimensional
magnetization-prepared rapid acquisition gradient echo
images (repetition time=8.6 milliseconds, echo time=3.8 mil-
liseconds, 256#192 acquisition matrix, 180#1.2–mm slices)
were obtained on a 1.5-T magnetic resonance system at each
of the 6 centers. Quality control was undertaken using the
ADNI Magphan phantom and 2 volunteers who visited each
of the centers, ensuring compatibility across the study. Thick-
ness of the ERC was calculated with Freesurfer using a corti-
cal reconstruction technique.22,23
11C–Pittsburgh Compound B
Positron Emission Tomographic Studies
Dynamic 11C–Pittsburgh Compound B (11C-PiB) positron
emission tomographic (PET) studies (37 time frames across
90 minutes) were acquired in 3-dimensional mode on a GE
Advance scanner immediately after intravenous bolus injec-
tion of approximately 5.55#108 Bq (15 mCi) of 11C-PiB.
Dynamic images were reconstructed using filtered back pro-
jection with a ramp filter (image size, 128#128; pixel size,
2#2 mm; slice thickness, 4.25 mm), yielding a spatial resolu-
tion of about 4.5 mm full width at half maximum at the center
of the field of view. Parametric images of distribution volume
ratios were calculated by simultaneously fitting a reference tis-
sue model using linear regression and spatial constraint with
the cerebellum as a reference region.24,25 The SPM5 program
(Statistical Parametric Mapping 5; Wellcome Department of
Imaging Neuroscience, London, England) was used to investi-
gate the association between clusterin and medial temporal
11C-PiB retention (significance threshold of P$ .05, with a
spatial extent of 25 voxels). Based on a priori hypotheses in
light of our results on the association between ERC atrophy
and clusterin concentration in AD, a restricted search of the
MTL was performed using the regional definition from the
WFU PickAtlas.26
PROTEOMICS
Two-dimensional gel electrophoresis and liquid chromatogra-
phy coupled to tandemmass spectrometry (LC-MS-MS)wereper-
formed as previously described.7 Gels were analyzed using im-
age analysis software (eitherMelanie 2-DorProgenesis SameSpots
version, 3.0,NonlinearDynamics). Protein spots of interest were
excised,washed, digested in gelwith trypsin, and analyzedbyLC-
MS-MS.7Mass spectral datawere processed into peptide peak lists
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and searched against the Swiss-Prot Database usingMascot soft-
ware (Matrix Science, London, England).
Forvalidationexperiments,plasmaclusterinconcentrationwas
assayedby a commercially availableELISAkit (HumanClusterin
ELISA, RD194034200R; Biovendor Laboratory Medicine Inc,
Modric, Czech Republic). Samples were run in duplicate. Coef-
ficientofvariationoftheELISAforallstudiesoverallwas3.5%(base-





































































2-Dimensional gel electrophoresis is used to identify plasma proteins 
associated with hippocampal volume in MCI and AD (left) and 
accelerated rate of cognitive decline in AD (right)
Plasma concentration of clusterin is measured by a sandwich ELISA 
method to test associations with ERC volume in AD (left) and 
accelerated rate of cognitive decline in AD (right)
A priori criteria for validation of clusterin as a plasma biomarker of 
AD were association with:
 1. Atrophy on MRI
 2. MMSE score at baseline




In older humans using 11C-PiB PET
In hAPP/PS1 transgenic mice
A B
C
Figure 1. Study design. Schematic diagram of the design of discovery- (A) and validation- (B) phase studies for the identification of blood-based Alzheimer disease (AD)
biomarkers associated with both in vivo disease pathology as well as rate of disease progression. C, Association of plasma clusterin concentration with brain amyloid
burden was tested in both nondemented older humans and a transgenic mouse model of AD. ADAS-cog indicates Alzheimer Disease Assessment Scale–cognitive
subscale; ELISA, enzyme-linked immunosorbent assay; ERC, entorhinal cortex; HRP, horseradish peroxidase; LC-MS-MS, liquid chromatography coupled to tandem
mass spectrometry; MCI, mild cognitive impairment; MMSE, Mini-Mental State Examination; MRI, magnetic resonance imaging; NCBI, National Center for
Biotechnology Information; TMB, tetramethylbenzidine; and 11C-PiB PET, 11C–Pittsburgh Compound B positron emission tomography.
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GENOMICS
Gene Expression of Clusterin
Approximately 2.5mLof venous bloodwas collected into a PAX-
gene tube for each subject at the baseline visit, processed accord-
ing to themanufacturer’s instructions, and stored at −20°C over-
nightprior to−80°Cstorage.RNAwasextractedusing thePAXgene
Blood RNA kit according to the manufacturer’s instructions.
Samples were assessed for yield using a spectrophotometer and
quality using the RNA 6000 Pico Chip on the Agilent Bioanaly-
ser. Sampleswith anRNA integrity number greater than 7.0were
used for polymerase chain reaction (PCR) assays.
Using theQuantitect Reverse Transcription kit (Qiagen), 500
ng of RNA was reverse transcribed to complementary DNA in a
40-µL reaction and subsequently diluted to 200 µL. Reverse tran-
scriptase–PCR reactionswere performed in 384-well plates in the
7900HTFast Real-TimePCRmachine (Applied Biosystems, Fos-
ter City, California). The geNORM housekeeping selection kit
(Primer Design Ltd, Southampton, England) was used to assay
12 housekeeping genes in a subset of the samples. Using Norm-
Finder software, the 2 most stable genes for normalization were
determined to be SF3A1 andATP5B. Sampleswere assayed in du-
plicate, and a standard curve of known copy number was run on
each plate for clusterin, SF3A1, and ATP5B. Data were nonpara-
metric and were therefore log transformed.
Clusterin Genotyping
Tagger software (http://www.broad.mit.edu/mpg/tagger/) iden-
tified 7 single-nucleotide polymorphisms (SNPs) (rs9331908,
rs11136000, rs867231, rs867230, rs9331888, rs9314349, and
rs484377) that capturedmore than 90% of variation in the clus-
terin gene. Genotypes were determined using a TaqMan allele-
specific assay (Applied Biosystems). The PCR amplifications
were performed on an ABI PRISMR 7000 Sequence Detection
System (Applied Biosystems). A total of 946 individuals (358
AD subjects, 373 controls, and 215 MCI subjects) were geno-
typed for the 7 SNPs.
TASTPM Transgenic Mouse Model Experiments
Heterozygote transgenic mice overexpressing hAPP695swe
(Tas10) and presenilin 1 M146V mutations (Tpm) were gen-
erated as previously described.27 Western blot analysis of clus-
terin was performed in plasma samples at 6 months using an
anti–apolipoprotein J mouse polyclonal antibody (Abcam
AB349-50; 1:5000). For immunohistochemistry, antigen re-
trieval was undertaken as described previously.27,28 Primary an-
tibodies were 1E8 (pan-A!), 20G10 (A!42; GlaxoSmithKline;
1:1000), and anticlusterin (R&D Systems goat polyclonal
AF2747; 1:20 000). Images were captured at #4 magnifica-
tion on an Axioscopemicroscope and analyzed by Image J soft-
ware to generate percentage A! or clusterin load. Animal ex-
periments were conducted according to the Council of Europe
guidelines.
STATISTICAL ANALYSIS
Discovery-phase proteomic data were analyzed by partial least-
squares regression using SIMCA-P, version 8.0. Spot data were
scaled to unit variance and log10 transformed where appropri-
ate. Observations with greater than 50% missing values were
excluded. Partial least-squares discriminant analysis was used
to derive a panel of protein spots that discriminated between
rapidly and slowly declining AD groups.
Validation-phase protein data were examined using SPSS,
version 17. Covariates were chosen in cases in which such vari-
ables were significantly different between the groups of inter-
est or in which theywere likely to influence the dependent vari-
able. To test associations betweenplasma clusterin concentration
and ERC thickness, partial correlation analysis was performed
with age and sex as covariates. In analyzing associations be-
tween MMSE score and plasma clusterin concentration, par-
tial correlation was performed with age as a covariate. While
testing differences in clusterin concentration between rapidly
and nonrapidly declining AD patients, age and sex were not
included as covariates because they were not significantly dif-
ferent between the 2 groups. However, duration of disease was
significantly different between these groups (retrospective analy-
sis) and was therefore included as a covariate in an analysis of
covariance (ANCOVA)model. In the prospective analysis, there
was no significant difference in disease duration between rapid
and nonrapid decliners, and clusterin concentration between
these groups was therefore compared using an independent
samples t test. Linear regression adjusting for disease status,
age, sex, and APOE ε4 status was performed to investigate the
association betweenCLU SNPs and clusterin plasma levels and
to examine the relationship between CLU messenger RNA
(mRNA) and disease. Image analysis is described in the rel-
evant sections. All other statistical analyseswere performedusing
SPSS, version 17, and are described in the text.
RESULTS
PROTEOMIC IDENTIFICATION
OF PLASMA PROTEINS ASSOCIATED
WITH HIPPOCAMPAL ATROPHY AND
RAPID CLINICAL PROGRESSION IN AD
To identify plasma proteins associated with disease as re-
flected by cerebral atrophy,we first performed a discovery-
phaseproteomics experimentusing2-dimensional gel elec-
trophoresis and LC-MS-MS, with hippocampal atrophy as
the independent variable. We analyzed samples from 44
subjects from the KCL-ART cohort, representing a con-
tinuum of disease (27 individuals with mild to moderate
AD and 17 with MCI; eTable 1). Bivariate correlation of
integrated optical densities of spots detected by 2-dimen-
sional gel electrophoresis revealed 13 spots that were sig-
nificantly associatedwith hippocampal volume (r%±0.35,
P& .05). Subsequently, using partial least-squares regres-
sion,29 a method suited to analysis of proteomic data in
which colinearity among predictor variables is common,
amodel with 2 components was fitted to the hippocampal
volume data. This was constituted by 8 of the 13 spots
which, together, explained 34% of the variance (R2Y, ie,
explained variance in the outcome variable) in hippocam-
pal volume. Using LC-MS-MS, we identified these 8 spots
as complementC3,'-fibrinogen, serumalbumin, comple-
ment factor I, clusterin (in 2 spots),(1-macroglobulin, and
serum amyloid P (Figure 2). We then performed a sec-
ond discovery-phase experiment in an independent set of
samples in 51 carefully matched (for age, sex, severity at
the time of blood sampling, and cholinesterase inhibitor
treatment [all were taking the drug]) AD subjects from the
AddNeuroMedcohortwhowecoulddivide into fast (n=22)
or slow (n=29) progressors based on their annualized rate
of cognitive decline (eTable 1).Wedefined a priori fast de-
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cline as a fall of 2 or more points on the ADAS-cog scale
during6months.Apartial least-squaresdiscriminant analy-
sis model distinguishing the rapidly from the slowly pro-
gressing AD groups was constituted by the integrated op-
tical densities of 27 silver-stained 2-dimensional gel
electrophoresis spots. Of these, 8 were well defined, dis-
crete, and present in all 51 gels andwere identified by LC-
MS-MS.These spots contained complement componentC4
(in 3 spots), complementC8, clusterin, apolipoproteinA1
(in 2 spots), and transthyretin (Figure 2).
CLUSTERIN AND ATROPHY OF THE ERC,
SEVERITY OF COGNITIVE IMPAIRMENT,
AND SPEED OF PROGRESSION IN AD
Only 1proteinwas common to both discovery-phase stud-
ies: clusterin. We therefore sought to confirm this find-
ing in a large cohort of 689 subjects, including 344 from
the AddNeuroMed study (119 with AD, 115 with MCI,
and 110 controls) and 345 (all with AD) from the KCL-
ART cohort (eTable 2). We used atrophy in the ERC as
an alternative measure of disease pathology (Figure 1).
The 689 validation-phase subjects included the 95 sub-
jects in the discovery phase albeit with entirely different
analytical measures in the 2 studies.
Confirming the discovery-phase study, we observed a
trend toward association between clusterin concentration
and ERC atrophy in the combined AD and MCI cohort
(n=219; R=−0.12, P=.06) after covarying for age and sex.
This relationship was driven primarily by a highly signifi-
cant association between ERC atrophy and clusterin con-
centration in ADpatients (n=113;R=−0.30, P=.001).We
also correlated plasma clusterin concentrationwithMMSE
score—ameasureof cognitionavailable in576 subjectswith
MCI and AD—and again found a highly significant nega-
tive correlation (r=−0.22; P& .001, age as a covariate).
We then compared clusterin levels in rapidly declining
AD patients relative to slow decliners using both retro-
spective andprospectivemeasures of decline relative to the
time of blood sampling (Figure 1 and eTable 2). Retro-
spective decline was estimated from the duration of dis-
ease and the MMSE score at the point of blood sampling,
allowing the annualized fall in MMSE score to be calcu-
lated. We used MMSE score, as the ADAS-cog score was
not available in all subjects, and defined fast decline as a
fall of 2 points or more during a 1-year period relative to
the time of blood sampling. Prospective decline was di-
rectlymeasured as the fall inMMSE score 1 year after blood
sampling. We observed a significant increase in clusterin
concentration inADpatientswith accelerated cognitive de-
clineprior toblood sampling (n=344;ANCOVA, t341=3.40,
P&.001, duration of disease as covariate) (Figure3A) and
an increase in clusterin concentration in AD patients with
faster cognitive decline subsequent to blood sampling
(n=237; independent samples t test, P=.01) (Figure 3B).
Cox proportional regression analysis showed that higher
plasmaclusterin concentrationwas associatedwithagreater
risk of rapid cognitive decline 1 year after blood sampling
(Figure 3C). We then performed an analysis of variance
(age and sex as covariates) between AD,MCI, and control
groups in the entire sample to test for differences in plasma
clusterin concentration. There were no significant differ-
ences:AD,82.4ng/mL(SD,25.6ng/mL;n=336);MCI, 77.6
ng/mL (SD, 22.5ng/mL;n=222); and control subjects, 82.2
ng/mL (SD, 23.8ng/mL; n=385). Finally,we compareddif-
ferences in plasma clusterin concentration betweenAPOE
ε4 carriers and noncarriers (independent samples t test) in
the combined cohort of AD,MCI, and control subjects and
did not find any significant difference.
CLUSTERIN AND FIBRILLAR A! BURDEN IN THE
ERC IN NONDEMENTED OLDER INDIVIDUALS
Because high clusterin levels are associated with brain
atrophy and amore rapid rate of cognitive decline in AD
patients, we hypothesized that increased clusterin con-
centration might be an antecedent marker of pathology
in otherwise normal older individuals.We tested this hy-
pothesis in participants of the Baltimore Longitudinal
Study of Aging who had stored samples of plasma and
underwent PET imaging of fibrillar A! burden with 11C-
PiB (n=60; eTable 3). Although all participantswere non-
demented at the time of the PiB-PET study, a range of in
vivo amyloid burden is observed in cognitively normal
individuals30 and increased amyloid depositionmay rep-
resent the earliest phase of AD pathology in these sub-
jects. Measuring plasma clusterin concentration from
samples collected 10 years before the PiB-PET studies,
we investigated associations between clusterin concen-
tration and subsequent development of in vivo fibrillar
amyloid burden.
We conducted a directed search of significant associa-
tions between clusterin andMTLPiB values using theMTL
region defined by theWFUPickAtlas26 and the SPM5mul-
tiple regression module, adjusting for age and sex. These
results indicated that higher antecedent clusterin concen-
trations were associated with greater PiB retention in bi-
lateral ERC; it was higher on the right (right ERC, P=.009;
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Figure 2. Gel-based proteomic discovery-phase studies. Proteomic
identification of plasma proteins associated with hippocampal volume in
subjects with Alzheimer disease (AD) and mild cognitive impairment (MCI) and
those associated with fast AD progression (bottom panel). A representative
2-dimensional gel electrophoresis gel is shown with spots outlined in green
denoting proteins associated with hippocampal volume in AD and MCI and
those in red highlighting proteins associated with fast AD progression.
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Figure 3. Increased concentration of plasma clusterin and rate of clinical progression in Alzheimer disease (AD). Patients with AD with a rapid progression rate,
measured prior to blood sampling (A) and 1 year after blood sampling (B) have significantly increased clusterin concentration relative to slow progressors. C, High
levels of clusterin are associated with a significantly greater risk of accelerated cognitive decline subsequent to blood sampling. Patients with AD (n=204) were
assigned a prognostic index derived as their plasma clusterin concentration multiplied by its corresponding regression coefficient (!) in a Cox proportional
regression analysis. C, Cumulative hazard functions for the effect of the prognostic factor (ie, plasma clusterin concentration) on the survival probability, ie,
maintaining a nonaggressive clinical course (decline in Mini-Mental State Examination score $2 points per year). The cumulative survival functions represent
estimated survival probabilities for 3 representative AD patients with the lowest (5.87 ng/mL), median (76.84 ng/mL), and highest plasma clusterin (159 ng/mL)
concentrations showing that an AD patient with the highest clusterin concentration has the lowest probability of maintaining a nonaggressive clinical course 1 year
after sampling. The reported hazard ratio for a 10-ng/mL rise in plasma clusterin concentration for risk of becoming a rapid AD decliner was 1.071 (95%
confidence interval; 1-1.147; P=.05).






















































































Figure 4. Clusterin expression and amyloid pathology. A, Clusterin is an antecedent biomarker of in vivo fibrillar amyloid-! (A!) burden in the entorhinal cortex in
nondemented older individuals (n=60). SPM analysis shows correlation between plasma clusterin concentration and 11C–Pittsburgh Compound B (11C-PiB) uptake
controlling for age and sex (P& .05, uncorrected). Highlighted areas denote regions in the entorhinal cortex of both hemispheres that show significant association
with plasma clusterin concentration 10 years prior to the PiB positron emission tomographic scans. B, Gene expression of clusterin is altered in Alzheimer disease
(AD). Clusterin messenger RNA levels are significantly elevated in blood cells from AD patients (n=182) relative to healthy controls (n=179, *P& .001) and
subjects with mild cognitive impairment (MCI) (n=207, †P=.008) after correcting for age. C, Transgenic TASTPM mice (n=10) overexpressing both human APP
and PS1 genes have significantly higher plasma concentration of clusterin relative to wild-type litter mates (n=10) at 6 months of age (P=.02). Inset shows
hippocampal and cortical amyloid plaques in a 6-month-old TASTPM mouse stained by a monoclonal antibody against A!1-42. Wild-type mice show no amyloid
pathology at this age (not shown). ‡Statistically significant. D, Representative photomicrograph of cortical amyloid plaques in a 6-month-old TASTPM mouse.
A close association is observed between A! within amyloid plaques (black arrows indicate monoclonal antibody to A!42; gray-black labeling, diaminobenzidine)
and clusterin (white arrows indicate polyclonal antibody; brown-labeled with Novared). Colors have been slightly enhanced digitally for illustrative purposes.
E, TASTPM mice show age-dependent increases in cortical A! and clusterin load as determined by quantitative image analysis of immunohistochemical labeling.
F, TASTPM mice demonstrate a highly significant (P& .001) correlation between A! and clusterin load (n=39, male and female mice, 8-30 weeks of age).
B, C, and E, Error bars indicate standard error.
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increased plasma concentration of clusterin, even in non-
demented older individuals, predicts a greater extent of
fibrillar amyloid burden in theERC, the same regionwhere
we have also demonstrated robust association with atro-
phy in subjects with MCI and AD.
GENE EXPRESSION OF CLUSTERIN
IS ALTERED IN AD
To investigate the mechanisms underlying the associa-
tions between plasma concentration of clusterin and
both imaging measures of atrophy and accelerated
clinical progression, we measured clusterin mRNA
levels in blood cells from AD patients (n=182), MCI
subjects (n=179), and controls (n=207) (eTable 4). Di-
agnosis had a significant effect on clusterin gene expres-
sion (ANCOVA, df=2, P& .001, age as a covariate). Pair-
wise comparisons between the 3 groups showed
significantly higher clusterin gene expression in AD pa-
tients than in MCI and control subjects (P=.008 and
P& .001, respectively, Bonferroni adjustment for mul-
tiple comparisons) (Figure 4B). Sex and presence of the
APOE ε4 allele did not have a significant effect on clus-
terin mRNA levels. We did not observe a significant as-
sociation between clusterin mRNA in blood cells and
plasma concentration of clusterin protein nor didwe find
a correlation between plasma mRNA levels and either
MMSE score or rate of decline in MMSE score within
groups or with atrophy on neuroimaging.
LACK OF EFFECT OF VARIATION
IN THE CLUSTERIN GENE ON PERIPHERAL
CLUSTERIN EXPRESSION
We did not observe significant effects of the 7 clusterin
gene SNPs on either clusterinmRNA expression in blood
cells or plasma concentration of clusterin (eTable 5 and
eTable 6). The SNPs analyzed included those reported
on in the recent large Genome-Wide Association Stud-
ies to be associated with risk of sporadic AD.31,32
PLASMA CONCENTRATION
OF CLUSTERIN IN TRANSGENIC MICE
WITH PLAQUE PATHOLOGY
To extend our findings on the association of clusterinwith
brain amyloid deposition, we examined its plasma con-
centration in a transgenic mouse model of AD. TASTPM
mice overexpress the hAPP695swe and presenilin 1
M146V mutations, resulting in overproduction of hu-
man amyloid precursor protein,27 andmimic various hall-
marks of AD including amyloid plaques as well as cog-
nitive and behavioral deficits.27,28 In light of ourmagnetic
resonance imaging data in AD patients and PiB-PET re-
sults in nondemented older individuals, we hypoth-
esized that plasma clusterin concentration in transgenic
TASTPMmice would be higher than wild-type controls.
As predicted, we observed a significantly greater plasma
concentration of clusterin (P=.02, independent samples
t test) in 6-month-old transgenic TASTPMmice (n=10)
relative towild-type littermates (n=10) (Figure 4C). Pre-
vious studies have established both marked cerebral A!
deposits as well as cognitive deficits in TASTPMmice at
this age relative to wild-type litter mates.27,28
BRAIN CLUSTERIN AND AMYLOID
IN A TRANSGENIC MOUSE MODEL OF AD
Using double-labeling immunohistochemistry, we dem-
onstrated that cortical plaques in TASTPM mice con-
tained both A! and clusterin (Figure 4D). Finally, we es-
tablished the close association between A! and clusterin
by showing that both cortical A! burden and clusterin
deposition increase with age in TASTPM mice (n=9-
11) (Figure 4E) and that there is a highly significant cor-
relation (F1,37=107.57, P& .001, adjusted R2=0.737) be-
tween cortical A! and clusterin load (Figure 4F).
COMMENT
We have combined a novel proteomic and neuroimaging
approach to establish that plasma concentration of clus-
terin is associated with in vivo pathology, disease sever-
ity, and clinical progression in patients with AD. The pri-
mary outcomes in our discovery-phase studies were
association with both atrophy of the MTL and the rate of
progression of cognitive decline. In the discovery phase,
we used hippocampal atrophy derived frommanual trac-
ing of the hippocampal formation from magnetic reso-
nance imaging, and in the much larger validation phase,
from automated regional analysis of the ERC, an adjacent
region of theMTL and the site of earliest pathology in AD.
Hippocampal atrophy is an early event in the patho-
genesis of AD, is associated with an increased risk of con-
version from MCI to AD, and may even precede the de-
velopment of cognitive decline.33,34 Cerebrospinal fluid
levels of phosphorylated tau correlate with hippocam-
pal volume, indicating that this measure reflects an in-
tegral feature of ADpathology.35Moreover, decreased hip-
pocampal volume in AD patients is associated with
neuronal loss, confirming its validity as a marker of neu-
rodegeneration.35 A second independent outcome vari-
able in the discovery-phase studies was rate of cognitive
decline, derived as a measure of decrease in the ADAS-
cog scores during a 6-month interval inADpatients. Using
this measure, we dichotomized AD patients as fast and
slow decliners, an approach previously shown to pre-
dict long-term prognosis in AD.36
Only clusterin was associated both with hippocampal
atrophy in AD and MCI subjects and with fast progress-
ing, or more aggressive, AD. Evidence from human cere-
brospinal fluid, postmortem brain, and transgenic animal
models suggests a plausible link between clusterin andAD
pathology.37-40 We therefore sought to confirm the asso-
ciation of clusterin with AD pathology, severity, and pro-
gression in a much larger validation-phase study.
We confirmedhighly significant associations of plasma
clusterin concentrationwith atrophyof theERC (P=.001),
MMSE score (P& .001), and rate of progression in AD
(P& .001). We also demonstrated a significantly greater
risk of subsequent accelerated cognitive decline associ-
ated with increased concentration of clusterin in pa-
tients with AD and, in normal individuals, with subse-
(REPRINTED) ARCH GEN PSYCHIATRY/VOL 67 (NO. 7), JULY 2010 WWW.ARCHGENPSYCHIATRY.COM
745
©2010 American Medical Association. All rights reserved.
63
quent deposition of fibrillar A! in the ERC. Our finding
of raised plasma clusterin concentration 10 years before
fibrillar A! deposition in the brain in normal elderly in-
dividuals suggests that clusterin is raised very early, pos-
sibly as an etiopathological event, and is not simply a re-
action to other pathology in AD. The observation that
clusterin mRNA is significantly increased in blood cells
in AD suggests that the observed changes in protein lev-
els reflect changes in expression in disease and not, for
example, altered turnover. However, the increase in clus-
terin mRNA in AD patients does not correlate directly
with plasma clusterin concentration, suggesting that the
primary sources of plasma clusterin that we find predic-
tive ofmore aggressive disease are organs other than blood
cells such as the liver or possibly even the brain. In the
course of this study, 2 groups, including one in which
we participated, reported from genome-wide studies that
polymorphic variation in CLU, which encodes clus-
terin, was associated with AD.31,32 One possible mecha-
nism for this association would be for the SNPs associ-
ated with disease to be modifiers of gene expression. To
investigate this, we determined the effect of variations
in the clusterin gene on both peripheralmRNA levels and
plasma concentration of clusterin protein, including the
principal variant associatedwith disease and 6 other SNPs
determined to cover most of the variation in the gene.
We did not find significant effects of these SNPs on either
peripheral mRNA levels or plasma clusterin concentra-
tion, suggesting that our observed association of clus-
terin protein andmRNAwithAD-related pathological pro-
cesses is independent of genetic variation in the clusterin
gene.Our findings raise the possibility of 2 possibly linked
mechanisms whereby both altered expression and some
other factor in the gene linked to the disease-associated
SNPs are active in moderating disease pathology. How-
ever, we cannot exclude an effect of genetic variation not
examined in this study on clusterin expression or a small
effect of CLU variation, below the power of our study to
detect, on expression. Nonetheless, the finding of asso-
ciation with both genetic variants and, as we now re-
port, gene and protein expression adds considerable
weight to the importance of clusterin to AD pathogen-
esis. It is interesting that we observe clusterin in 2 closely
related but distinct spots in the discovery-phase 2-di-
mensional gel electrophoresis studies. Proteins are com-
ponents of multiple spots on 2-dimensional gel electro-
phoresis because of changes in posttranslational
modification, complex formation, and splicing changes
resulting in different isoforms. It is possible that some
of these variations might be associated with disease pro-
cesses in addition to the overall amount of protein asmea-
sured in the validation-phase study. Finally, we con-
firmed a previous report of significantly higher plasma
concentration of clusterin in TASTPMmice overexpress-
ing APP/PS1 mutations,41 and we also show that clus-
terin is closely associated with cortical amyloid plaques,
showing an age-dependent concomitant increase with
brain amyloid burden.
Previous studies suggest that clusterin belongs to a fam-
ily of extracellular chaperones that regulate amyloid for-
mationandclearance.42 Invitro experiments showthat clus-
terin regulates amyloid formation in abiphasicmannerwith
low clusterin to substrate ratios enhancing and higher ra-
tios inhibiting amyloid formation, respectively.43 In mice,
in vivo binding of A! to clusterin enhances its clearance
and efflux through the blood-brain barrier.44 However, pre-
vious studies reporting differences in cerebrospinal fluid
clusterin concentration between ADpatients and controls
have been inconclusive.39,40 Our findings may have impli-
cations for the discovery and characterizationof other amy-
loid chaperone proteins in blood linked to AD pathogen-
esis. In this context, (2-macroglobulin has recently been
characterized as an amyloid chaperone that inhibits fibril
formation.45,46 In a previous proteomic analysis of plasma,
we reported thedifferential expressionof(2-macroglobulin
in AD patients and have also found associations between
the plasma concentration of(2-macroglobulin and hippo-
campal metabolite abnormalities in AD.7,47 In this previ-
ous study,7 in addition to(2-macroglobulin, we also iden-
tified components of the complement pathway associated
with AD. In the discovery phase of the current study, we
notemany of the sameproteins and also that clusterinmay
itself play a role in complement activation, suggesting that
further examination of this pathwaymay be useful to iden-
tify markers associated with AD.7
In summary, we have used a novel proteomic-
neuroimaging discovery paradigm in which the primary
end points were well-established measures of pathology
in the MTL and rate of disease progression. We identi-
fied clusterin as a plasma protein associated with dis-
ease pathology, severity, and progression in AD. Al-
though these findings do not support the clinical utility
of plasma clusterin concentration as a stand-alone bio-
marker for AD, they reveal a robust peripheral signature
of this amyloid chaperone protein that is responsive to
key features of disease pathology. Our findings clearly
implicate clusterin, but there may well be other pro-
teins in plasma related to the disease process, and in-
deed our previous studies and those of others suggest this
is the case. These results may have wider implications
for the identification of other amyloid chaperone pro-
teins in plasma, both as putative AD biomarkers as well
as drug targets of disease-modifying treatments.
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4.2 Paper 2 
PLASMA	  TRANSTHYRETIN	  AS	  A	  CANDIDATE	  MARKER	  FOR	  ALZHEIMER’S	  DISEASE 
Velayudhan	  L	  et	  al.	  Journal	  of	  Alzheimer’s	  disease,	  2012; 28(2):369-75  
4.2.1 My contribution: Transthyretin (TTR) was another key protein that I had identified in the mass spectrometry-gel based proteomics study in plasma differentiating fast and slow progressors in Alzheimer disease (AD) dementia patients (paper 1, table 1). I carried out a further validation study evaluating this protein in an independent larger cohort of subjects with AD dementia, using quantitative enzyme-linked immunosorbent assays (ELISA), to examine it as a marker of AD dementia progression. Following sample selection, I carried out the ELISA experiments, did detailed analysis and interpretation, and wrote the manuscript for publication. I further carried out the necessary corrections following detailed and anonymous peer review process from the submissions under the guidance of my Supervisors, Dr John Powell and Prof Simon Lovestone. I am the corresponding author for this paper.  
4.2.2 Introduction In the discovery phase experiment, proteins differing in plasma between fast and slow progressors included those previously identified in biomarkers studies – including clusterin, complement proteins and Apolipoprotein A1. Validation for clusterin protein was described in the previous chapter. One novel plasma protein was identified in my discovery experiment – transthyretin.   TTR is a 55 kDa homotetrameric transport protein that is synthesized in the liver and choroid plexus and is present in both blood (3−7 μM) and cerebrospinal fluid (CSF, 0.1−0.4 μM) (Richardson, 2007, Du et al., 2012). An increased level of TTR expression in mouse models of AD has been confirmed by various groups (Tsai et al., 2009, Li et al., 2011). Furthermore, neurons from human AD patients, but not age-matched controls, secrete TTR (Li et al., 2011).  The protective effect of TTR against Aβ	  toxicity has been observed in vitro (Giunta et al., 2005, Costa et al., 2008) and supported by other animal studies. For example, progeny from Swedish mutation of APP (APPSw) mice crossed 
68 
 
with mice engineered to express human TTR performed as well as wild-type and better than APPSw mice in cognitive tests (Buxbaum et al., 2008) and AD mice raised in an enriched environment expressed more TTR and performed better on cognitive tests than those raised in a control environment (Costa et al., 2007). TTR plays an important role in keeping intracerebral proteins such as amyloid fibrils in a soluble form and it might inhibit Aβ	  aggregation and the formation of senile plaques (Stein and Johnson, 2002b, Choi et al., 2007).   Previous studies have reported decreased TTR levels in CSF of AD patients compared to non-demented controls and in those with severe illness (Merched et al., 1998, Riisoen, 1988, Puchades et al., 2003, Castano et al., 2006, Gloeckner et al., 2008a, Hansson et al., 2009a). Low levels of TTR in CSF have been reported to be AD-specific compared when analysed in samples from 35 subjects with AD, 18 subjects with fronto-temporal dementia (FTD) and 29 non-demented (Hansson et al., 2009a).  In a recent report TTR is one of the 6 CSF biomarkers in AD describing six clinic-pathological stages from cognitive normalcy to mild dementia, including stages defined by increased risk of cognitive decline (Perrin et al., 2011).   To confirm the findings from the discovery phase that the plasma transthyretin levels was altered between fast and slow progressors,  plasma TTR levels were further tested in a larger, independent AD dementia cohort and correlated with the rate of cognitive decline and severity.  
 
4.2.3 METHODS: 
4.2.3.1 Subjects, experiment and classification of AD dementia group for cognitive 
decline and severity Subjects were recruited, sampled and assessed as previously described in chapter 4-paper 1 (subjects and samples, 4.1.2.1).  TTR protein was assayed by a commercial ELISA kit (Assaypro- AssayMax Human 
prealbumin	   ELISA	   Kit).	   The	   experiment	   was	   carried	   out	   as	   per	   the	   manufacturer’s	  instruction. Baseline plasma samples of AD subjects in an independent sample set (n=270) from both AddNeuroMed (n=177) and KCL-ART (n=93) collections were run in duplicate. Coefficient of variance was less than 10%.  
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Cognitive decline was defined using MMSE scores, as this was available for all the subjects and as previously described in chapter 4 (4.1.2.3.1). Briefly, annualized fall in MMSE was calculated from the duration of disease and MMSE at the point of blood sampling and rapid cognitive decliners were defined as subjects with fall of 2 or more points over a period of one year (chapter 4, 4.1.2.3.1). I further defined mild AD as those subjects with probable AD dementia with MMSE scores 20 and above points. Moderate to severe AD dementia (Mod-severe AD) was defined as AD dementia in those subjects with MMSE scores between 0-19. MMSE score change over a period of 6 months post-venepuncture was calculated for prospective cognitive decline.  Western blot analysis was carried out to measure and compare TTR levels between AD subjects and age matched non-demented controls. Equal volumes of plasma from AD (n=90) and controls (n=50) (ART-KCL) were immunoblotted for TTR, in duplicate. A standard pooled sample was loaded in duplicate on each gel, to which each test sample was normalised, and which allowed inter-gel comparisons to be made. When assessing the reproducibility of the duplicate gels, a large positive correlation of 0.84 was obtained (Pearson correlation test).  
4.2.3.2 Statistical Analysis Protein data was analysed using SPSS version 17 (for Windows). Chi-square, student t-test, correlation analysis (Spearman non-parametric test) and non-parametric Mann-Whitney-Wilcoxon test were used to compare the socio-demographics, MMSE test scores and TTR protein between groups: rapid and non-rapid cognitive decliners; and mild and mod-severe AD dementia subjects. Linear regression was performed to determine association between TTR and change in the MMSE scores in 6 months from the baseline.  Characterisation of the ELISA analytical performance is important to establish what type of difference can be detected with confidence in future studies of this biomarker. For this, the within-sample variance was determined. For 320 AD dementia plasma samples run in duplicates for TTR concentration with the commercially available assay (Assaypro), the mean within sample variance between replica samples was 3.1%. So, 
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the assay was able to detect differences as low as 12% difference in the mean TTR levels between the rapid decliners and non-rapid decliners (lower in rapid decliners). 
 
4.2.4  MAIN RESULTS The main results were as below: 1. TTR levels were significantly (p=0.004) reduced in AD compared to NDC, when compared between AD subjects and age matched non-demented controls.  2. When comparing AD subjects by speed of decline, TTR levels were significantly lower in subjects with more rapid cognitive decline (p= 0.036) and also in subjects with moderate-severe AD (p<0.01) (Mann-Whitney U test). 3. Linear regression analysis showed TTR levels as a better predictor factor for MMSE score change in the six months following venepuncture(p=0.029), in both adjusted and unadjusted models with variables such as age, gender, duration of illness, baseline MMSE and APOE4 carrier status.  Discussion as in the published paper and also further elaborated in chapter 6, section 6.4.2. 
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Abstract. Diagnosis of the progressive neurodegenerative disorder Alzheimer’s disease (AD) can only definitively be made
postmortem. The most promising AD biomarkers identified to date are found in cerebrospinal fluid (CSF). Among these, one
of the most interesting candidates is transthyretin (TTR), the carrier of thyroxine and retinol, which also binds with amyloid-!
(A!), and it has been suggested that it protects against A! deposition. A biomarker detectable in plasma would have great
diagnostic value and could be of use for determining disease progression and the monitoring of therapeutic efficacy due to
its greater accessibility over CSF-based markers. We aimed to validate TTR as a prognostic marker in AD and to determine
its relation with cognitive measures. We examined the plasma protein levels of TTR in 90 people with late-onset AD and 50
age-matched non-demented controls (NDC) by immunoblotting and found lower plasma TTR levels in AD compared to NDC
(p = 0.004). We then quantified plasma TTR by enzyme-linked immunosorbent assays in a larger independent cohort (n = 270)
including subjects with mild to severe AD. Plasma TTR levels were significantly lower in AD cases with rapid cognitive decline
and with severe cognitive impairment. Regression analyses showed plasma TTR levels also predicted cognitive decline over
the ensuing 6 months. These data indicate that plasma TTR is a strong candidate AD biomarker that should be included in the
development of blood based biomarker panels for disease diagnosis and also suggests that plasma TTR is a marker of disease
severity and progression.
Keywords: Alzheimer’s disease, cognitive impairment, plasma proteins, transthyretin
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INTRODUCTION
With the rapidly aging global population, the num-
ber of people with dementia is estimated to quadruple
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worldwide in the next 20 years [1]. Alzheimer’s dis-
ease (AD) is by far the most common dementia and
is progressive in nature. A biomarker to aid the early
diagnosis of AD, allowing the use of disease modify-
ing therapies before overt dementia manifests or in the
monitoring of disease progression would therefore be
of great clinical value.
Considerable progress in the search for biomarkers
has been made with markers derived from amyloid
ISSN 1387-2877/12/$27.50 © 2012 – IOS Press and the authors. All rights reserved
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plaques (amyloid-! (A!)) [2] and neurofibrillary
tangles (tau and phospho-tau) [3]. The most promising
sources for biomarkers in AD are cerebrospinal fluid
(CSF) and blood plasma, because compared to brain
tissue, these fluids are more easily accessible and, in
the CSF, which is in close contact with the central
nervous system, where key biochemical changes take
place. However, while CSF is a good resource for the
study of biomarkers in AD, its clinical application is
limited by the relatively invasive nature of the pro-
cedure. Blood-based biomarkers have an advantage
in that they are suitable for large scale studies, in
community settings, with the ease of venepuncture
allowing for repeatability in old and frail people and
applicable to clinical settings.
Many approaches to identifying factors associ-
ated with disease characteristics such as speed of
progression, have been employed. These include
clinical factors, neuroimaging, genetics and various
approaches to discover biomarkers in body fluids.
Proteomic studies using CSF and blood have identi-
fied potential AD diagnostic markers, distinguishing
AD patients from healthy elderly controls and other
neurodegenerative disorders [4–6], and other studies
have used protein-based studies to identify poten-
tial predictive markers in mild cognitive impairment
(MCI) [7]. However, few studies have yet sought to go
beyond diagnostic markers to identify potential prog-
nostic markers in AD. Here we report the validation
of one of the key proteins, transthyretin (TTR), identi-
fied from a mass spectrometry-gel based proteomics
study in plasma, evaluating them further in larger
independent cohorts using immunoblotting and quanti-
tative enzyme-linked immunosorbent assays (ELISA).
We investigated whether TTR distinguished AD from
healthy controls and also its correlations with the rate
of cognitive decline and severity in AD.
MATERIAL AND METHODS
Subjects and samples
The samples used in these analyses came from two
studies: AddNeuroMed studies and the Alzheimer’s
Research Trust cohort, Kings College London (KCL-
ART). As a part of the KCL-ART study, people with
AD, MCI, and non-demented controls (NDC) have
been recruited and sampled from 2001 onwards [8].
All subjects were white Europeans with grandparents
born in the UK and underwent assessments annually.
The AddNeuroMed project, a European Union study,
recruited subjects with AD, MCI, and NDC from 6
centers in the UK, France, Italy, Finland, Poland, and
Greece [9]. All subjects were assessed at 3-monthly
intervals over a year. Assessments in both the studies
included a semi-structured interview for demograph-
ics, case history, family history, medical history, and
standardized tools used to assess cognition, function,
behavior, global severity [8]. Patients with probable
AD (National Institute of Neurological and Commu-
nicative Disorders and Stroke and the Alzheimer’s
disease and Related Disorders Association [NINCDS-
ADRDA] criteria) in both the studies were identified
as previously described [8] and evaluated with a stan-
dardized assessment shown to have high diagnostic
validity [11]. Age-matched NDC, defined as having
no evidence of cognitive impairment (with a MMSE
greater than 28), were recruited systematically from
primary care patient lists (KCL-ART study) [8]. The
full standardized assessments in both of the studies are
similar and included demographic and medical infor-
mation, scales to assess function, behavior, and global
levels of severity including the Cambridge Examina-
tion for Mental Disorders of Older People (CAMDEX)
[12]; and cognitive assessment including Mini Men-
tal State Examination (MMSE) [13] (both studies;
all subjects) and Alzheimer disease assessment scale-
Cognitive (ADAS-cog) [14] (AddNeuroMed only) [15,
16]. Peripheral venous blood was collected at base-
line (initial assessment) and at subsequent time points,
including plasma samples collected in 9 ml EDTA
tubes and stored at −80◦C according to rigorous
standard operating procedures. In total, we studied
50 NDC and 90 AD subjects for immunoblotting
(KCL-ART cohort) and 270 AD subjects for ELISA
(AddNeuroMed cohort), with an additional 40 subjects
(AddNeuroMed cohort) for determining correlation
between the two techniques. Ethical approval was
obtained from local ethic committees.
Criteria for cognitive decline and severity in AD
patients
Cognitive decline was defined using MMSE scores,
as this was available for all the subjects and previ-
ously described [15, 16]. Briefly, annualized fall in
MMSE was calculated from the duration of disease and
MMSE at the point of blood sampling and rapid cogni-
tive decliners were defined as subjects with a drop of 2
or more points over a period of one year [15]. We fur-
ther defined mild AD as those subjects with probable
AD with MMSE scores of 20 points and above. Moder-
ate to severe AD (Mod-severe AD) was defined as AD
in those subjects with MMSE scores between 0–19.
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MMSE score change over a period of 6 months post-
venepuncture was calculated for prospective cognitive
decline.
Validation of TTR using western blotting and
enzyme-linked immunoassay
The discovery phase (mass spectrometry-gel based
proteomics) for this study has been previously reported
[15]. Briefly, plasma samples from AD subjects
(AddNeuroMed cohort) characterized as rapid (n = 22)
and non-rapid progressors (n = 29) were subjected
to two-dimensional difference-in-gel electrophoresis
(2DGE). PLS-DA model discriminating the fast from
slow progressing AD groups was constituted by the
integrated optical densities of silver-stained 2DGE
spots. Transthyretin was identified as one of the pro-
teins from these well-defined, discrete spots, present
in all 51 gels by mass spectrometry LC-MS/MS [15].
Western blot analysis was carried out to measure
TTR levels in a sample set of 90 AD subjects and
50 healthy controls (KCL-ART cohort). Plasma sam-
ples were diluted (4"l raw plasma plus 96"l of PBS
containing protease inhibitor cocktail (Complete®,
1836145, Roche Applied Science, Penzberg, Ger-
many) and mixed with 100"l of 2× reducing Laemmli
sample buffer (S3401, Sigma). Samples were then
boiled at 100◦C for 5 min, centrifuged at 15,500 g
and separated on NuPAGE® (24 well), 4–12% Bis-
Tris SDS-polyacrylamide gels (Invitrogen, Paisley,
UK). Proteins were electroblotted onto 0.2"m nitro-
cellulose membranes (Schleicher & Schuell, Dassel,
Germany), blocked in 5% dried skimmed milk in
PBS + 0.1% Tween (PBST) and probed with a rab-
bit anti-human TTR antibody (Dako, Ely, UK) for
2 h at room temperature. Primary antibody immunore-
activity was detected with an anti-rabbit antibody
conjugated to a 680 nm fluorophor (Alexis, Invitrogen,
Paisley) and visualized on an Odyssey near infrared
scanner (LI-COR Biosystems, Nebraska, USA). Den-
sitometric analysis was performed using the Odyssey
software v 2.1. All samples were run in duplicate
and intensities were normalized to a reference plasma
sample run on each gel (also loaded in duplicate) to
allow inter-gel comparisons. The densitometric values
obtained for each duplicate run were averaged post
normalization to the in gel control sample.
To validate the novel finding that transthyretin
levels correlated with cognitive decline, the protein
was assayed by a commercial ELISA kit (Assaypro-
AssayMax Human prealbumin ELISA Kit). The assay
was carried out as per the manufacturer’s instruction.
Baseline plasma samples from an independent cohort
of AD subjects (n = 270) from both AddNeuroMed and
KCL-ART were run in duplicate.
Genotyping
Venous blood was obtained for DNA extraction
and genotyping for the apolipoprotein (APOE) alle-
les using standard methods [17]. The APOE haplotype
was determined using two allelic discrimination assays
(rs7412 and rs429358) based on fluorogenic 5′ nucle-
ase activity: TaqMan single nucleotide polymorphism
Genotyping Assays (Applied Biosystems).
Statistical analysis
Protein data was analyzed using SPSS version 17
(for Windows). Chi-square, student t-test, correlation
analysis (Spearman non-parametric test) and non-
parametric Mann-Whitney-Wilcoxon test were used
to compare the sociodemographics, MMSE test scores
and TTR protein levels between groups: rapid and non-
rapid cognitive decliners; and mild and mod-severe
AD subjects. Linear regression was performed with
the loss of MMSE scores over 6 months follow up as
the dependent variable and plasma transthyretin lev-
els, age, baseline MMSE scores, duration of illness,




We have previously reported the discovery phase
experiments; comparing fast to slow progressors, using
two-dimension gel electrophoresis (2DGE) and tan-
dem mass spectrometry (LC/MS/MS) [15]. Proteins
differing in plasma between fast and slow progres-
sors included those previously identified by us, and by
other groups, as potential markers for AD, including
complement proteins and apolipoprotein A1. We have
previously reported the validation studies for clusterin,
a protein which is also altered in relation to degree of
entorhinal cortex atrophy. One novel protein was iden-
tified in this discovery program, transthyretin (TTR),
also known as pre-albumin.
Transthyretin levels lower in AD subjects
compared to NDC
In order to validate this finding, we first compared
the plasma TTR levels between AD subjects and age
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Table 1
Comparison of plasma transthyretin level and socio-demographic-clinical parameters between the groups: a) AD subjects and non-demented
controls; b) Within independent cohort of AD subjects: rapid cognitive decliners and non-rapid cognitive decliners and mild AD and moderate-
severe AD












AD (n = 142)
p-value
Female/male 70/20 38/12 N.Sa 120/60 57/29 N.Sa 79/49 99/43 N.Sa
Age, years 81.4 (6.5) 80.8 (7.2) N.Sb 77.5 (6.5) 77.1 (6.2) N.Sb 76.6 (5.9) 78 (6.6) N.Sb
TTR levels 63.9 (0.1) 82.3 (0.1) 0.01∗¶ 130.3 (64.6) 146.4 (62.9) 0.04∗§ 144.2 (61.2) 128.1 (65.8) <0.01∗§
APOE4 53 (60.2%) 9 (20%) <0.001a 106 (60.6%) 46 (54.8%) N.Sa 71 (57.3%) 82 (60.5%) N.Sa
MMSE score,
baseline
15.8 (8.1) 28.7 (1.1) <0.001∗ 14.8 (7.6) 22.8 (4.7) <0.001∗ 23.8 (2.6) 11.9 (6.5) <0.001∗
Duration of illness,
months
n/a n/a n/a 3.9 (2.6) 6.3 (3.6) <0.001b 4 (2.7) 5.2 (3.4) <0.01b
Values are mean (SD) or n (%); acalculated using the χ2 test, bcalculated using the student t-test.
Wilcoxon paired test, ¶Western blotting experiments, §Enzyme linked immunoassay (ELISA).
AD, Alzheimer’s disease; NDC, non-demented controls; MMSE, Mini Mental State Examination; TTR, transthyretin; APOE4, presence of one
E4 allele; n/a, not applicable.
Fig. 1. Representative blot from immunoblotting experiment for
plasma transthyretin levels in Alzheimer’s disease patients and non-
demented controls.
matched non-demented controls. Equal volumes of
plasma from AD (n = 90) and controls (n = 50) (ART-
KCL) were immunoblotted for TTR, in duplicate, as
described above. A standard pooled sample was loaded
in duplicate on each gel, to which each test sample
was normalized, and which allowed inter-gel compar-
isons to be made. When assessing the reproducibility
of the duplicate gels, a large positive correlation of 0.84
was obtained (Pearson correlation test). We found that
TTR levels were significantly (p = 0.004) reduced in
AD compared to NDC (Table 1a, Figs. 1 and 2). There
was no association between APOE4 carrier status and
TTR concentration (p = 0.47) as tested by analysis of
covariance.
Transthyretin levels and cognition within AD
subjects
We then used samples from an independent sam-
ple set of 270 AD subjects (AddNeuroMed = 177 and
ART-KCL = 93). These included 178 females (66%),
with a mean age of 77.4 years (±6.3) and mean
MMSE score 17.49 (±7.8). APOE genotyping was
available for 247 AD subjects, with 145 subjects hav-
ing at least one E4 allele. The mean TTR level for the
whole cohort was 135.5"g/ml (±64). Information on
anticholinesterase inhibitors treatment was available
from the AddNeuroMed cohort, with n = 123 having
Fig. 2. Box plot showing lower plasma transthyretin levels in
Alzheimer’s disease subjects compared to non-demented controls.
ongoing treatment. We found no difference in the
plasma TTR levels with and without treatment. There
was also no difference in TTR levels between APOE4
carrier and non-carriers. There was no significant dif-
ference between depressed and non-depressed AD
subjects as assessed by the neuropsychiatry inventory.
There were 15 subjects with known thyroid dysfunc-
tion, however, there was no difference in TTR levels
between subjects who had thyroid dysfunction (n = 15)
and those without. There were no subjects with known
liver dysfunction.
When comparing AD subjects by speed of decline,
TTR levels were significantly lower in subjects
with more rapid cognitive decline (p = 0.036), and
also in subjects with moderate-severe AD (p < 0.01)
(Table 1b) (Mann-Whitney U test).
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Table 2
Linear regression analysis with the loss of MMSE scores over 6 months follow up as the dependent variable and
plasma transthyretin levels, age, baseline MMSE scores, duration of illness, gender and APOE4 alternatively
(Model 1) or simultaneously (Model 2) entered as predictive variables within the whole Alzheimer’s disease sample
R2 (%) Beta T -value P value
Model 1
Plasma transthyretin 3.6 0.012 2.32 0.022*
Age in years 0.6 −0.039 −1.072 0.285
Duration of illness 0.4 −0.074 −0.924 0.356
MMSE baseline 1.8 0.092 1.903 0.058
Gender 0.2 −0.295 −0.592 0.555




5.7 TTR 0.011 2.168 0.032*
MMSE 0.100 1.779 0.077
R2 (%) =R2 value in percent for the overall model; *p < 0.05; MMSE, Mini Mental State Examination; TTR,
Transthyretin; APOE4, presence of one E4 allele.
The change in MMSE scores from baseline over
the following six months was then calculated. Lin-
ear regression analysis showed TTR levels as a better
predictor factor for MMSE score change in the six
months following venepuncture (p = 0.029), in both
adjusted and unadjusted models with variables such
as age, gender, duration of illness, baseline MMSE,
and APOE4 carrier status (Table 2). Correlation anal-
ysis showed positive association of TTR levels with
baseline MMSE scores; decreasing plasma TTR levels
with lower MMSE scores (p = 0.006, r2 = 0.2).
To determine the degree of correlation between
the two techniques (ELISA and immunoblotting)
used to measure TTR plasma levels, we performed
both techniques on 40 new plasma samples, each
run in duplicate in both assays. The samples were
from 40 AD subjects (22 women) (AddneuroMed
cohort), with a mean age 77.5 years (±6.6) and
mean MMSE scores, 20.9 (±4.9). We found a
good positive correlation between the two techniques




Previously we reported, in a discovery study, that
TTR was one of the proteins in plasma discriminat-
ing between fast and slow progressing AD [15]. All
other proteins from this discovery had been previ-
ously identified in biomarker studies [15]. Here we
set out to determine whether this novel observation
could be replicated in an independent sample set. By
immunoblotting we found that TTR levels are signif-
icantly lower in AD subjects compared to the NDC.
Measuring TTR by ELISA in an independent cohort
of AD subjects, we found decreased TTR levels in
moderate-severe stages of AD and in subjects present-
ing with rapid cognitive decline. We also found that
plasma TTR level predicted subsequent decrease in
MMSE score over the ensuing 6 months. The abso-
lute concentration of TTR using TTR ELISA and
immunoblotting correlated positively on a common set
of plasma samples.
Previous studies have reported decreased TTR lev-
els in CSF of patients with AD [18–23]. Low levels of
TTR in CSF have been reported to be AD-specific com-
pared with other dementia types, i.e., fronto-temporal
dementia and Lewy body dementia [23, 24]. Lower
TTR levels in CSF have been reported in severe AD
[19, 22]. In a recent report, TTR is one of the six CSF
biomarkers for AD describing six clinicopathologi-
cal stages from cognitive normalcy to mild dementia,
including stages defined by increased risk of cognitive
decline [25]. Our findings are consistent with a recent
report demonstrating lower serum TTR levels in AD
subjects compared to NDC, although the study used a
different detection method [26].
TTR, a 55-kDa homotetramer, is an abundant pro-
tein in CSF and human plasma, serving as the main
transporter of thyroid hormones from the blood stream
into CSF and in plasma, and is associated with retinol-
binding protein [27]. It has been proposed that TTR
acts as a scaffold protein, binding to A! and in so
doing protects against A! deposition and the forma-
tion of senile plaques [28–30]. TTR seems to play an
important role in keeping intracerebral proteins such
as amyloid in a soluble form and helps prevent fur-
ther aggregation [31]. In a recent study in mice, we
found that deletion of insulin receptor substrate 2 (Irs2)
resulting in insulin resistance increased tau pathol-
ogy as expected but paradoxically decreased amyloid
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pathology. We showed that this unexpected protection
against plaque pathology was due to an increase in TTR
expression [32], in line with a previous genome-wide
expression study which found that increased TTR was
one of the protective factors preventing transgenic mice
with plaque pathology progressing to other pathologi-
cal features of AD [33].
An alternative mechanism to explain the observa-
tion of lower TTR in more severe and more rapidly
progressing AD is that TTR functions as a rate-limiting
factor for the plasma transport of retinol [34]. Deple-
tion of retinoic acid derivatives has been associated
with deposition of A! peptides [35]. Whatever the
mechanism, TTR is a prime candidate to influence A!
pathology both directly and indirectly. The reasons
for decreased plasma TTR levels in AD subjects
could be from altered morphology of the choroid
plexus in AD with possible change of expression
profile including TTR production and its transport
into blood [36]. Another possible explanation could
be the down regulation of TTR expression in choroid
plexus caused by activated !-secretase activity in
AD with decreased sA!PP# [37]. Decreased hepatic
TTR expression is another possible cause of reduced
TTR in AD but none of our AD subjects had recorded
liver dysfunction and additionally we did not find any
differences in TTR levels of AD subjects with and
without thyroid dysfunction.
In conclusion, significantly lower level of plasma
TTR were found in AD subjects compared to non-
demented controls and within AD subjects, TTR
plasma levels were lower in subjects with rapid cog-
nitive decline and severe cognitive impairment. In
addition, TTR level predicted subsequent cognitive
decline. These data suggest that plasma TTR is a
strong candidate AD-specific biomarker that should be
included in the development of blood-based biomarker
panels for disease diagnosis and also suggests that
plasma TTR may act as a marker for disease severity
and progression.
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5.1 My contribution: 
Another	   study	   related	   to	   the	   topic	   of	   Alzheimer’s	   disease	   (AD)	   progression	   marker	  evolved during the thesis work whilst analysing the plasma proteins with neuroimaging done on the same patient cohort. I took lead in the data extraction, statistical analysis, interpretation, writing up the manuscript after detailed literature review and submission for publication. I then carried out necessary corrections following detailed and anonymous peer review process under the guidance of Dr Andy Simmons and my supervisors, Prof Simon Lovestone and Dr John Powell.  I am the corresponding author for this paper. 
 
5.2 Introduction Biomarkers for AD based on non-invasive methods are highly desirable and neuroimaging markers provide an alternative and objective assessment of progression (Frank et al., 2003, Galasko, 2005).  A range of neuroimaging techniques provide insight into AD-related neurodegeneration, including structural magnetic resonance imaging (MRI), positron emission tomography (PET), and functional MRI. Neuroimaging techniques can improve early detection and aid in identifying individuals at risk of developing AD. In particular, structural MRI has provided insight into the neuroanatomical profile of pre-clinical and early AD. MRI has demonstrated significant value in the prediction of conversion and disease progression (Fennema-Notestine et al., 2009c).   From a neuropathological perspective, it has been suggested that the medial temporal lobe is the anatomical site of the first pathological	   alterations	   in	   Alzheimer’s	   disease	  (Braak and Braak, 1991, Braak et al., 2006). It is well accepted that the medial temporal lobe plays an essential role in associative memory (Squire et al., 2004).  It is clear that 
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the pathological processes of AD, which begin in the entorhinal cortex before spreading to hippocampus proper and other neocortical regions, affect the formation of new memories early in disease development. MRI is useful for detecting atrophy in the medial temporal structures affected early in the neurodegenerative process (Fennema-Notestine et al., 2009b). Decreased volumes of hippocampus and entorhinal cortex are connected to AD and that atrophy of the medial temporal lobe can predict conversion in subjects in the prodromal stages of the disease, MCI to AD (Fennema-Notestine et al., 2009a, Jack et al., 2004, Killiany et al., 2002, Varon et al., 2011).   The European Union AddNeuroMed multi-centre MRI study has reported that structural MRI measures discriminated AD from controls and MCI and also demonstrated potential for prediction of conversion from MCI to AD (Liu et al., 2010a, Westman et al., 2011c, Costafreda et al., 2011). The hippocampus, amygdala, and caudate volumes were significantly smaller in progressive MCI subjects than in controls and stable MCI subjects (Liu et al., 2010a). The volume of amygdala and caudate were independent variables in predicting conversion from MCI to AD in 100 amnestic MCI subjects, 118 AD patients, and 94 age-matched healthy controls from the AddNeuroMed study. The regional cortical thickness and volumes in MCI subjects were significantly decreased in limbic/paralimbic areas and temporal lobe compared to controls and also atrophy was much more extensive in the AD patients compared to MCI subjects and controls (Liu et al., 2011b). The use of whole-brain atrophy measured from serial MR imaging, correlates well with clinical progression (Fox et al., 1999, Sluimer et al., 2008).  These studies have used baseline and serial MRI measures to predict future cognitive decline but mostly for conversion from MCI to AD and there is need for assessing these MRI measures as potential markers of disease progression in dementia due to AD.  The aims of the current study were to examine (a) the relationship between baseline hippocampal volume, entorhinal cortex thickness and whole brain volume with baseline cognitive measures in subjects with (i) AD dementia (ii) MCI and (iii) age matched non-demented controls (NDC); and (b) to assess the associations of the baseline MRI measures with subsequent cognitive change over one year period.  The hypothesis was 
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that smaller brain structures would be associated with worse baseline cognition and greater cognitive decline.   
5.3 METHODS 
5.3.1 Subjects and assessments This paper included data from 120 AD dementia, 106 mild cognitive impairment (MCI) and 99 non demented control (NDC ) participants from the AddNeuroMed study, a European Union funded FP6 program ( as described in Chapter 4, Subjects and samples) (Hye et al., 2006, Thambisetty et al., 2010, Velayudhan et al., 2012). Assessments included a structured interview including a detailed case and family history, Cambridge Examination for Mental Disorders of Older People (CAMDEX) (Roth et al., 1986); cognitive testing with Mini Mental State Examination (MMSE)(Folstein et al., 1975) and Alzheimer disease assessment scale – Cognitive (ADAS-cog) (Rosen et al., 1984) and stage of dementia with Clinical Dementia Rating (CDR) (Hughes et al., 1982) sum of boxes score. The cognitive testing with ADAS-cog and MMSE were repeated every 3 months for a period of a year. These subjects had structural MRI data which was acquired as designed to be compatible with the Alzheimer Disease Neuroimaging Initiative (ADNI) (Jack et al., 2008). This paper focussed on regional brain volumes and cortical thickness measures, specifically hippocampal volume, entorhinal cortex thickness and whole brain volume which have been proposed to be related to AD and have received high level of attention in the recent literature (Jack et al., 2004, Varon et al., 2011, Cardenas et al., 2011).  
5.3.2 Statistical analysis:  Chi-square, non-parametric and T-test analyses were used to test for differences in MRI-based measures, cognition, severity measures, age, gender  and education between AD dementia, MCI and NDC subjects.  Correlation analysis (Spearman non-parametric test) was used for were used for associations between brain region volumes, cognitive scores (MMSE, ADAS-cog) and CDR for illness staging within the groups.  
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Rates of cognitive decline were determined by change in the cognitive measures – MMSE and ADAS-Cog total scores. These measures were estimated by fitting a random intercept and slope model using xtmixed in STATA 10 (Stata Corporation, College Station, TX, USA). The average baseline cognitive outcome and the average change in the cognitive outcome over the follow-up time were calculated for all the AD dementia patients, MCI and NDC as a group (fixed effects). Subject-specific intercept and slope terms which reflected deviation from the group average (random effects) were also calculated. Follow-up time was defined as the number of years (days/365.25) passed since the baseline visit, and up to 5 time points (three months apart) was recorded for each patient.  Time squared was also used to assess nonlinear cognitive decline.   An interaction between the MRI-based brain volumes and follow- up time (Entorhinal Cortex X TIME, Whole Brain X TIME or Hippocampus X TIME) was used to test the null hypothesis that there was no difference in the rate of cognitive function i.e. in slopes for different baseline brain volumes. The coefficient of the time variable in this case (TIME)  would indicate the association between follow-up time with cognitive decline for average brain volume (since the variables are centred around their mean); the coefficient of the brain volume for each subject (Entorhinal Cortex , Whole Brain  or Hippocampus) would indicate the association of baseline brain volume with baseline cognitive assessment score and the coefficient of the interaction term (MRI brain volume x follow-up time) would indicate the effect of brain volume on cognitive decline over time. The results were based on using the brain measures as continuous variables and the quartiles for graphical view.      
 
5.4 Discussion The main findings of the study were (A) Patients with mild to moderate AD dementia had thinner ERC, smaller hippocampal volume and WBV compared to subjects with MCI and NDC. Within the AD group, (B) Baseline ERC and WBV were significantly associated with baseline cognition measured by MMSE, ADAS-cog and also with stage of dementia as measured by CDR sum of boxes scores. (C) Baseline ERC thickness but not hippocampal volume was associated with longitudinal changes in cognition over one year and could predict the degree of decline slopes as measured by MMSE and ADAS-
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cog. (D) Baseline WBV was also associated with greater subsequent cognitive decline measured with ADAS-cog, although the association with the MMSE was marginal. The models were controlled for age at baseline, education years, gender, cholinesterase inhibitors, centre and apolipoprotein E genotype.  Pathologically, H. Braak and E. Braak demonstrated in post mortem brains that the hallmark neurofibrillary tangles evident in AD appear first in the prealpha transentorhinal neurons and then spread to the ERC proper (Braak and Braak, 1991). From here, the tangles spread to the subiculum (Sub) and Cornu Ammonis (CA) 1, then to CA 2 and 3 (Schonheit et al., 2004). The specificity of this pattern predicts specific cognitive deficits related to disease-related regionally specific neuronal death. This hypothesis was confirmed in a study which used high-resolution MRI, combined with a cortical unfolding technique to increase visibility of the convoluted medial temporal lobe, to assess whether grey matter thickness in subjects with MCI correlated to decline in cognition over two years, demonstrating that information in the initial encoding stage is most susceptible to early AD-related pathology and related to thinning in ERC and Sub (Burggren et al., 2011).  In another study, atrophy rate of ERC was higher than that of hippocampus in patients with AD (n=20) evaluated twice approximately 1.9 years apart on volumetric T1-weighted MR images and the delayed list verbal recall test correlated significantly with atrophy rates ERC>hippocampus (Du et al., 2004). In a study wherein 71 non-demented participants were studied with structural MRI and neuropsychological testing at baseline and 1-year follow-up, smaller right hippocampal and entorhinal cortex (ERC) volumes at baseline were associated with worse delayed verbal memory performance at baseline while smaller left ERC volume was associated with greater longitudinal decline (Cardenas et al., 2011). Recently in a genome-wide study of atrophy in regions associated with neurodegeneration in AD, single-nucleotide polymorphism (SNP) with a disease-specific effect  was associated with ERC volume in an intron of the ZNF292 gene (rs1925690) and an intergenic SNP, flanking the ARPP-21 gene, with an overall effect on entorhinal cortical thickness (rs11129640) (Furney et al., 2011). Gene-wide scoring also highlighted phosphatidylinositol-binding clathrin assembly protein (PICALM), one of the AD risk gene, as the most significant gene associated with entorhinal cortical thickness (Furney et al., 2011).  
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Abstract. Biomarkers for Alzheimer’s disease (AD) based on non-invasive methods are highly desirable for diagnosis, disease
progression, and monitoring therapeutics. We aimed to study the use of hippocampal volume, entorhinal cortex (ERC) thickness,
and whole brain volume (WBV) as predictors of cognitive change in patients with AD. 120 AD subjects, 106 mild cognitive
impairment (MCI), and 99 non demented controls (NDC) from the multi-center pan-European AddNeuroMed study underwent
MRI scanning at baseline and clinical evaluations at quarterly follow-up up to 1 year. The rate of cognitive decline was estimated
using cognitive outcomes, Mini-Mental State Examination (MMSE) and Alzheimer disease assessment scale–cognitive (ADAS-
cog) by fitting a random intercept and slope model. AD subjects had smaller ERC thickness and hippocampal and WBV
volumes compared to MCI and NDC subjects. Within the AD group, ERC > WBV was significantly associated with baseline
cognition (MMSE, ADAS-cog) and disease severity (Clinical Dementia Rating). Baseline ERC thickness was associated with
both longitudinal MMSE and ADAS-cog score changes and WBV with ADAS-cog decline. These data indicate that AD subjects
with thinner ERC had lower baseline cognitive scores, higher disease severity, and predicted greater subsequent cognitive decline
at one year follow up. ERC is a region known to be affected early in the disease. Therefore, the rate of atrophy in this structure
is expected to be higher since neurodegeneration begins earlier. Focusing on structural analyses that predict decline can identify
those individuals at greatest risk for future cognitive loss. This may have potential for increasing the efficacy of early intervention.
Keywords: Alzheimer’s disease, biomarker, cognitive decline, entorhinal cortex, hippocampus, whole brain volume
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INTRODUCTION
Alzheimer’s disease (AD) is the most common
form of dementia and its prevalence is set to rise in
the coming decades [1]. Biomarkers for AD, based on
non-invasive methods are highly desirable for diagno-
sis, disease progression, and monitoring therapeutics
ISSN 1387-2877/12/$27.50 © 2012 – IOS Press and the authors. All rights reserved
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[2, 3]. A range of neuroimaging techniques provide
insight into AD-related neurodegeneration, includ-
ing structural magnetic resonance imaging (MRI),
positron emission tomography (PET), and functional
MRI. Neuroimaging techniques can improve early
detection and aid in identifying individuals at risk
of developing AD. In particular, structural MRI has
provided insight into the neuroanatomical profile of
pre-clinical and early AD. MRI has demonstrated
significant value in the prediction of conversion and
disease progression [4].
From a neuropathological perspective, it has been
suggested that the medial temporal lobe is the anatom-
ical site of the first pathological alterations in AD [5, 6].
It has been shown that MRI is useful for detecting atro-
phy in the medial temporal structures affected early in
the neurodegenerative process [4]. Decreased volumes
of hippocampus and entorhinal cortex are connected to
AD and to individuals at risk of developing the disease.
It has been shown that atrophy of the medial temporal
lobe can predict conversion in subjects in the prodro-
mal stages of the disease, referred to as mild cognitive
impairment (MCI) [4, 7–9]. Atrophy also correlates
with memory impairment. Numerous studies have used
baseline and serial MRI measures to predict future cog-
nitive decline but mostly for conversion from MCI to
AD [9–12], and there is need for assessing these MRI
measures as potential markers of disease progression
in AD.
We have previously reported from the European
Union AddNeuroMed multi-center MRI study that
structural MRI measures discriminated AD from con-
trols and MCI; and also demonstrated potential for
prediction of conversion from MCI to AD [13–18].
The aims of the current study were to examine (a) the
relationship between baseline hippocampal volume,
entorhinal cortex thickness, and whole brain volume
with baseline cognitive measures in (i) AD (ii) MCI,
and (iii) age matched non-demented controls (NDC);
and (b) to assess the associations of the baseline MRI
measures with subsequent cognitive change over one
year period. Our hypothesis was that smaller brain
structures would be associated with worse baseline
cognition and greater cognitive decline.
METHODS
Participants and clinical assessment
This study included data from 120 AD, 106
MCI, and 99 NDC participants from the AddNeu-
roMed study, a European Union funded FP6 program.
AddNeuroMed is a longitudinal, multi-center study of
biomarkers for AD [19]. All subjects underwent MRI
scanning at baseline and cognitive testing at baseline
and every 3 months up to one year.
Data was collected from six different sites across
Europe: University of Kuopio, Finland; University
of Perugia, Italy; Aristotle University of Thes-
saloniki, Greece; King’s College London, United
Kingdom; University of Lodz, Poland; and Univer-
sity of Toulouse, France. Written consent was obtained
where the research participant had capacity, and in
those cases where dementia compromised capacity,
then assent from the patient and written consent from
a relative, according to local law and process, was
obtained. This study was approved by ethical review
boards in each participating country. The inclusion and
exclusion criteria were as follows.
Alzheimer’s disease
Inclusion criteria. Patients with probable mild to
moderate AD (National Institute of Neurologi-
cal and Communicative Disorders and Stroke and
the Alzheimer’s disease and Related Disorders
Association [NINCDS-ADRDA] criteria) [20] and
Mini-Mental State Examination (MMSE) [21] score
range between 12 and 28, age 65 years or above.
Exclusion criteria. Significant neurological or psychi-
atric illness, significant unstable systematic illness, or
organ failure.
Mild cognitive impairment
Inclusion criteria. MMSE score range between 24 and
30, Clinical Dementia Rating (CDR) [22] scale score
of 0.5, Geriatric Depression Scale score less than or
equal to 5, age 65 years or above, medication stable,
and good general health.
Exclusion criteria. Met the DSM- IV criteria for
dementia, significant neurological or psychiatric ill-
ness, significant unstable systematic illness, or organ
failure. The distinction between MCI and NDC was
based on two criteria: CDR = 0 labeled the subject as
control and a CDR = 0.5 labeled the subject as MCI. For
the MCI subjects it was preferable that the subject and
informant reported occurrence of memory problems.
Non-demented control
Inclusion criteria. MMSE score range between 24 and
30, CDR = 0, Geriatric Depression Scale score less
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than or equal to 5, age 65 years or above, medication
stable, and good general health.
Exclusion criteria. Met the DSM- IV criteria for
dementia, significant neurological or psychiatric ill-
ness, significant unstable systematic illness, or organ
failure.
The clinical assessment and cognitive testing of
the AddNeuroMed subjects followed a standard pro-
tocol described previously [13, 23, 24]. Assessments
included a structured interview including a detailed
case and family history, Cambridge Examination for
Mental Disorders of Older People (CAMDEX) [25];
cognitive testing with MMSE and Alzheimer disease
assessment scale – Cognitive (ADAS-cog) [26] and
stage of dementia with CDR sum of boxes score. The
cognitive testing with ADAS-cog and MMSE were
repeated every 3 months for a period of a year.
Genotyping
Venous blood was obtained for DNA extraction
and genotyping for the apolipoprotein (APOE) alle-
les using standard methods [27]. The APOE haplotype
(rs7412 and rs429358) was determined using two
allelic discrimination assays based on fluorogenic 5′
nuclease activity: TaqMan single nucleotide polymor-
phism Genotyping Assays (Applied Biosystems,).
Magnetic resonance imaging
Data acquisition for the AddNeuroMed study
was designed to be compatible with the Alzheimer
Disease Neuroimaging Initiative (ADNI) [28]. The
imaging protocol included a high resolution sagit-
tal 3D T1-weighted MPRAGE volume (voxel size
1.1× 1.1× 1.2 mm3) and axial proton density/T2-
weighted fast spin echo images. The MPRAGE
volume was acquired using a custom pulse sequence
specifically designed for the ADNI study to ensure
compatibility across scanners [28]. Full brain and skull
coverage was required and detailed quality control was
carried out on all MR images according to the AddNeu-
roMed quality control procedure [23, 29].
Regional volume segmentation
We applied the Freesurfer pipeline (version 4.5.0)
to the MRI images to produce regional cortical thick-
ness and subcortical volumetric measures. Cortical
reconstruction and subcortical volumetric segmenta-
tion includes removal of non-brain tissue using a
hybrid watershed/surface deformation procedure [30],
automated Talairach transformation, segmentation of
the subcortical white matter and deep grey matter
volumetric structures (including hippocampus, amyg-
dala, caudate, putamen, ventricles) [30–32], intensity
normalization [33], tessellation of the grey matter
white matter boundary, automated topology correction
[34, 35], and surface deformation following inten-
sity gradients to optimally place the grey/white and
grey/cerebrospinal fluid borders at the location where
the greatest shift in intensity defines the transition
to the other tissue class [36–38]. Once the cortical
models are complete, registration to a spherical atlas
takes place which utilizes individual cortical folding
patterns to match cortical geometry across subjects
[39]. This is followed by parcellation of the cerebral
cortex into units based on gyral and sulcal struc-
ture [40, 41]. This segmentation approach has been
used for multivariate classification of AD and healthy
controls [16, 17, 42, 72], neuropsychological-image
analysis [15, 18], imaging-genetic analysis [43, 44],
and biomarker discovery [24, 73, 74]. The current
study focused on regional brain volumes and cortical
thickness measures, specifically hippocampal volume,
entorhinal cortex (ERC) thickness, and whole brain
volume (WBV) which have been proposed to be related
to AD and have received high level of attention in the
recent literature [4, 7–12, 16, 17]. Volumes from the
left and the right hemisphere were averaged together.
All volumetric measures from each subject were nor-
malized by the subject’s intracranial volume. Cortical
thickness measures were not normalized and were used
in their raw form [45].
Statistical analysis
Non-parametric and t-test analyses were used to
test for differences in continuous outcomes such as
MRI-based measures, cognition, severity measures,
age, and education between AD, MCI, and NDC.
The chi-square test was used to test for differences
in categorical outcomes such as gender and the pres-
ence of the APOE !4 allele. Correlation analysis
(Spearman non-parametric test) was used for associ-
ations between brain region volumes, cognitive scores
(MMSE, ADAS-cog), and CDR for illness staging
within the groups.
Rates of cognitive decline were determined by
change in the cognitive measures (MMSE and ADAS-
Cog total scores). These measures were estimated
by fitting a random intercept and slope model using
xtmixed in STATA 10 (Stata Corporation, College
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Station, TX, USA). The average baseline cognitive
outcome and the average change in the cognitive out-
come over the follow-up time were calculated for all
the AD patients, MCI, and NDC as a group (fixed
effects). Subject-specific intercept and slope terms
which reflected deviation from the group average (ran-
dom effects) were also calculated. Follow-up time was
defined as the number of years (days/365.25) passed
since the baseline visit, and up to 5 time points (three
months apart) was recorded for each patient. Time
squared was also used to assess nonlinear cognitive
decline.
Adjustment for age at baseline, education years,
gender, cholinesterase inhibitors, center, and APOE
genotype was made. Continuous outcomes were cen-
tered to their mean to aid interpretation of the model. As
the main focus of the study was to study associations
for cognitive decline in AD, we did not differentiate
MCI into converters and non-converters and used all
MCI as a group.
An interaction between the MRI-based brain vol-
umes and follow- up time (Entorhinal Cortex×TIME,
Whole Brain×TIME, or Hippocampus×TIME) was
used to test the null hypothesis that there was no dif-
ference in the rate of cognitive function, i.e., in slopes
for different baseline brain volumes. The coefficient of
the time variable in this case (TIME) would indicate
the association between follow-up time with cognitive
decline for average brain volume (since the variables
are centered around their mean); the coefficient of
the brain volume for each subject (Entorhinal Cor-
tex, Whole Brain, or Hippocampus) would indicate
the association of baseline brain volume with base-
line cognitive assessment score and the coefficient of
the interaction term (MRI brain volume× follow-up
time) would indicate the effect of brain volume on
cognitive decline over time. The results were based
on using the brain measures as continuous variables
and the quartiles for graphical view.
RESULTS
Demographics, brain region, and baseline
cognition
The subject characteristics are shown in Table 1.
Predictably the AD patients had smaller regional brain
measures and lower cognitive scores compared to age-
matched MCI and NDC subjects. Within AD subjects,
ERC volumes correlated significantly with base-
line MMSE (p < 0.01, r2 = 0.3), ADAS-cog (p < 0.01,
r2 =−0.3), and CDR scores (p < 0.001, r2 =−0.3) and
WBV with CDR (p < 0.001, r2 =−0.3). Within NDC,
MMSE correlated with WBV (p = 0.02, r2 =−0.2) and
with hippocampal volume (p = 0.04, r2 =−0.2). Within
the MCI group, there were no significant correlations
between MMSE and brain volumes.
Brain region and longitudinal changes in cognition
We did not identify any deviation from a linear cog-
nitive decline model by including the TIME squared
variable in the model (non-significant coefficient) and
all the models therefore assumed a linear cognitive
decline.
Association of baseline ERC thickness with
cognitive decline in AD subjects
Mixed effects models indicated a significant inter-
action between follow-up time measured with the
Table 1
Demographics and brain volumes between subjects with Alzheimer’s disease (AD), mild cognitive impairment (MCI), and non-demented
controls (NDC)
AD (n = 120) MCI (n = 106) NDC (n = 99) p < 0.001∗∗ p < 0.05∗∗
Gender (Female %) 64 49 53 NS¶ a
Age in years 74.82 (6.21) 74.00 (5.64) 74.56 (5.14) NS∗
Education 7.91 (4.01) 9.03 (4.18) 10.67 (4.89) b∗ a, c
APOE4 (%) 56 38 28 b¶ a
MMSE 20.83 (4.83) 27.21 (1.64) 28.96 (1.28) a, b, c∗
Hippocampus (cm3) 1.95 (0.37) 2.27 (0.35) 2.67 (0.27) a, b, c∗
% reduction to NDC 27 15
Entorhinal cortex (mm) 2.62 (0.53) 3.00 (0.36) 3.24 (0.36) a, b, c∗
% reduction to NDC 19 7
Whole brain volume 0.82 (0.04) 0.85 (0.03) 0.85 (0.03) a, b∗
% reduction to NDC 4 0
Mean (SD); ¶, chi-square; ∗, t-test; MMSE, Mini-Mental State Examination; APOE4, presence of at least one e4 allele. ∗∗Multiple comparisons
abbreviated as: (a) AD subjects differ from subjects with MCI, (b) AD subjects differ from NDC subjects, (c) MCI subjects differ from NDC
subjects.
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Fig. 1. Mini-Mental State Examination (MMSE) and Alzheimer disease assessment scale–Cognitive (ADAS-cog) decline over the quarterly
visits for a year for Alzheimer’s disease subjects in the four entorhinal cortex (ERC), whole brain volume (WBV), and hippocampus (HC)
quartiles. MMSE score represents number of correct items; ADAS-cog score represent the number of errors. A) ERC thickness in mm [mean
(SD)]: 1st ERC quartile: 1.97 (0.21); 2nd ERC quartile: 2.42 (0.10); 3rd ERC quartile: 2.83 (0.11); 4th ERC quartile: 3.31 (0.26). B) WBV
divided by intracranial volume [mean (SD)]: 1st WBV quartile: 0.77 (0.02); 2nd WBV quartile: 0.81 (0.01); 3rd WBV quartile: 0.84 (0.01); 4th
WBV quartile: 0.87 (0.02). C) HC volume in cm3 [mean (SD)] 1st HC quartile: 1.47 (0.17); 2nd HC quartile: 1.83 (0.09); 3rd HC quartile: 2.08
(0.06); 4th HC quartile: 2.40 (0.19).
Fig. 2. Mini-Mental State Examination (MMSE) decline over 1 year for non-demented control subjects in the four entorhinal cortex (ERC),
whole brain volume (WBV), and hippocampus (HC) quartiles showing no significant associations. MMSE score represents number of correct
items. A) ERC thickness in mm [mean (SD)]: 1st ERC quartile: 2.76 (0.20); 2nd ERC quartile: 3.15 (0.07); 3rd ERC quartile: 3.37 (0.06);
4th ERC quartile: 3.67 (0.18). B) WBV divided by intracranial volume [mean (SD)]: 1st WBV quartile: 0.81 (0.02); 2nd WBV quartile: 0.85
(0.00); 3rd WBV quartile: 0.86 (0.01); 4th WBV quartile: 0.89 (0.01). C) HC volume in cm3 [mean (SD)]: 1st HC quartile: 2.31 (0.12); 2nd HC
quartile: 2.58 (0.06); 3rd HC quartile: 2.78 (0.06); 4th HC quartile: 3.01 (0.12).
MMSE and ADAS-Cog and baseline ERC thickness
(p = 0.009 and p < 0.001, respectively) which indicated
that baseline ERC thickness was related to the rate of
cognitive decline measured with these two cognitive
scales (Table 2).
Higher baseline ERC thickness was associated with
slower cognitive decline measured with MMSE and
ADAS-cog. In more detail, after adjusting for covari-
ates, higher baseline ERC thickness in AD cases
were associated with both higher baseline cognition
measured with the MMSE and ADAS-cog measures
(beta = 2.661 (0.755), p < 0.001 and beta =−5.083
(1.55), p = 0.001, respectively) and with slower cog-
nitive decline, measured with MMSE (beta = 1.705
(0.648), p = 0.009) and ADAS-cog (beta =−5.737
(1.282), p < 0.001). To aid the interpretation, Fig. 1A
displays the predicted MMSE and ADAS-cog slopes
for the four baseline ERC thickness quartiles, high-
lighting the differences both in baseline cognitive
scores but also in the rate of cognitive decline between
different ERC quartiles, especially, for patients in the
4th quartile. For example, the expected average MMSE
decline for patients in the lower ERC quartile was
−2.34 per year (p = 0.001), whereas there was no
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Fig. 3. Mini-Mental State Examination (MMSE) decline over 1 year for mild cognitive impairment subjects in the four entorhinal cortex (ERC),
whole brain volume (WBV), and hippocampus (HC) quartiles showing no significant associations. MMSE score represents number of correct
items. A) ERC thickness in mm [mean (SD)]: 1st ERC quartile: 2.30 (0.27); 2nd ERC quartile: 2.85 (0.14); 3rd ERC quartile: 3.25 (0.11); 4th
ERC quartile: 3.62 (0.19). B) WBV divided by intracranial volume [mean (SD)]: 1st WBV quartile: 0.80 (0.02); 2nd WBV quartile: 0.84 (0.01);
3rd WBV quartile: 0.8 (0.01); 4th WBV quartile: 0.89 (0.01). C) HC volume in cm3 [mean (SD)]: 1st HC quartile: 1.86 (0.18); 2nd HC quartile:
2.18 (0.05); 3rd HC quartile: 2.39 (0.07); 4th HC quartile: 2.72 (0.18).
significant decline for patients in the upper ERC quar-
tile (beta = 0.372, p = 0.557). The same effect was
observed for ADAS-Cog.
Association of baseline WBV with cognitive
decline in AD subjects
As in the case of ERC, mixed effect models
indicated that baseline WBV was associated with
higher baseline cognitive scores (MMSE beta = 0.028
(0.012), p = 0.016; ADAS-cog beta =−0.065 (0.024),
p = 0.006) and also appeared to modify the rate of
cognitive decline measured with MMSE and ADAS-
cog, although the effect on MMSE measured decline
was only marginal (Table 2). In more detail, base-
line WBV appeared to have a strong influence on the
rate of cognitive decline measured with ADAS-cog
(beta =−0.052 (0.019), p = 0.007) and showed a mod-
est effect on MMSE assessed decline (beta = 0.018
(0.009), p = 0.049). Lower baseline WBV predicted
cognitive decline when assessed with the ADAS-cog
and also to an extent with the MMSE (Fig. 1B, Table 2).
Association of baseline hippocampal volume with
cognitive decline in AD subjects
Finally, mixed effects models indicated that the
baseline volume of the hippocampus was associated
with baseline MMSE (beta = 2.471 (1.105), p = 0.025),
i.e., patients with larger hippocampus volumes had
higher MMSE (Table 2), but was not associated with
baseline ADAS-cog scores, neither did it seem to mod-
ify the rate of cognitive decline assessed by the two
cognitive tools (Fig. 1C, Table 2).
Association of baseline ERC, WBV, and
hippocampal volume with cognitive decline in
NDC and MCI subjects
Finally, mixed effects models indicated that the
baseline ERC thickness, WBV, and volume of the hip-
pocampus was not associated with cognitive decline
measured using MMSE in control and MCI subjects,
over a period of one year (Table 2, Figs. 2 and 3).
DISCUSSION
The main findings of the study were: (A) patients
with mild to moderate AD had thinner ERC, smaller
hippocampal volume, and WBV compared to subjects
with MCI and NDC. Within the AD group, (B) base-
line ERC and WBV were significantly associated with
baseline cognition measured by MMSE and ADAS-
cog and also with stage of dementia as measured by
CDR sum of boxes scores. (C) Baseline ERC thickness
but not hippocampal volume was associated with lon-
gitudinal changes in cognition over one year and could
predict the degree of decline slopes as measured by
MMSE and ADAS-cog. (D) Baseline WBV was also
associated with greater subsequent cognitive decline
measured with ADAS-cog, although the association
with the MMSE was marginal. The models were con-
trolled for age at baseline, education years, gender,
cholinesterase inhibitors, center, and APOE genotype.
Reductions in the hippocampal and entorhinal
regions between the AD and NDC in our study were
similar to previous studies [4, 46]. The differences
in these regions between MCI and NDC were also
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comparable with a previous study [46]. We found
greater reductions in hippocampus compared to ERC
regions similar to these studies in both AD and MCI
groups. However, the focuses of these studies were on
predictors of MCI conversion to AD, and they did not
report on the association between the regions and the
cognitive measures within the AD group.
Our findings are in line with previous studies that
ERC measures correlate better with baseline cognitive
scores than hippocampal volume and that atrophy in
ERC predicts cognitive decline better than hippocam-
pal atrophy [7, 11, 47–48]. Recently in a genome-wide
study of atrophy in regions associated with neurode-
generation in AD, we identified one single-nucleotide
polymorphism (SNP) with a disease-specific effect
associated with ERC volume in an intron of the
ZNF292 gene (rs1925690) and an intergenic SNP,
flanking the ARPP-21 gene, with an overall effect on
entorhinal cortical thickness (rs11129640) [41]. Gene-
wide scoring also highlighted PICALM as the most
significant gene associated with ERC thickness [49].
Although we found that hippocampal volume
associated with the baseline cognitive measures as pre-
viously reported [8, 50, 51], we found no association
between hippocampal volume and subsequent cogni-
tive change, which has also been previously reported
by some [52, 53], but not all authors [54]. Mungas and
colleagues previously reported that hippocampal atro-
phy predicted decline in AD but only in those subjects
without lacunes [12].
WBV correlated with baseline clinical measures
and predicted future cognitive decline, which probably
reflects the correspondence between these measures of
overall cerebral loss and global cognitive measures in
the moderate stages of AD as reported earlier [52, 55].
Structures within the temporal lobe have long been
associated with AD decline because of their critical
role in the formation of long-term memory, one of
the first functions to be affected in disease progres-
sion [51]. Both ERC and hippocampus are essential
parts of the medial temporal lobe system that supports
declarative (conscious) memory [56]. AD pathology
primarily begins in ERC, followed by immediate pro-
gression through subiculum to the hippocampus proper
[5]. Pathologically, Braak and Braak demonstrated that
the spread of neurofibrillary tangles in postmortem
brains appear first in the prealpha transentorhinal
neurons and then spread to the ERC proper [5]. Devel-
opmental, morphological, functional, and molecular
features of layer II neurons in the ERC interact to
promote early susceptibility of this cell type to aging
and AD [57]. Within the ERC, there is subregional
specificity for molecular alterations that may initiate
cognitive decline and with a potential to directly con-
tribute to downstream cascades in its primary afferent
regions, the hippocampus [57]. Previous clinical stud-
ies demonstrated that the rates of cognitive decline
accelerated with time in AD [58, 59], suggesting accel-
erated neurodegeneration in AD. Both cross-sectional
and serial MRI studies on patients with AD have
consistently found volume losses in both ERC and
hippocampus [48, 51, 60–64]. Taken together, these
findings suggest that AD is associated with progres-
sive atrophy of both ERC and hippocampus, providing
potential surrogate markers for this disease. Assuming
that degenerative processes proceed at similar rates in
the ERC and hippocampus, one might therefore expect
to find higher atrophy rates in the structure where neu-
rodegeneration began earlier. Our results substantiate
this hypothesis, which is consistent with the view of
earlier involvement of AD pathology in the ERC than
the hippocampus [65]. Risacher et al., however, have
found similar atrophy rates of 4-5% per year in the hip-
pocampus and entorhinal cortex in the ADNI cohort
[66].
APOE !4 had no influence on the relation between
the ERC, hippocampal, and WBV with cognitive sever-
ity or cognitive decline in our study, similar to other
reports [67, 68]. We have previously reported that the
homozygous !4 carriers had significant volume loss
in hippocampus and amygdala in AD [43]. Possibly
the influence is not seen due to lack of association of
hippocampus volume with cognitive severity or longi-
tudinal cognitive decline in AD. This warrants further
evaluation in future longitudinal studies. We found sig-
nificant correlations between structural MRI measures
and baseline MMSE for healthy control subjects in our
study, but the small range of MMSE for healthy sub-
jects means that this finding should be viewed with
some caution.
Strengths of the current study include the sample
size and our use of automated MRI measures. The
study compares cognitive decline for AD, MCI, and
NDC subjects using the baseline brain measures as
continuous variables and the quartiles for graphical
view.
In conclusion, subjects with AD had thinner ERC,
smaller WBV, and hippocampal volume compared to
subjects with MCI and NDC. In addition, with in
AD subjects, thinner ERC was associated with lower
baseline cognitive scores, higher disease severity, and
predicted greater subsequent cognitive decline at one
year follow up. MRI is superior in defining disease
stage clinically and has been shown to be a slightly
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better predictor of future clinical decline than cere-
brospinal fluid biomarkers [69, 70]. Neuroimaging
biomarkers that predict decline would have a great
potential for increasing the efficacy of early interven-
tion [71]. By focusing structural analyses on regions
known to be first affected in AD, we may better iden-
tify those individuals at greatest risk for future memory
decline, valuable in determining the course of future
care needed by these individuals, requiring more sub-
stantial care at an earlier time point.
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6.2 DISEASE PROGRESSION IN AD Disease progression is measured, most commonly, by change in cognition over time (Kraemer et al., 1994, Marra et al., 2000, Schmidt et al., 2011, Behl et al., 2005). The studies in the thesis defined rapid progression based on the rates of cognitive decline at the time of presentation and also tested the progression markers for associations with prospective cognitive decline. It is interesting to note that these markers which associated with disease severity at time of presentation and the initial rates of decline also predicted the subsequent progression.  This is in keeping with observations from previous studies that an estimate of initial rates of decline at the time of presentation 





6.3 Effects of APOE4 on the markers of AD progression: APOE4 status had no effect on the concentrations of plasma TTR, plasma clusterin or  different brain region volumes for their influence on the disease progression. The  disease progressions in all these studies were measured as cognitive decline. The  association of APOE with cognitive decline in the literature vary. Several studies report  a positive association of APOE ε4	  with	  more	  rapid	  cognitive	  decline	  (Corder et al., 1993, Martins et al., 2005, Craft et al., 1998, O'Hara et al., 2008). Conversely, in an individual 
growth	   curve	   analysis	   of	   APOE	   ε4-associated cognitive decline in AD, report that 
although	   the	   APOE	   ε4allele is associated with an increased risk of developing AD, 
subjects	  with	   2	   ε4	   alleles	   have	   a	   slower	   clinical	   course	   (Hoyt et al., 2005). However, there is also report that	  although	  APOE	  ε4	  increased	  the	  risk	  for	  AD	  and	  decreased	  the	  age of disease onset in population studies, it did not significantly influence the rate of disease progression in cognitive or functional domains (Kleiman et al., 2006). The results from thesis studies (paper 1, 2 and 3) which were all derived from AddNeuromed multi-centred cohort are in keeping with lack of association of the APOE4 status with markers for cognitive decline (Schmidt et al., 2010, Schmidt et al., 2011, Wilkosz et al., 2010). Olfaction study which examined a different clinical population from 2 UK centres however did not test for the APOE4 status and this is something to look at in future studies. 
  
6.4 FURTHER DISCUSSIONS AND DEVELOPMENT ON PLASMA MARKERS SINCE 
PUBLICATION 
 6.4.1 CLUSTERIN Single-nucleotide polymorphisms in the clusterin gene, CLU, were recently found to be associated with the risk of developing late-onset AD (Harold et al., 2009, Lambert et al., 2009). Clusterin, a multifunctional lipoprotein, comprises disulphide linked _ (34–36 kDa) and (∼36–39 kDa) peptides (de Silva et al., 1990). It is expressed in a number of tissues, but expression is particularly high in the brain (de Silva et al., 1990, Nuutinen et al., 2009).  
101 
 
Although the work to date has not confirmed the clinical utility of plasma clusterin concentration as a stand-alone biomarker for AD, this study establishes this amyloid chaperone protein as a robust peripheral signature that is responsive to key features of disease pathology. The research clearly implicates clusterin but there may well be other proteins in plasma related to disease process. Nevertheless, this data has attracted major collaborative translational funding for long term trials and biomarker validation. Further work done has been done by the research group (Thambisetty et al., 2012b, Thambisetty et al., 2012a, Hardy et al., 2011)and replicated by other groups since our data publication (Schrijvers et al., 2011). In a recent study the AD genetic risk variant rs11136000  in CLU is found to influence longitudinal changes in brain function in asymptomatic individuals and is associated with faster cognitive decline in presymptomatic stages of disease progression, suggesting mechanisms underlying the role of CLU in AD and important in monitoring disease progression in at-risk elderly (Thambisetty et al., 2012b). Plasma clusterin was found to be associated with rate of brain atrophy in MCI and reflect its concentration within brain regions vulnerable to AD pathology (Thambisetty et al., 2012a). Another study in a cohort of 3709 participants found plasma clusterin levels significantly associated with baseline prevalence and severity of AD measured by the MMSE, but the study did not examine association with disease progression in AD (Schrijvers et al., 2011). In a recent study the association of the AD clusterin common risk polymorphism rs9331888 with blood clusterin levels was tested in 104 AD subjects and 104 healthy controls (Xing et al., 2012). Blood clusterin levels were significantly elevated in AD patients compared to control subjects, however, the rs9331888 AD-risk variant was associated with low clusterin mRNA and protein levels in an allele-dose dependent manner in both groups.   The many roles of clusterin make it a candidate neuroprotective agent and the neurodegenerative changes that occur in AD may trigger an increased expression of clusterin (Nuutinen et al., 2009). Several protective effects of clusterin on the brain that may play a role in AD have been described in in vitro or in vivo studies, including inhibition of amyloid formation (Yerbury et al., 2007) through binding amyloid-beta or enhancing its clearance over the blood-brain barrier (Bell et al., 2007), clearance by endocytosis of amyloid beta aggregates and cell debris to brain phagocytes, involved in 
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regulation of brain cholesterol and lipid metabolism, inflammation of the brain, and the inhibition of neuronal apoptosis/ potentiation of neuroprotection (Nuutinen et al., 2009). Thus, clusterin is not a typical target, since it has so many functions and isoform-specific effect; however, this may be an advantage for a multi-etiological disorder such as AD (Yu and Tan, 2012).  6.4.2 TRANSTHYRETIN Transthyretin (TTR) is a homotetrameric protein of 55KDa found mainly in plasma and cerebrospinal fluid. In 1981, the International	  Union	  of	  Biochemists	  adopted	  the	  name	  ‘	  
transthyretin’	   to	  change	   the	  prior	  descriptive	   term- ‘thyroxine	  binding	  prealbumin’	   to	  more preferable functional nomenclature based on its physiologic role (transporter of 
thyroxine and retinol) (Buxbaum and Reixach, 2009).    A role of TTR, in association with retinol-binding protein, is to transport retinol (vit A) from liver storage to target tissues where it can be metabolized to retinoic acid in response to physiologic needs (Monaco, 2000). Some evidence has suggested a role of perturbed RA pathway in age related memory impairments (Chiang et al., 1998, Etchamendy et al., 2001, Misner et al., 2001, Cocco et al., 2002). Knock-out mice lacking TTR showed spatial memory deficits during aging (Brouillette and Quirion, 2008). They also demonstrated reversal of cognitive deficits with R treatment in TTR-/- mice and aged rats suggesting that the mechanisms underlying the role of TTR in memory formation during aging is linked to its ability to regulate brain retinoid availability. Taken together, these results provide evidence that TTR is involved in the maintenance of memory capacities during aging.  The formation of insoluble aggregates of amyloid-β	   peptides	   (Aβ)	   in	   the	   brain	   is	  considered critical event in AD (Hardy and Selkoe, 2002). Aβ,	  consisting	  of	  39-43 amino acids, is produced from amyloid- β	  protein precursors (AβPP)	  by	  the	  combined	  actions	  
of	  β	  and	  γ	  secretase	  (Kang et al., 1987). Among the Aβ	  species,	  the	  Aβ1-42 peptide has the greatest tendency to form amyloid fibrils (Barrow and Zagorski, 1991) and it is the peptide initially deposited in the plaques (Miller et al., 1993). An alternative non-
103 
 
amyloidogenic cleavage of AβPP	  by	  a	  α-secretase	  generates	  soluble	  α-sAβPP,	  a	  fragment	  that might be neuroprotective (Goodman and Mattson, 1994, Thornton et al., 2006).   In vitro studies have suggested TTR can bind to Aβ1-40 and Aβ1-42 monomers, preventing its transformation into toxic fibrils and amyloid plaques (Schwarzman et al., 1994, Buxbaum et al., 2008, Liu and Murphy, 2006). TTR seems to play an important role in keeping intracerebral proteins such as amyloid in a soluble form and helps prevent further aggregation (Liu and Murphy, 2006). Binding of the aggregates are better than that of the monomers and it also appears that the affinity of TTR is greater for Aβ1-42 than for Aβ1-40.  Earlier studies in Tg2576 AD model mice showed that ttr transcripts were increased and TTR protein was immunochemically detected in neurons in hippocampal and cerebral cortical slices (Stein and Johnson, 2002, Wu et al., 2006). In the well validated APP23 transgenic mouse model, rather than amplifying disease, TTR over-expression suppressed both the neuropathologic and behavioral manifestations of AD (Buxbaum et al., 2008). In the same model, silencing the endogenous ttr gene accelerated disease pathogenesis (Buxbaum et al., 2008). In a recent study in mice we found that deletion of insulin receptor substrate 2 (Irs2) resulting in insulin resistance increased tau pathology as expected but paradoxically decreased amyloid pathology. We showed that this unexpected protection against plaque pathology was due to an increase in TTR expression (Killick et al., 2009), in line with a previous genome-wide expression study which found that increased TTR was one of the protective factors preventing transgenic mice with plaque pathology progressing to other pathological features of AD (Stein and Johnson, 2002). 
 In human AD a number of studies have reported reduced TTR levels in the cerebrospinal fluid (CSF) (Serot et al., 1997, Gloeckner et al., 2008, Hansson et al., 2009). Recent results from the MIRAGE study of AD families indicated that at least one TTR SNP (rs3764479) is associated with MRI documented hippocampal atrophy in AD patients and are consistent with a role for TTR in AD pathogenesis (Cuenco et al., 2011). Another recent study measured TTR levels in serum samples from 90 non demented 
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controls and 111 AD patients and observed significantly lower serum TTR levels in AD, suggesting it as possible peripheral biomarker for AD diagnosis in serum level (Han et al., 2011).  
Whatever	   the	   mechanism,	   TTR	   is	   a	   prime	   candidate	   to	   influence	   Aβ	   pathology	   both	  directly and indirectly. The reasons for decreased plasma TTR levels in AD dementia subjects could be from altered morphology of the choroid plexus in AD with possible change of expression profile including TTR production and its transport into blood (Serot et al., 2000)]. Another possible explanation could be the down regulation of TTR 
expression	   in	   choroid	   plexus	   caused	   by	   activated	   β-secretase activity in AD with decreased	  sAβPPα	  (Stein et al., 2004).   
TTR,	   ApoE	   and	   clusterin	   (ApoJ)	   are	   major	   Aβ-binding proteins in human CSF (Schwarzman et al., 1994, Strittmatter et al., 1993, Ghiso et al., 1993). In a recent report TTR was one of the 6 CSF biomarkers for AD describing six clinico-pathological stages from cognitive normalcy to mild dementia, including stages defined by increased risk of cognitive decline (Perrin et al., 2011). A recent review proposed a mechanism of TTR inhibition of Aβ toxicity, directly and indirectly (figure 6.1) (Li and Buxbaum, 2011). It is interesting that both clusterin and TTR proteins were identified and validated in human plasma, which differentiated fast and slow AD dementia progressors (Thambisetty et al., 2010, Velayudhan et al., 2012) .   The study compared cases versus control and within patient cohort, fast versus slow  decliners. Internal validation in an independent dataset was also performed. These  studies have provided interesting candidates, however comparing AD with other  neurodegenerative disorders for differential diagnosis is important and independent  replications are critical for establishment of these markers.   The quest for AD plasma biomarkers is complicated by the fact that the rate of the  progressive build-up of the pathology most likely varies from one individual to another  and there is no precise pattern of disease onset across the AD population (Bazenet and Lovestone, 2012). The problem caused by this lack of synchronicity causes large 
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variability and can be partly addressed by examining large sample cohorts. Another caveat is that the normal population is also composed of individuals who may have biomarkers of AD pathology without the clinical manifestation of AD because of the long prodromal period (Bazenet and Lovestone, 2012).   There are number of challenges in order to translate the increasing optimism that these  plasma proteins and other known and future candidate proteins could form a  biomarker signature in blood specific for AD diagnosis. Platforms used in discovery are  not necessarily the platforms used for either further validation/ replication or, more  importantly, the platforms chosen for the clinical assays (Bazenet and Lovestone, 2012, Clark and Kodadek, 2013). Different technology, data processing and analyses performed can affect replication studies. For example, an MS-based method and an immunoassay trying to measure the same protein can produce discrepant findings. Different isoforms or post translational modification of proteins in plasma can give varied findings. It is also important to develop standardized protocols for plasma collection and of assays used for appropriate and meaningful comparison across studies, especially during the replication and validation phases (an issue also for CSF and imaging biomarkers) and finally, powerful and innovative bioinformatics tools will be needed to unravel multivariate plasma signatures (Bazenet and Lovestone, 2012).  
Figure 6.1 - Proposed	  mechanisms	  of	  TTR	  inhibition	  of	  Aβ	  toxicity. TTR inhibition 
of	  Aβ	  aggregation	  (fibril	  formation)	  was	  reported	  by	  many	  groups	  and	  current	  evidence	  
suggested	  that	  the	  binding	  is	  mediated	  by	  association	  of	  monomeric	  TTR	  to	  Aβ.	  It	  is	  also	  
possible	  that	  TTR	  facilitates	  Aβ	  degradation	  directly	  or	  indirectly,	  transports	  of	  Aβ	  from	  
CNS	   into	   serum	   (plasma	   sink	   hypothesis).	   TTR	   may	   also	   inhibit	   Aβ	   production	   by	  






6.5 LIMITATION OF THE THESIS: Most of the limitations have been discussed in detail in individual papers and studies.  Some further issues raised by the reviewers are discussed as below; For the olfaction study, participants with head injury, depression and other psychiatric disorders were ruled out, as these conditions can influence the olfactory function. Therefore, the generalizability of the study findings remains to be established.  People with head injury have been studied to typically have anosmia, rarely regain normal olfactory ability and damage to olfaction-related brain structures observed in most such patients (Doty et al., 1997).  Olfactory dysfunction including identification deficits is well known in schizophrenia and described extensively in literature review (Nguyen et al., 2010, Turetsky et al., 2009). University of Pennsylvania Smell Identification Test (UPSIT) was tested in 131 patients with schizophrenia, 21 patients with major depression, 31 women with eating disorders along with 77 normal control subjects and olfactory identification deficits were observed only in patients with schizophrenia (Kopala et al., 1994). Olfactory abilities in Major Depressive Disorder (MDD) have been less investigated, and available studies have provided inconsistent results. A recent study assessed odour recognition memory and odour identification in 12 mild MDD patients, 12 severe MDD 
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patients and 12 age and gender matched healthy normal controls. Data analyses revealed that Severe MDD patients performed significantly worse than Mild MDD patients and Normal controls on both tasks, with these last groups not differing significantly from one another (Zucco and Bollini, 2011). Depression was not associated with any major deficit in olfactory threshold or identification in a study including subjects with unipolar and bipolar depression (Swiecicki et al., 2009). In view of the inconsistent results it was decided to not include subjects with depression.  However smell identification test helps to distinguish people with dementia and depression in the elderly. A simple three-item test of olfactory identification differentiated AD dementia patients (n=40) from those with major depression (n=20) (Solomon et al., 1998).  Another study used a German odor identification test in 20 patients with dementia due to AD, 20 with depressive disorder and 30 controls and found 100% sensitivity and 95% specificity with a score of 10/11 in differentiating AD from elderly with depression (Pentzek et al., 2007). Depression and other psychiatric disorders were ruled out for both the cases and controls in the olfaction study. AD dementia patients were recruited from the clinical services within MHSOP and MHOA and the history of known depression or any other psychiatric illness was assessed by the referring psychiatric team. Patients with such a history were excluded.  However, for the elderly controls recruited from on-going studies at the centre, a depression questionnaire (Geriatric Depression Scale) was used to exclude depression.  For the control subjects, although the MMSE range was between 24-30, a history of any subjective and objective memory problems was also noted. MMSE has its limitation and with its ceiling effect for education and age and also cannot completely rule out people with mild cognitive impairment. However as all the control subjects were also participants in on-going biomarker studies at the Institute of Psychiatry centre and evaluated annually, I was able to confirm that they continued to remain stable as control subjects for the duration of this study and analysis.  The cut off range for MMSE decline was 2 points within 6 months.  A number of investigators have previously reported average annual rate of change (ARC) of 
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approximately 2 to 4 points for the MMSE (Salmon et al., 1990, Behl et al., 2005, Galasko et al., 2000, Morris et al., 1993, Doody et al., 2001). These studies also supported reports that AD-associated drop in MMSE scores over time is non-linear. Mean cognitive decline of approximately 3 MMSE points per year has been described in classic AD (Morris et al., 1993). In a longitudinal study spanning 2 years among 686 patients with mild to moderate AD; 30% of patients had a decline that exceeded 3MMSEpoints per year, and 11% of patients had a mean (SD) decline	  of	  −4.57	  (0.23)	  MMSE	  points	  per	  year,	  which	  was twice as fast as the mean of the whole cohort (Cortes et al, 2008). The limitation of use of MMSE rate of change, as with any clinical cognitive testing, is that it could be influenced by the day-to-day variability, behavioural problems, or medical illnesses (Sluimer et al., 2008). To minimise this, details of medical problems, medications and behaviour problems was noted at every assessment.    The short duration of follow up, 3 months may have under sampled individuals, whose disease progressed too slowly to be identified within the observation period or too rapidly to meet the eligibility criteria, leading to an underestimation of the heterogeneity in cognitive trajectories.  One of the limitations with the plasma proteins is that they can be influenced by diet, medications and medical conditions. To minimise the dietary effects, blood samples were collected following a 2 hour fast.  The medical and treatment history were noted in detail at every assessment and included in the analysis. Decreased hepatic TTR expression is another possible cause of reduced TTR in AD but none of our AD dementia subjects had recorded liver dysfunction and additionally we did not find any differences in TTR levels of AD dementia subjects with and without thyroid dysfunction. Some general issues relating to all the studies merit further discussion.  Firstly, MMSE score was used to measure cognitive decline in all the thesis studies. This was mostly as this was available for all the patients from different cohort and to increase the number of patient inclusion. As cognition can be influenced by behaviour, inter-current illness and medications etc, this was noted and assessed at every visit and considered during analysis. In the olfaction marker study, the patients and families account of symptoms worsening was also accounted in addition to loss of points on the 
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MMSE in the previous 6 months. The MMSE is the most widely used test as a measure of cognitive decline followed by ADAS-cog (Galasko et al., 1991, Behl et al., 2005, Schmidt et al., 2011). Paper 3 on the brain regions used both ADAS-cog and MMSE as measures of decline and associations were seen with both the cognitive measures. Also for the plasma markers, ADAS-cog was used for discovery phase to define the decliners and thereafter association of the markers were significant with the retrospective and prospective decliners defined by MMSE scores. Future studies should investigate these progression markers predictive of decline on other cognitive measures.  Secondly, all these subjects have not yet been observed throughout the duration of their illness. Therefore, the findings apply only to individuals with mild-moderate AD dementia observed up to 1 year of illness. It cannot be said that the predictive utility of these markers are equally strong in the second, third and later stages of the illness. Better understanding of models and mechanisms of rates of progression in AD would help clinical prognostication and also independent replication and validation of these markers in well -designed and well-controlled studies with larger cohorts essential for their research and clinical utility. 
 Finally, although the sample was drawn from AddNeuromed study for the biological 
markers	   i.e.,	   plasma	   proteins	   and	   the	   brain	   regions,	   the	   subjects	   examined	   didn’t	  overlap completely, so the sample size was not large enough to assess for common markers. However, the subjects assessed for plasma clusterin, who also had imaging data, showed association with smaller ERC (Thambisetty et al., 2010).   
6.6 IMPLICATIONS AND FUTURE DIRECTIONS IN CLINICAL CONTEXT Late-onset Alzheimer disease dementia is a clinically heterogeneous complex disease defined by progressively disabling cognitive impairment and the rate of the progressive build-up of the pathology most likely varies from one individual to another causing large variability (Bazenet and Lovestone, 2012, Yang et al., 2011). In the clinical setting, it is important to recognize disease heterogeneity and to understand the biologic variables involved for advancing diagnostic procedures, improving estimation of progression, and adapting treatment strategies (Schmidt et al., 2011). Non-invasive 
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markers of progression will also be of great importance to monitor therapeutic efficacy with disease-modifying treatments.  Tremendous progress has been made in the area of biomarkers, undoubtedly, others will emerge over time and despite the robustness of many of the biomarkers, such as CSF markers, multiple magnetic resonance (MR) biomarkers; temperoparietal hypometabolism on fluorodeoxyglucose-positron emission tomography (FDG-PET) or hypoperfusion on SPECT, and most recently amyloid PET imaging (McKhann et al., 2011, Jack et al., 2011), there remains interest in finding cheap, simple, and reliable alternatives, most especially those that could be easily collected, example blood biomarkers (O'Brien, 2013).  Dubois and colleagues, of the International Work Group (IWG) and the National 
Institute	   on	   Aging	   (NIA)	   and	   the	   Alzheimer’s	   Association	   (AA),	   NIA/AA	  work	   groups	  support the diagnosis of AD prior to the onset of dementia and point to how best to integrate biomarkers into diagnostic criteria (Dubois et al., 2007, McKhann et al., 2011). It is hypothesized that amyloid biomarkers may be abnormal 10–20 years before the onset of symptoms, while abnormalities in biomarkers of neurodegeneration occur later (Jack et al., 2011). The presence of the biomarker represents a risk factor for progressing to AD in the future, however, the proportion of people who progress, the time frame for progression, and additional risk factors for progression are currently not fully defined (Cummings, 2012).   In a recent debate, Dubois, Gauthier and Cummings argue the need for revision of 
Alzheimer’s	   diagnostic	   accuracy	   and	   many benefits to moving to a new diagnostic system, representing a fundamental paradigm shift, moving AD from a clinic-pathological to a clinic-biological	   entity	   and	   separating	   the	   diagnosis	   of	   Alzheimer’s	  
disease	   from	   Alzheimer’s	   dementia	   (O’Brien, 2013). The new diagnostic criteria is supported by large body of research over 25 years, enhancing diagnostic specificity for 
the	  first	  time	  by	  using	  CSF	  and	  imaging	  markers	  to	  ‘rule	  in’	  rather	  than	  simply	  rule	  out	  other disorders.  However, it is also emphasized that these are research criteria and require validation and further investigation of clinical utility (Chiu and Brodaty, 2013).  
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ABSTRACT
Background: Olfactory dysfunction, impaired smell identification in particular, is known as a diagnostic and
a marker of conversion in Alzheimer’s disease (AD). We aimed to evaluate the associations of olfactory
identification impairments with cognition, illness severity, and progression in AD patients.
Methods: Fifty-seven outpatients with late onset mild to moderate AD and 24 elderly non-demented controls
(NDC) were assessed, at baseline and after three months, for Mini-Mental State Examination (MMSE),
University of Pennsylvania Smell Identification Test (UPSIT), and Bristol Activities of Daily Living and
Neuropsychiatry Inventory. AD participants were classified as Rapid Cognitive Decliners (RCD) defined on
a priori with a loss of ≥2 points in MMSE within the previous six months.
Results: AD participants had lower olfactory scores than NDC. RCD had lower olfaction scores compared
with Non-Rapid Cognitive Decliners (NRCD). Although the baseline UPSIT scores were associated with
baseline MMSE scores, it did not interact significantly with change in MMSE over the follow-up period.
Using a median split for olfactory scores, the AD participants were classified as Rapid Olfactory Progressors
(ROP) (UPSIT ≤ 15) and Slow Olfactory Progressors correlating significantly with RCD/NRCD groups.
The ROP group with higher olfactory impairment indicated more symptomatic illness or severity, i.e. lower
cognition, higher functional dependence, and presence of behavioral symptoms.
Conclusions: Our study supports association of smell identification function with cognition and its utility as
an adjunct clinical measure to assess severity in AD. Further work, including larger longitudinal studies, is
needed to explore its value in predicting AD progression.
Key words: smell identification test, dementia, Alzheimer’s disease, olfaction, disease progression, biomarkers
Introduction
Alzheimer disease (AD) is a progressive and the
commonest form of dementia. The course of AD
is variable and factors that influence or predict
progression are not well understood (Kraemer
et al., 1994; Marra et al., 2000). The ability to
differentiate rates of decline would help patients
and caregivers plan for future, and physicians plan
for appropriate treatment (Gauthier et al., 2006).
Disease progression is measured, most commonly,
by change in cognition over time (Kraemer et al.,
1994; Marra et al., 2000). However, clinical and
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neuropsychological measures may lack sensitivity
to change, are subject to day-to-day variability,
and are influenced by behavioral fluctuations and
inter-current illness andmedications (Sluimer et al.,
2008).
Olfactory dysfunction in general and impaired
odor identification in particular have been reported
in AD and are found to be occurring at early
stages of the disease (Mesholam et al., 1998). It
has been indicated that involvement of the olfactory
bulb and tract is one of the earliest events in the
degenerative process on the central nervous system
in AD (Christen-Zaech et al., 2003) and also that
tau pathology in the olfactory bulb increases with
severity of AD (Attems et al., 2005).
There are no published reports of smell
identification in AD which have failed to find
deficits relative to healthy elderly (Rahayel et al.,
2012). Smell identification tests have demonstrated
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high sensitivity and specificity for detecting
Alzheimer’s patients from controls (Morgan and
Murphy, 2002). Olfactory dysfunction has been
suggested to be included in the diagnostic criteria
of AD (Foster et al., 2008). However, a recent
systematic review concludes that although there
is evidence suggesting an association between
decreased olfaction and AD, rigorously designed
longitudinal cohort studies are necessary to clarify
the value of olfactory identification testing in
predicting the onset of AD (Sun et al., 2012). A
recent meta-analysis (Rahayel et al., 2012) suggests
that AD even more than Parkinson’s disease (PD)
affect more strongly smell identification and then
smell detection, suggesting that AD patients are
more strongly impaired on higher order olfactory
tasks involving specific cognitive processes.
Studies have reported association between
olfactory impairment and subsequent cognitive
decline (Wilson et al., 2006; 2007; Schubert et al.,
2008; Sohrabi et al., 2012) and also been studied
as a marker for predicting conversion from mild
cognitive impairment (MCI) to AD (Devanand
et al., 2000; 2008).
However, there is little known about associ-
ation of olfactory identification impairments and
cognitive decline with illness progression in AD
patients. In view of the common anatomical
substrate for memory deficits and the olfactory
function in AD, we hypothesized that olfactory
identification ability at baseline would correlate
with the cognitive ability and also predict altered
cognitive function in a follow-up assessment. The
specific questions examined by the current study
were the following: (1) What is the difference
between olfactory identification function between
patients with mild to moderate AD and non-
demented controls (NDC)? (2) Does olfactory
function deteriorate with time period and do they
differ for AD and NDC? (3) Is there any association
between olfactory function and cognition in mild
to moderate AD and can olfactory function predict
future cognitive decline? (4) Is there any association




AD participants: Late onset, mild to moderate
AD participants (Mini-Mental State Examination
(MMSE) score: 15–25) (n = 64) were recruited
from Mental Health for Older Adults (MHOA)
services of the South London and Maudsley
(SLaM)NHSFoundationTrust andMentalHealth
Services for Older People (MHSOP), Leicester-
shire Partnership NHS Trust, United Kingdom.
Diagnosis of probable late onset Alzheimer’s
disease was made according to the National
Institute of Neurological and Communicative
Disorders and Stroke and the Alzheimer’s Disease
and Related Disorders Association (NINCDS–
ADRDA) criteria (McKhann et al., 1984). The
exclusion criteria were dementia other than AD;
history of psychiatric disorder, including substance
abuse; medical conditions that may alter cerebral
functioning, or other conditions known to affect
olfactory functioning (e.g. common cold, blocked
nasal passages, polyps, etc.). Patients had either no
history at all of cigarette smoking or had stopped
smoking for 20 years or more. Informed consent
or assent as appropriate was taken from all the
patients. Participants received cholinesterase inhib-
itor therapy; either donepezil 5 mg/day (n = 21)
or galantamine 8 mg/day (n = 15) for initial four
weeks, which was then increased to 10 mg/day
(donepezil) or 24 mg/day (galantamine) by their
respective clinical teams, as per the local Trust
policy. Some patients (n = 28) were not on
cholinesterase inhibitors because of reasons such as
cardiac contraindications, intolerance, patients not
willing for therapy, or compliance issues.
Non-demented control patients
Eligible and interested NDCs were recruited
from the on-going AD biomarker studies at
the center for this olfaction study. As part of
these biomarker studies, patients with AD and
MCI, and NDCs were recruited and assessed
as per standard protocol described previously
(Thambisetty et al., 2010; Velayudhan et al., 2012).
Inclusion criteria: MMSE score range between 24
and 30, Clinical Dementia Rating (CDR; Hughes
et al., 1982) scale score of 0, age 65 years
or above, medication stable, and good general
health. Exclusion criteria: Meet the Diagnostic and
Statistical Manual of Mental Disorders (DSM)-
IV criteria for dementia, significant neurological or
psychiatric illness, significant unstable systematic
illness, or organ failure.
Assessments
Baseline assessments were performed with a follow-
up assessment after three months.
Assessment included cognitive testing with
MMSE (Folstein et al., 1975); non-cognitive
symptoms using Neuropsychiatric Inventory (NPI;
(Cummings et al., 1994), daily activities with Bristol
Activities of Daily Living Scale (BADL; Bucks
et al., 1996), and smell identification function using
University of Pennsylvania Smell Identification
Test (UPSIT; Doty et al., 1984; 1995). UPSIT
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is a standardized test of smell identification with
good test–retest reliability (r = 0.95) and strong
correlation with detailed olfactory threshold tests
(r = 0.80; Doty et al., 1984). This “scratch ‘n sniff”
olfactory test consists of four booklets containing
ten odorants apiece; one odorant per page. The
stimuli are embedded in 10–50-micron diameter
microcapsules fixed in a proprietary binder and
positioned on brown strips at the bottom of each
page. Above each odorant strip is a multiple-
choice question with four response alternatives
for each item. The UPSIT has been used in
British population to differentiate dementia patients
from normal elderly British patients tested in their
homes (Gray et al., 2001) and as a treatment
response marker (Velayudhan and Lovestone,
2009).
Patients were classified as AD Rapid Cognitive
Decliners (RCD), based on a decline of ≥2 points
at baseline in the previous six months of MMSE, a
commonly used cognitive test to assess severity and
decline in clinical settings (Behl et al., 2005).
Using a median split, AD participants were
further divided into two groups: those with
more olfactory dysfunction, i.e. Rapid Olfactory
Progressors (ROP; UPSIT ≤ 15) and Slow
Olfactory Progressors (SOP), i.e. those with lesser
impaired olfaction (UPSIT ≥ 16).
SPSS 20.0, STATA 10 and Excel 2010 were
used for statistical analysis of the data and
graphs. Comparisons were made on demographic
information, clinical characteristics, and cognitive
and behavioral test results with parametric (students
t-tests) and nonparametric (Chi-square test,
Mann–Whitney tests, Spearman rank correlations)
statistics, as appropriate. Alpha level was set at
0.05; corrections for multiple comparisons were not
made, given the exploratory nature of the study.
Linear regression was performed with the MMSE
scores over follow-up as the dependent variable
and baseline UPSIT scores, age, baseline MMSE
scores, duration of illness, gender, education, and
follow-up time as predictive variables within the AD
cohort.
Results
Sixty-four AD patients were eligible and agreed to
participate in the study; however, 57 successfully
completed both the baseline and follow-up
assessments. Seven patients dropped out owing to
developing stroke, being hospitalized, or moving
to institutional care in a different locality. Of the
28 NDCs recruited, 24 completed the study and
four dropped out owing to physical ill health.
The study includes 57 AD patients and 24
NDCs who completed both baseline and follow-
up assessments. None of the AD patients reported
subjective impairment in olfaction. All participants
were white Europeans, except for one male and a
female in each group.
Comparison of AD patients and NDCs
The socio-demographic and clinical comparison
between the AD patients and NDCs are as
described in Table 1a. The NDCs were younger
and had higher education. They scored higher on
the baseline MMSE and UPSITmeasures. The AD
patients took longer to complete the UPSIT, and
more AD patients had a family history of dementia.
At follow-up, the MMSE and the UPSIT loss
was not different from baseline within the groups
(Table 1a, Figure 1). The patients who dropped
out were similar to the patients in main data in
their demographic and baseline data. The seven
AD patients had a mean age of 84.6 years (±5.5
years), 12.8 years of education (±2.7 years), mean
MMSE scores 21 (±4), and mean UPSIT scores
14.4 (±7.3). The four NDCs had a mean age of
77.5 years (±11.5 years), 15 years of education,
mean MMSE scores 28.8 (±0.5) and mean UPSIT
scores 26.5 (±11.8).
Comparison of rapid cognitive decliners and
non-rapid cognitive decliners
As described above, the AD patients were classified
as RCD (n = 28) and Non-Rapid Cognitive
Decliners (NRCD; n = 29), based on a decline
of ≥2 MMSE points in the previous six months
at the baseline. The two groups were not different
in age, gender, duration of illness, follow-up
period, family history, or the number of patients
on cholinesterase inhibitors therapy. However,
the RCD had lower baseline MMSE (statistically
significant) and UPSIT (statistically not significant)
measures compared with NRCD (Table 1b,
Figure 1; Mann–Whitney U test). The follow-up
MMSE and UPSIT scores were low for RCD
compared with NRCD (statistically significant)
(Table 1b, Figure 1; Mann–Whitney U test).
The baseline UPSIT score correlated with both
baseline and follow-up MMSE (p < 0.01, r = 0.4)
and follow-up UPSIT scores (p < 0.001, r = 0.6).
The UPSIT scores improved in AD patients on
cholinesterase inhibitor treatment although this was
not statistically significant (Figure 2).
UPSIT progressors
Using a median divide, the AD participants were
further classified into ROP (UPSIT ≤ 15; n = 25)
and SOP (UPSIT ≥ 16; n = 32). The two groups
were similar in their socio-demographic data,
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Figure 2. Line plots representationofUPSIT scores betweenRCDandNRCDpatientswith andwithout cholinesterase inhibitor (CI) treatment.
Figure 3. Box plot representation of baseline and follow-up MMSE and UPSIT scores between Rapid Olfactory Progressors and Slow
Olfactory Progressors.
family history, follow-up time, and cholinesterase
inhibitors treatment (Table 1b). However, the ROP
patients had lower MMSE and lower UPSIT,
implying more cognitive and olfactory impairment
(Table 1b, Figure 3). They also had higher
BADL and NPI scores, reflecting more functional
deficits and more non-cognitive behavioral and
psychological symptoms (Table 1b).
Linear regression analysis in unadjusted models
showed baseline UPSIT scores, baseline MMSE
scores, and gender as a better predictor factor for
follow-up MMSE scores than variables such as age,
gender, duration of illness, education, and follow-
up time (Table 2). However, in the adjusted model,
baseline UPSIT score was not significant (Table 2).
Further, a linear mixed effects model using STATA
10 was fitted to investigate whether baseline UPSIT
score was associated with overall MMSE levels
measured in the two visits. The average baseline
MMSE and the average change in the MMSE over
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Table 2. Linear regression analysis with the follow-up MMSE scores as the
dependent variable and baseline UPSIT scores, age, baseline MMSE scores,
duration of illness, gender, follow-up in weeks, and cholinesterase therapy
alternatively (Model 1) or simultaneously (Model 2) entered as predictive
variables within the whole Alzheimer’s disease sample
R2 (%) β 95% CI p-VALUE
..........................................................................................................................................................................................................................
Model 1
UPSIT baseline 0.16 0.401 0.12, 0.5 <0.01∗
Age in years 0.01 0.075 −0.14 0.25 0.578
Education 0.00 −0.017 −0.8, 0.74 0.903
Duration of illness 0.03 0.179 −0.02, 0.08 0.187
MMSE baseline 0.49 0.698 0.56, 0.99 <0.001∗
Gender 0.08 −0.285 −4.4, −0.2 0.031∗
Follow-up in weeks 0.01 −0.112 −0.15, 0.06 0.406
CI therapy 0.01 0.085 −1.47, 2.82 0.531
Model 2
UPSIT baseline 0.165 −0.02, 0.28 0.098
MMSE baseline 0.619 0.47, 0.91 <0.001∗
Gender −0.205 −3.13, −0.17 0.030∗
Note: R2 (%): Percentage R2 value for the overall model; ∗p < 0.05; CI: confidence
interval; MMSE: Mini-Mental State Examination; UPSIT: University of Pennsylvania Smell
Identification Test; CI: cholinesterase inhibitor.
follow-up time was calculated for all patients as a
group (fixed effects) and subject-specific intercept
and slope terms which reflected deviation from
the group average (mixed linear effects) were
calculated. The calculation included adjustment
for follow-up time, age, disease duration, gender,
and cholinesterase inhibitor treatment. A significant
interaction between baseline UPSIT score and
follow-up time (visit) was used to test the null
hypothesis that there was no difference in the rate
of cognitive decline, i.e. in slopes for different
baseline UPSIT scores. We found that although
baseline UPSIT was associated with lower MMSE
at the baseline, the interaction between baseline
USPIT and time was not significant (p = 0.201),
indicating no association between baseline UPSIT
and MMSE change (decline) over the two time
points.
Discussion
Olfactory dysfunction has been studied as a
diagnostic marker as well as a marker of conversion
in AD. This is the first empirical attempt to
investigate olfactory dysfunction as a severity and
progression marker in AD. AD participants were
deliberately chosen in the early stages (mild to
moderate) of the disease so that there is little
question of their ability to understand and perform
the smell test. None of the AD participants had
speech or language difficulties.
Olfaction in patients with AD and NDCs
AD patients had lower olfactory identification
scores compared with NDCs, reported previously
(Doty et al., 1987; Richardson and Zucco, 1989;
Serby et al., 1991; Larsson et al., 1999; Bahar-
Fuchs et al., 2011; Makowska et al., 2011; Sun
et al., 2012). The median UPSIT scores in the
study for the AD cohort and NDCs were similar
to previous reports (Serby et al., 1991; Gray et al.,
2001; Velayudhan and Lovestone, 2009; Li et al.,
2010). As a group there was no difference in
the olfactory performance between the genders as
reported previously (Westervelt et al., 2007).
Olfaction and cognition
This study showed clear evidence of a relation
of olfactory function with cognition: (a) Olfactory
identification function was correlated with baseline
and follow-up cognition. (b) The rapid and slow
olfactory progressors correlated with the rapid and
non-rapid cognitive decliners group.
Previous studies have found strong correlations
between olfactory identification and cognitive
performances (Serby et al., 1991; Larsson
et al., 1999; Hidalgo et al., 2011). Olfactory
discrimination and identification have been more
closely associated with higher cognitive functions
and subsequent cognitive decline in community-
dwelling elderly individuals (de Wijk and Cain,
1994; Wilson et al., 2006; Sohrabi et al., 2009).
A large-scale study in older adults (n = 1920)
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on the relationship between olfactory identification
ability and general cognitive functioning (as
measured by MMSE) indicated that olfactory
dysfunction at baseline was significantly predictive
of future cognitive impairment after five years
(odds ratio (OR) = 6.62; confidence interval
(CI) = 4.36–10.04; Schubert et al., 2008). A
strong association between cognitive functions and
olfactory functioning has been reported and it has
been concluded that compared with the ability
to detect odors, identification of odors is more
challenging, perhaps due to a lack of access to verbal
or visual representations of odors (Richardson and
Zucco, 1989). Similarly, Schab (1991) noted that
odor identification might represent a semantic
memory function. Some researchers suggest that
olfactory identification is primarily predictive of
memory decline (Swan and Carmelli, 2002). A
recent meta-analysis (Rahayel et al., 2012) suggests
that AD affects more strongly odor identification
and odor detection, suggesting AD patients are
more strongly impaired on higher order olfactory
tasks involving specific cognitive processes. In a
functional magnetic resonance imaging (fMRI)
study, the blood oxygen level-dependent (BOLD)
signal at primary olfactory cortex (POC) was
found to be weaker in AD than in healthy
control participants (Wang et al., 2010). At the
lowest odorant concentration, the BOLD signals
within POC, hippocampus, and insula significantly
correlated with UPSIT, MMSE, and CDR scores,
demonstrating that olfactory fMRI is sensitive to
the AD-related olfactory and cognitive functional
decline (Wang et al., 2010).
Olfaction and non-cognitive symptoms
The present study showed that higher olfactory
impairment was associated with more dependence
in functional abilities at the baseline. Olfactory
function has been associated with functional
dependence previously in patients with MCI and
normal elderly participants (Wilson et al., 2007).
A previous report from our cohort had shown
that olfaction scores predicted improvement better
than cognitive scores as indicated by global and
functional improvement in AD patients receiving
cholinesterase inhibitor therapy (Velayudhan and
Lovestone, 2009).
Interestingly, the present study also found
an association in the olfactory rapid decliners
group with behavioral symptoms (NPI; Table 1b).
This has not been reported previously. This
could be, as most of the previous studies have
focused, an association of olfaction with cognition.
This needs to be explored further in future
studies.
On the whole, the study results reflect that
higher olfactory impairment is indicative of more
symptomatic illness or severity, i.e. lower cognition,
higher functional dependence, and presence of
behavioral symptoms.
The baseline UPSIT scores predicted the follow-
upMMSE in an unadjusted model, however, losing
this effect in adjusted model with MMSE and
gender. Further, a linearmixed effect model showed
that although baseline UPSIT was associated with
MMSE at the baseline, there was no association
between baseline UPSIT and MMSE change
(decline) over the two time points. This could have
been influenced by the cholinesterase inhibitors
therapy in some patients which influences UPSIT
scores more than the cognitive scores (Velayudhan
and Lovestone, 2009) and also the short follow-up
period. Also, there were more females than males
in the cohort, who perform better on the olfactory
tasks than men (Murphy et al., 2002; Mullol et al.,
2012).
Main limitations of the study are its small
sample size and single point follow-up over a short
duration. Longer follow-up with multiple point
testing and assessments of cognitive, functional and
behavioral changes, would be more informative of
predictive ability of the olfactory function for illness
progression in AD.
Gender was predictive of lower follow-upMMSE
scores, with women losing moreMMSE points over
follow-up period. The possible explanation could
be that women have a higher risk of developing AD
above 80 years of age (Copeland et al., 1999). The
present AD cohort had amean age of above 80 years
(81.5 years), so the progression too must have been
faster in women than in men.
A diminished sense of smell has practical
implications in relation to AD, such as decreased
appetite, with resultant weight loss and poor
nutritional status. Other problems may be the
inability to detect noxious odors such as gas and
smoke. Both patient and family should be made
aware of this deficit and the potential problems this
may cause.
In conclusions, the study confirms associations
of olfaction with cognition in mild to moderate AD
and supports the utility of the smell identification
function as an adjunct clinical measure to assess
severity in AD. Further work, including larger
longitudinal studies, is needed to explore its value
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